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Porphyrinoids with Designed Properties 
Michael P. Luciano, Ph.D. 
University of Connecticut, 2017 
This thesis focuses on the development of new synthetic methodologies toward 
porphyrinoids with properties designed for various applications. Among the chromophores 
studied are the quinoline-annulated porphyrins, a relatively unexplored class of π-extended 
porphyrinoids that absorb light in the near-infrared region (NIR). Another class studied are the 
pyrrole-modified porphyrins (PMPs), (hydro)porphyrin analogues containing a non-pyrrolic 
building block. 
The synthesis of chlorin and chlorin-analogues of the quinoline-annulated porphyrins are 
described that are characterized by even more red-shifted optical spectra than regular 
quinoline-annulated porphyrins (Chapter 2). The NIR-emitting platinum(II) complexes of the 
quinoline-annulated porphyrins suggest potential in vivo O2 sensing applications (Chapter 3). 
Photophysical studies of the free-base quinoline-annulated porphyrins, along with ex vivo 
photoacoustic imaging (PAI) studies, revealed their promise as novel PAI contrast agents. The 
preparation of water-soluble derivatives and their evaluation in vivo for the PAI imaging of an 
implanted tumor in a mouse model is described (Chapter 4).  
A new methodology toward hitherto inaccessible PMPs incorporating medium-sized rings is 
also delineated (Chapter 5). Initial experiments toward this class of PMPs resulted in a 
serendipitous finding of a more efficient route toward a known class of PMPs containing an 
imidazolone moiety, the porpholactams. The conversion of the porpholactam to a number of 
chelator-substituted imidazoloporphyrins toward the goal of generating metal-ion chemosensors 
for the selective and sensitive detection of M2+ cations is also delineated (Chapter 6). 
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1 Introduction 
1.1 Porphyrins and Hydroporphyrins 
Synthetic dyes that absorb light in the near-infrared region (NIR) have valuable applications 
in the biomedical sciences, particularly as novel bioimaging contrast agents,1 as drugs for 
photodynamic therapy (PDT)2 and as chromophores for in vivo molecular recognition.3 Among 
the commonly investigated synthetic dyes, porphyrins and porphyrin analogues are the most 
promising candidates due to their high molar extinction coefficient, and fluorescence and singlet 
oxygen quantum yields. 
Porphyrins are tetrapyrrolic aromatic heterocycles in which four pyrrolic subunits are linked 
by methine bridges. A porphyrin has an 18π conjugated aromatic system cross-conjugated with 
two additional double bonds, making it an 18 + 4π aromatic system. The numbering and 
positions of a porphyrin according to the IUPAC naming convention are shown in Figure 1-1. 
 
Figure 1-1. Numbering and naming of porphyrins and hydroporphyrins. 
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The two cross-conjugated β,β’ bonds of a porphyrin can be reduced to produce 
hydroporphyrins. A hydroporphyrin with one cross-conjugated β,β’-bond reduced is called a 
chlorin. The conversion of a porphyrin to a chlorin results in a bathochromic shift in the longest 
wavelength of absorption (Figure 1-2). 
 
Figure 1-2. UV-vis spectra of free-base porphyrin and chlorin (solid traces) and metalloporphyrin and metallochlorin 
(dotted traces). 
The synthesis of porphyrin analogues has been achieved by semisynthetic methods, 
starting from extracts of naturally derived porphyrinoids as well as total synthesis methods. 
Alternatively, synthetic methods toward new porphyrinoids have been achieved using model 
synthetic systems such as meso-tetraphenylporphyrin (1), which can be prepared by the Adler 
procedure (Scheme 1-1).4 The Adler procedure is flexible with respect to introducing different 
meso-substituents to the porphyrin, by using the appropriate benzaldehyde derivative. 
 
Scheme 1-1. Adler synthesis of meso-aryl porphyrins. 
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We have demonstrated in our lab the OsO4-mediated regioselective dihydroxylation of the 
β,β’ bond of TPP to form the vic-cis-diol (OH2TPP) (Scheme 1-2).5 This particular chlorin now 
has a vic-cis-diol synthetic handle and is thus amenable to a wide variety of modifications at the 
β,β’ position. The diol 2M can also be further oxidized to the dione 3M by treatment with DDQ. 
The diol 2M and dione 3M, or similar meso-aryl analogues, serve as the ultimate starting 
materials for all of the porphyrinoids described in this dissertation. 
 
Scheme 1-2. Synthesis of synthetic handles for the modification of meso-tetraarylporphyrins. 
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1.2 Quinoline-Annulated Porphyrins 
Even though the high extinction coefficients, fluorescence and singlet oxygen 
photosensitization quantum yields of regular porphyrins and chlorins are potentially attractive for 
their use in biomedical applications, e.g., as photochemotherapeutics,6 photoantimicrobials,7 
photoantifungals,8 or fluorescent markers,6c,9 most regular porphyrins and chlorins do not absorb 
light within the ~700-900 nm wavelength regime referred to as the ‘optical window’ of tissue.10 
For instance, the maximum wavelength of absorbance (λmax) for regular porphyrins, such as 
meso-tetraphenylporphyrin 1H2, rarely exceeds 650 nm. In comparison, the wavelength of 
maximum penetration of breast tissue is ~725 nm; whole blood has an absorption minimum at 
~710 nm.11 Regular porphyrins are thus unsuitable for biomedical in vivo applications. Non-
emitting chromophores may also be attractive as photoacoustic imaging agents but,12 again, 
only if they also absorb light within the optical window of tissue.13 Light-harvesting applications 
also benefit from NIR-absorbing dyes as a large portion of the irradiance energy of sunlight falls 
into this range. Panchromatic absorbers are also most desirable for light harvesting as these 
chromophores collect the maximum amount of energy.14  
A number of strategies have been employed to achieve this goal. For instance, the 
expansion of the conjugated π-system by increasing the number of conjugated pyrroles was 
highly successful, as the many examples of NIR absorbing expanded porphyrins demonstrate.15 
One other strategy is the establishment of π-systems that are annulated to the porphyrinic 
chromophore.14d,16 Among the latter class of porphyrins may be meso-arylporphyrin derivatives 
that bear a covalent linkage between one or more β-positions and the flanking meso-phenyl/aryl 
groups.17 In the absence of the linkage, a Hβ-pyrrole-Ho-phenyl steric interaction prevents the meso-
aryl groups from adopting low-energy coplanar conformations. The linkage removes this 
interaction but needs to be short enough to force the phenyl group(s) into (idealized) co-
planarity with the porphyrinic chromophore, thereby extending the π-conjugation pathway. This 
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linkage may be a ketone functionality, itself in conjugation with the chromophore (2H2).18 The 
resulting bathochromic shift of λmax of 2H2 compared to 1H2 is a respectable ~76 nm. On the 
other hand, the fusion of one through four anthracenes to a porphyrin, as in 3H2, results in an 
enormous perturbation of their UV-vis spectra, with λmax values red-shifted ~300 nm upon fusion 
of a single anthracene; the corresponding nickel(II) complex with four anthracenes shifted the 
λmax by more than 900 nm, to 1417 nm.19 Few examples exist in which a chlorin chromophore 
incorporates an annulated ring, as in bischromene-annulated chlorin 4H2, leading to a 24 nm-
shifted λmax compared to the parent chlorin.20 
 
In 2011, Jeandon and Ruppert, building on the extensive work by Ruppert, Callot, and co-
workers in the construction of peripheral conjugated chelates,21 published the formation of 
bisquinoline-annulated porphyrin 7H2 from nickel porphyrin 1Ni via a multi-step sequence 
(Scheme 1-3).22 The key β-to-o-linkage formation step involved a Cadogan reaction of 
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nitroporphyrin 5Ni to form the amine-linked porphyrin 6Ni. Subsequent nitrogen protection, 
regioselective nitration, thermally induced oxidation and ring-closure, and acid-induced 
demetallation produced the bisquinoline-annulated system 7H2 in good yield.  
 
Scheme 1-3. The two independent paths toward bisquinoline-annulated porphyrin 7H2 developed by Ruppert (1Ni → 
5Ni → 7H2) and Brückner (1H2 → 10H2 → 7H2). 
Concurrently with Jeandon and Ruppert, we independently described in a preliminary report 
the conversion of free base porphyrin 1H2 to free base bisquinoline-annulated porphyrin 7H2.23 
The key steps were two consecutive acid-mediated electrophilic aromatic substitution reactions 
of oximes, such as 10H2, formed from the corresponding ketone 8H2. We prepared this well-
known dione 8H2 along a dihydroxylation-diol oxidation sequence from porphyrin 1H2,24 but this 
product can be made along a number of alternative routes.25 
The quinoline-annulated porphyrins are characterized by their significantly red-shifted optical 
spectra, with λmax values in their absorption spectra in the realm of 750 – 800 nm (Figure 1-3). 
We attribute the dramatic shift in the optical spectrum of these chromophores to the increase of 
π– conjugation established by the annulation reaction, as well as a marked increase in the non-
planarity of the macrocycles, as observed in their solid-state structures.26 
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Figure 1-3. UV-vis spectra (CH2Cl2) of mono- and bis-quinoline annulated porphyrins. 
The broad and intense absorption of the quinoline-annulated porphyrins in the NIR region 
suggests their use in biomedical applications. However, their very low fluorescence and singlet 
oxygen quantum yields prevent their use as PDT agents. Taking these properties into 
consideration, we were able to show that these NIR absorbers are excellent in vitro contrast 
agents for photoacoustic imaging applications.13 Further evaluation of the quinoline-annulated 
porphyrin platinum complexes, particularly 7Pt, also suggests their use as O2 sensors for their 
NIR emission and long phosphorescence lifetimes. Unfortunately, their insolubility in aqueous 
systems prevents the evaluation of these dyes in biological contexts.  
  
0
1.2E+5
2.4E+5
400 600 800
9H
2
12H
2
7H
2
15H
2
Wavelength [nm]
ε 
[c
m
-1
M
-1
]
!
N
Ph
N
O
N
Ph
N
O
O
N
N
N
N
N
N
O
9H2 11H2
7H2 12H2
1. Introduction 
 
8 
 
1.3 The Breaking and Mending Approach 
Replacing one of the pyrroles of a porphyrin with a non-pyrrolic heterocycle has also been a 
strategy used to gain access to porphyrinoids with altered optical spectra.27 The formal 
replacement is accomplished by using a methodology termed the ‘breaking and mending’ 
approach (Scheme 1-4).28 First, the β position of a porphyrin is activated, most often by OsO4-
mediated dihydroxylation. Then, a breaking step is performed, where the β,β’ bond of the 
porphyrin is cleaved to generate a secochlorin. Finally, the secochlorin is subjected to 
‘mending’, i.e. a cyclization step, to generate a wide variety of pyrrole-modified porphyrins 
(Scheme 1-5).  
 
Scheme 1-4. The breaking and mending approach toward pyrrole-modified porphyrins (PMPs). 
 
Scheme 1-5. Scope of the ‘breaking and mending approach’.  
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1.4 Modifications of Porphyrins and Hydroporphyrins for their Solubilization in 
Aqueous Media 
The utility of porphyrins and hydroporphyrins (chlorins and bacteriochlorins) in a variety of 
biomedical applications was demonstrated.29 These include photodynamic cancer therapy,6b,6c,30 
antifungal photodynamic therapy,8 their use as photoantimicrobials,7 as fluorescence and photo-
acoustic imaging agents,6c,9,12a,31 (single) cell imaging32 and fluorescence labelling,33 and as in 
vivo chemosensors.34 In addition, they have shown value in a number of technical applications, 
such as chemosensing,34a electronic devices and materials,35 catalysis,36 photocatalysis,37 and 
light harvesting.38 These applications rest on the favorable optical, chemical and electronic 
properties of these porphyrinoids: Their intense absorbance in the visible to near infrared (NIR) 
region, high fluorescence or singlet oxygen quantum yields, good photoacoustic signal 
generation efficiency, ease of ejection of a photo-excited electron, etc. Many of these 
applications will greatly benefit from an inherent solubility of the porphyrins in aqueous media, 
i.e., not requiring any surfactants or liposome vesicles to mediate solubility. However, even 
though the methodologies toward synthetic porphyrins,39 hydroporphyrins,6b,40 and their 
analogues,28,40d,41 have advanced enormously in the past decades, the vast majority of the 
synthetic porphyrinoids presented are not naturally water-soluble, preventing—or at least 
complicating—their utilization in, for example, biological contexts. 
Initial efforts to impart water-solubility relied on the utilization of meso-pyridyl and meso-p-
sulfonatophenyl-substituents in (mostly) symmetric porphyrins. These porphyrins were based on 
Adler syntheses of tetrapyridyl- and tetraphenylporphyrin, followed by quarternization with a 
suitable alkyl halide or direct sulfonation, respectively. Albeit simple, both methods have draw-
backs. They are difficult to translate to β-alkyl-substituted porphyrins, the sulfonation reaction 
conditions are harsh and therefore incompatible with many hydroporphyrin chromophores or 
substituents that convey desirable properties onto the porphyrin. This led to the development of 
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a range of alternative methods to impart water-solubility that are mild, selective, and that 
generate the water-soluble porphyrin derivative late in the synthetic sequence, thus facilitating 
its isolation and purification. 
Rather than attempting to be comprehensive, we aim to present here a tutorial-style review 
that highlights recent (since ~2000) synthetic strategies. Where data is available, we compare 
the resulting solubilities and report on other notable practical considerations. This summary 
extends a review on water-soluble porphyrins published in the year 200042 that provides a 
detailed account of the acid-base properties and aggregation behavior of conventional water-
soluble porphyrins. A 2014 review on amphiphilic porphyrins by Gryko and co-workers43 is also 
available; overlap with this review is minimized and these reviews are thus complementary. 
Porphyrins linked to sugars, many of which are also water-soluble, have been reported.43-44 We 
chose not to include them here because glycosylation strategies are frequently not driven by 
achieving water-solubility but to increase tumor targeting; they were also reviewed in the context 
of amphiphilic porphyrins.43 Water-soluble porphyrins conjugated to biomolecules (e.g., oligon-
ucleotides and peptides), appended to functionalities such as cyclodextrans,45 crown ethers,46 
porphyrin nanoparticles,47 or porphyrins that were solubilized with the help of surfactants or 
vesicles48 are also beyond the scope of this discussion. Likewise, we do not cover the 
solubilization of expanded porphyrins or most other porphyrinoids. 
The review is organized along the charge the solubilization groups introduce: Cationic 
(amine/ammonium, pyridyl/pyridinium), anionic (sulfonate, phosphonate, carboxylic 
acid/carboxylate) and neutral (polyethylene glycol (PEG) chains). Each section discusses the 
examples loosely in increasing order of complexity and the position of the solubilizing group. 
Three principle strategies for the introduction of solubilizing groups can be distinguished 
(Scheme 1-6). Strategy A encompasses the synthesis of porphyrin macrocycle using building 
blocks bearing solubilizing groups (protected or not). Strategy B involves the synthesis of a 
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porphyrin macrocycle with precursor functionalities that can later be manipulated to hydrophilic 
groups. Strategy C employs synthetic modifications of an already-formed porphyrin to impart 
water solubility.  
 
Scheme 1-6. Principle strategies toward hydrophilic porphyrin derivatives. 
1.4.1 Water-Soluble Porphyrins Bearing Cationic Substituents 
Cationic porphyrins were among the first synthetic water-soluble porphyrins to be 
discovered.49 These early methods of solubilization relied on the N-alkylation of meso-tetra-
pyridylporphyrins and their metal complexes (see also section 1.4.1.2).43 These types of cationic 
porphyrins were widely studied for their association with the polyanion DNA,50 as part of the 
quest for new photosensitizers for photodynamic therapy (PDT), and for their promise as photo-
antimicrobials for gram positive and gram negative bacteria.51 Tetra-pyridyl/pyridiniumporphyrins 
are also commercially available.52 
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1.4.1.1 Amine/Ammonium functionalized porphyrins 
One possibility for the preparation of cationic water-soluble porphyrins and hydroporphyrins 
is through derivatization with amines or polyamines. Porphyrinoids with amine functional groups 
may be soluble in aqueous media at low pH, but quarternization of the amines with suitable 
electrophiles is frequently employed to furnish freely water-soluble derivatives. The resulting 
(poly)cationic derivatives are usually purified by crystallization protocols or reverse phase 
chromatography. Ion-exchange chromatography offers an option to subsequently exchange the 
halide counterion (typically Br– or I–) to another anion.53 
A number of symmetric and asymmetric amphiphilic meso-aryl porphyrins bearing amine 
functional groups have been reported.43 The strategies toward their generation often rely on 
Adler or Lindsey porphyrin syntheses incorporating amine-containing building blocks or through 
modification of other functionalities, such as phenols. 
Krausz and co-workers, for example, synthesized polyamine- meso-arylporphyrin 
conjugates by DCC-mediated amide-coupling of carboxylic acid-functionalized A3B porphyrin 2, 
made by functionalization of phenol 1 with di-Boc-protected-spermidine or tri-Boc-protected-
spermine (Scheme 1-7).54 The ultimate starting A3B porphyrin 1 was synthesized using a mixed 
aldehyde Adler condensation, followed by alkylation of the phenolic oxygen with ethyl 4-
bromobutanoate and saponification. The thus generated polyamines were submitted to standard 
Boc-deprotection conditions to afford the polyamine-porphyrin conjugates 3 and 4, respectively. 
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Scheme 1-7. Spermine- and spermidine-porphyrin conjugates, as described by the group of Krausz.54  
Bacteriochlorins derived from natural sources and bearing an anhydride functionality could 
also be derivatized by amide formation with polyamines.55 Sol and co-workers prepared water-
soluble chlorin polyamine derivative 6 through amidation of a chlorin extracted from Spirulina 
maxima (Scheme 1-8). The polyamine groups were introduced by nucleophilic ring opening of 
anhydride 5 with polyethylenimine (PEI, MW 600 Da). Alternatively, polyamination was 
performed at the propionic acid side chain. The anhydride moiety in chlorin 5 was first converted 
to an acetate-protected cycloimide chlorin 7 by treatment with hydroxylamine, followed by 
acylation. The subsequent polyamination at the propionic acid side chain required activation of 
the carboxylic acid moiety, followed by reaction with PEI. In a similar fashion, water-soluble 
polyaminated bacteriochlorins 9 and 10 were prepared starting from bacteriochlorins extracted 
from Rhodobacter spaeroides. In water, the resulting compounds exhibited split and/or 
broadened Soret bands, indicating some degree of aggregation. 
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Scheme 1-8. Chlorin and bacteriochlorin polyamines derived from Spirulina maxima and Rhodobacter spaeroides, 
respectively, as described by the group of Sol.55  
Amine groups were also introduced to porphyrins bearing carboxylic acid groups by 
esterification with an amino-alcohol. An example of this strategy was the preparation of a 
tricationic water-soluble ester of chlorin e6 11 (Scheme 1-9).56 Methyl pheophorbide a was 
saponified, and the acid groups in product 11 were activated as acid chlorides and esterified 
with N,N-dimethylaminoethanol to provide triamine 12. Quarternization by reaction with CH3I 
gave the tricationic water-soluble chlorin derivative 13.56 
N
N N
N
CH2
H3C
CH3
CH3
CH3
O OO
H3C
HO2C
N
N N
N
CH2
H3C
CH3
CH3
CH3
N OO
H3C
HO2C OAc
N
N N
N
O
H3C
CH3
CH3
CH3
O
H3C
HO2C
N
N N
N
N
H3C
CH3
CH3
CH3
N OO
H3C
H3C H3C
OAc
OAc
OH
O
N
N N
N
CH2
H3C
CH3
CH3
CH3
O
H3C
HO2C
N
N N
N
CH2
H3C
CH3
CH3
CH3
N OO
H3C
H3C H3C
OAc
OH HN
O
Spirulina maxima extract
H
H
H
H
H
H
H
H
H
H
H
H
1. O2, NaOH
2. HCl
1. NH2OH·HCl,
pyridine
2. Ac2O
1. HBTU, DIPEA
2. PEI 600 DaPEI 600 Da
5 7
6
8
9
Rhodobacter spaeroides extract
N
NH2
H
N
x CH3y
HN
O
N
H
N
NH2
CH3x y
HN N
NH2
H
N
x CH3y O
HN N
H
N
NH2
CH3x y
10
1. Introduction 
 
15 
 
 
Scheme 1-9. Cationic esters of chlorin e6 with terminal ammonium groups, as described by the group of Inoue.56 
 
Scheme 1-10. β-substituted cationic ammonium bacteriochlorin derivatives, as described by the group of Lindsey.57 
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Amine groups have been introduced to the β-positions of hydroporphyrins by transition 
metal-mediated coupling strategies using β-bromo precursors. Thus, Lindsey and co-workers 
prepared a range of water-soluble cationic bacteriochlorin derivatives utilizing the versatile 3,13 
dibromobacteriochlorin building block 14. The bromo groups are susceptible to a variety of 
transition metal-mediated C-C bond forming coupling reactions (Scheme 1-10).57 For example, 
bacteriochlorins 15a-15c were prepared from 14 through a carbonylation → acid chloride 
reaction with secondary amines. Additionally, reaction of amide salts with 14 in a carbonylation 
→ amidation sequence gave the amino-bacteriochlorins 16a and 16b. Sonogashira coupling of 
14 with an ethynyl-amine, followed by reduction, gave the bacteriochlorin 17 with amine-
terminated alkyl chains. Lastly, a variety of secondary amines was employed in a β-formylation 
→ reductive-amination strategy to produce amine-functionalized bacteriochlorins 18a-18e. The 
resulting amines were amenable to purification by silica gel column chromatography (EtOAc or 
CH2Cl2/MeOH/NH4OH as eluents). Subsequent N-alkylation of the amines was achieved using 
standard conditions, and the water-soluble cationic products that precipitated from the CHCl3 
reaction mixtures were isolated by precipitation and centrifugation. Some of these compounds 
were investigated for their efficacy as antimicrobial photosensitizers.58 
Lindsey and co-workers also used similar dibromobacteriochlorin 19 to directly introduce 
arylamines to the β-positions via Suzuki couplings (Scheme 1-11).59 After the coupling of 
dibromobacteriochlorin 19 with an aryl boronic ester bearing two Boc-protected amines, the Boc 
groups in product 20 were removed, and the free amine quarternized by treatment with CH3I to 
afford the final ammonium-functionalized bacteriochlorin product 21.  
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Scheme 1-11. β-Substituted cationic ammonium bacteriochlorin derivatives prepared by Suzuki coupling, as 
described by the group of Lindsey.59 
Related compounds with terminal amine functional groups, such as 3,13-diaryl 
bacteriochlorin 22, were prepared using similar Suzuki coupling strategies. Bioconjugatable 
derivatives of these compounds carrying an NHS-ester functional group, such as 23, were also 
prepared by a regioselective meso-bromination → Suzuki coupling sequence (see also Section 
2.2.2).59 
The Lindsey group also prepared a range of amphiphilic bacteriochlorins of limited aqueous 
solubility bearing one amine side chain by reductive amination of a β-formylated bacteriochlorin 
(see also Scheme 1-10).60 A representative example is bacteriochlorin 24, which possesses an 
ammonium-terminated dialkyl chain, a so-called swallowtail functionality. This moiety was 
designed to project solubilizing groups above and below the plane of the macrocycle, leading to 
facial encumbrance that inhibits macrocycle stacking and increases hydrophilicity. A similar 
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strategy was used to solubilize meso-aryl porphyrins in organic solvents.61 Other ammonium-
based water-soluble derivatives were also prepared by the Lindsey group by introduction of 
spiro-linked piperidine moieties at the β-positions of a bacteriochlorin.62 The integral 
spiropiperidine functional groups were quarternized using standard conditions to furnish water-
soluble derivatives, such as bacteriochlorin 25. 
 
The direct introduction of ammonium groups using a nucleophilic Senge arylation strategy 
was performed by Anderson and co-workers on 1,15 diaryl porphyrin 26Zn (Scheme 1-12).63 
Porphyrin 26 was functionalized at the meso-position with a Boc-protected amino-phenyl group. 
The resulting derivative 27 was carried through multiple steps to afford porphyrin dimer 28 that 
was rendered water-soluble by quarternization of the amine functionality with CH3I. 
 
Scheme 1-12. meso-Aryl-ammonium bis-acetylene linked porphyrin dimers prepared via Senge arylation, as 
described by the group of Anderson.63  
N
N N
N
H
H
N
N
CH3
CH3
H3C
H3C
H3C
EtO2C
CO2Et
CH3
OMe
25
2 I–
N
N N
N
H
H
24
2 I–
CH3
CH3
H3C
H3C
N
N CH3
H3C CH3
N
H3C
CH3
CH3
N
N N
N
Zn
Ar 26Zn
N
N N
N N
N N
N
ZnZn
Ar
Ar
Ar
Ar
Ar
Ar =
O(CH2CH2O)3CH3
Li N(TMS)2,
1.THF, 0 °C
then H2O
2. DDQ
3. Boc2O, THF
N
N N
N
Zn
Ar
Ar
BocHN NH2H2N
CH3I, DIPEA, DMF
N
N N
N N
N N
N
ZnZn
Ar
Ar
Ar
Ar
NN
2 AcO–
27 28
29
CH3
CH3
CH3
H3C
H3C
H3C
1. Introduction 
 
19 
 
1.4.1.2 Porphyrins Carrying Pyridyl/Pyridinium Groups 
meso-Tetrakispyridiniumporphyrins 
meso-Tetrapyridylporphyrins and the corresponding meso-tetrakis(methylpyridinium)por-
phyrins are long known, and their intercalation into DNA was studied in detail.50 Pyridinium 
porphyrins continue to attract attention as next generation photosensitizers for PDT. Various 
new meso-tetrakispyridiniumporphyrin derivatives were prepared using a range of elecrophiles 
to quarternize the pyridine nitrogens (Scheme 1-13). Orlandi and co-workers prepared meso-
tetrakis(4-pyridinium)porphyrins (31) by reaction of meso-tetra(4-pyridyl)porphyrin (30) with 
various benzyl chlorides to study the effect of polar alkylating groups on their antibacterial 
activity.64 The benzylation conditions required were more vigorous (reflux in DMF for 24 h) than 
typical for pyridine alkylations using alkyl halides. The water-soluble products were recovered by 
precipitation with Et2O and filtration. Similarly, Ghazaryan and co-workers prepared a variety of 
meso-substituted N-substituted tetrapyridiniumporphyrins with different central metals (Ag, Zn, 
Co and Fe) and alkylating agents (allyl-, oxyethyl-, butyl- and methallyl-substituted 
derivatives).65 
 
Scheme 1-13. Quarternization options of meso-tetrakis(4-pyridyl)porphyrin. 
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Fluorinated derivatives of m- or p-linked meso-pyridyl porphyrins were prepared along Adler 
synthesis routes.66 N-Alkylation of the pyridyl substituents by treatment with (CH3)3O+BF4– 
afforded the tetra-alkylated products 32 and 33, respectively as their tetrafluoroborate salts. 
 
In search of dual-action photo- and cyto-toxic anti-cancer agents, various metal complexes 
were coordinated to the outer pyridyl nitrogens in tetrapyridylporphyrins (Scheme 1-14). 
Ruthenium, rhodium and iridium complexes were thus prepared by Therrien and co-workers67 
by treatment of meso-tetrapyridylporphyrin (30) with various metal arene salts to afford the 
water-soluble organic metallic complexes of type 34. They also prepared mixed 
arene-ruthenium substituted porphyrins in a similar manner, producing mono- and 
tetrametallated derivatives of 3- and 4-tetrapyridylporphyrins.68 Both cis- and trans-platin 
conjugates of porphyrins were prepared by treatment of 30 with cis- or trans-Pt(II) complexes, 
respectively.68 The gallium complexes of these compounds (such as 35) were prepared by 
Odani and co-workers69 and also tested as photosensitizers for cancer therapy. In addition, 
tetrapyridylporphyrins with ruthenium nitrosyl groups substituted at their periphery were reported 
by the group of Alessio, generated by reaction of 30 with ruthenium nitrosyls and purified by 
column chromatography (CHCl3/5% EtOH as eluent).70 
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Scheme 1-14. M-Arene complexes of meso-tetra(4-pyridyl)porphyrin, as described by the groups of Therrien,67-68 and 
Odani.69 
A3B and Other meso-Pyridiniumporphyrins 
A number of symmetrically substituted pyridylporphyrins have been prepared in the search 
for the next generation of anticancer PDT agents. However, to further optimize their tumor-
targeting and biodistribution properties, the porphyrin needs to be amenable to further 
modifications that will allow, for example, the conjugation of the porphyrin to a targeting 
molecule. Thus, a variety of examples emerged that use A3B porphyrins bearing three meso-
pyridinium groups as the water-soluble framework of the chromophore, with the fourth meso-aryl 
ring available for further manipulations (Scheme 1-15). The parent A3B porphyrins are typically 
synthesized as statistical mixtures by Adler condensation of pyridylaldehyde, the desired 
arylaldehydes, and pyrrole, followed by chromatographic separation of the product mixture. The 
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A3B porphyrin precursors are functionalized at the remaining meso-aryl group and N-alkylated 
with CH3I, with the order of these operations depending on the functionality present (see below). 
 
Scheme 1-15. A3B tri-pyridyl porphyrins prepared by Adler synthesis and subsequent synthetic modification.  
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derivatives allowed a wide range of functionalizations. For instance, Song et al. synthesized A3B 
pyridyl porphyrin 37j with the fourth aryl group bearing a Pt(II) complex linked to the hydroxyl 
group of the meso-phenol group by a triethylene glycol linker.73 N-Alkylation of the three pyridyl 
groups, followed by Boc-deprotection and complexation with the Pt(II) precursor, yielded the 
A3B platinum-porphyrin conjugate 37j. A similar approach was taken by the group of Alessio to 
synthesize water-soluble 99mTc(I)/Re(I)-porphyrin conjugates, such as 37l, utilizing an amide-
linked spacer between the aryl group and the 99mTc(I)/Re(I) ion.74 The water-soluble derivatives 
were purified by normal phase silica gel column chromategraphy (CH2Cl2/MeOH mixtures). 
These types of compounds can also be conjugated to cancer-targeting peptides for use in 
cancer therapy.75 Cu(II)-based acylhydrazone porphyrin-derivatives 37m and 37n could be 
obtained using a similar strategy.76 The Boyle group synthesized an A3B porphyrin that could be 
further functionalized to establish an azide group.77 The azide functionality was used in a click 
reaction to introduce an 18F-terminated short PEG chain to generate water-soluble porphyrin 
37k for PDT/PET theranostic applications.77 After N-methylation of the pyridyl nitrogens, the 
subsequent synthetic steps required precipitation of the product using Et2O/MeOH mixtures. 
The final products were purified by passing through a column of neutral alumina.  
Gasparyan and co-workers synthesized an A3B amphiphilic trispyridylporphyrin with one 
meso-aryl group carrying a long alkyl chain using a mixed aldehyde Adler condensation.78 Quar-
ternization of the pyridyl groups with 3-bromopropene provided the water-soluble vinyl-
substituted trispyridiniumporphyrins 38 and 38Ag that were isolated by precipitation with 
acetone. 
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Yasuda and co-workers prepared AB3 phosphorus porphyrin 39.79 Its axial chloro-ligands 
could be exchanged for simple alcohols and oligoethylene glycol chains to generate hydrophilic 
phosphorus porphyrins 40 and 41. N-Alkylation of the meso-pyridyl group in 40a-40d or 41 then 
furnished water-soluble derivatives, with solubility in water of around ~10 mM for compounds 
42a-42d and 43. (Scheme 1-16).79 An equivalent methodology was used to introduce axial PEG 
chains.80 
 
Scheme 1-16. Water-soluble AB3 phosphorus porphyrins, as described by the group of Yasuda.79 
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Using a fundamentally different strategy toward meso-pyridyl porphyrins, pyridyl substituents 
can be introduced to meso-brominated porphyrins by using Suzuki couplings. For instance, the 
Lindsey group reported the synthesis of a series of amphiphilic hydroporphyrins prepared by 
Suzuki coupling of a pyridyl boronic ester with meso-bromo-chlorins or bacteriochlorins.40d Key 
chlorin building block 45 was prepared by regioselective meso-bromination of chlorin 44 using 
NBS (Scheme 1-17).81 In the final step of the synthesis, the pyridyl functional group was 
quarternized with CH3I to furnish bacteriochlorin 46. This strategy is flexible and tolerant of a 
number of other substituents on the hydroporphyrin framework. Thus, chlorin 47 and 
bacteriochlorin 48 were prepared along analogous routes. 
 
Scheme 1-17. Amphiphilic meso-pryridyl chlorins and bacteriochlorins, as described by the group of Lindsey.81 
In an analogous manner, Anderson and co-workers employed a Suzuki coupling strategy to 
introduce pyridyl functional groups to meso-dibrominated bis-acetylene linked porphyrin dimer 
49 (Scheme 1-18).63 After coupling with 4-pyridinylboronic acid, both meso-pyridyl functional 
groups in 50 were methylated under standard conditions to afford the dicationic product 51. This 
water-soluble porphyrin dimer was purified by precipitation from DMF/Et2O. 
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Scheme 1-18. Preparation of a meso-pyridinium-functionalized bis-acetylene linked porphyrin dimer, as described by 
the group of Anderson.63 
Other Pyridyl-Substituted Porphyrins 
Porphyrins bearing alkylated pyridinium substituents in positions not directly linked to the 
meso- or β-positions of the macrocycle were also prepared. For example, Marzilli and co-
workers synthesized porphyrins with the pyridyl groups linked through sulfonamide linkages (52) 
to the p-phenyl positions of meso-tetraarylporphyrins.53,82 They investigated whether distant 
pyridinium groups are equally competent in mediating DNA-intercalation. Dipicolylamine (DPA) 
substituents could also be linked through the sulfonamide group (53).83 
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A remarkable octapyridiniumporphyrin 55 was prepared by Prato and co-workers84 by 
treatment of meso-tetrakis(2,6-bis-(bromomethyl)-4-t-butylphenyl) porphyrin 54 with t-butyl 
pyridine (Scheme 1-19). The octapyridyl porphyrin 55 was purified by crystallization from 
Et2O/MeOH. The octacationic compound 55 was used in studies toward assemblies for light-
harvesting applications. 
 
Scheme 1-19. An octapyridiniumporphyrin, as described by the group of Prato.84 
The introduction of pyridinium groups can also be achieved by esterification of a β-alkylester 
with a suitable pyridine-derivatized alcohol. Thus, cationic water-soluble ester 56 was prepared 
from chlorin e6 (11) by esterification with 2-(2-hydroxyethyl)pyridine, followed by quarternization 
with CH3I (cf. Scheme 1-9).56 Derivatives 56 and related 13 possess sharp absorbance spectra 
in Tris-HCl buffer at pH 7.6, indicating little aggregation of the chromophores. 
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Pyridinium substituents have also been introduced in the axial positions of phosphorus and 
antimony meso-tetraphenyl porphyrins by axial exchange using a pyridine-derivatized alcohol 
(cf. to Scheme 1-16).79,85 Alkylation of the axial pyridyl moiety with a range of alkyl bromides 
furnished derivatives such as 57, with a water-solubility of ~3 mM.79 
meso-Imidazolium Porphyrins 
The synthesis of porphyrins carrying N-alkylated meso-imidazolyl functionalities represents 
another strategy for the preparation of cationic porphyrins.86 Lindsey and co-workers prepared 
porphyrins with one or two meso-imidazolyl groups by starting from imidazole-functionalized 
dipyrromethane precursors.87 Mono-imidazolyl porphyrin 58 was alkylated with various 
alkylating reagents. The resulting imidazolium porphyrins were studied for their use in 
photodynamic therapy. The zwitterionic imidazolium sulfonate porphyrin 60Zn, for example, is 
the product obtained when 1,4-butane sultone was used as the alkylating reagent (Scheme 
1-20).87a 
 
Scheme 1-20. meso-Imidazolium porphyrins, as described by the groups of Lindsey and Hamblin.87 
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1.4.2 Water-Soluble Porphyrins Bearing Anionic Substituents 
1.4.2.1 Porphyrins with Carboxylate Functional Groups 
Many naturally occurring porphyrins contain acetic acid or propionic acid side chains.88 With 
increasing number of acid side chains, their solubility in aqueous solution increases, with the 
uroporphyrins being freely soluble, particularly in solutions of basic pH (Scheme 1-21).88  
 
Scheme 1-21. Increasing water-solubility of the naturally occurring porphyrins with increasing number of carboxylic 
acid functionalities. 
This suggests that the introduction of carboxylic acid functional groups to the periphery of 
porphyrins might be an effective way of furnishing water-soluble derivatives. This is, in fact, also 
observed. To simplify the purification of the porphyrins, the carboxylate groups are often 
masked throughout the synthesis as esters and are revealed by saponification in the final step. 
meso-Tetrakis(4-carboxyphenyl)porphyrin, and its tetraester, are well known, and readily 
synthesized by condensation of the corresponding aldehydes with pyrrole.89 They are also 
commercially available.52 Carboxylate groups may also be introduced to the porphyrin by 
starting with more elaborate building blocks containing esters. Classic carboxylated meso-aryl 
porphyrins, such as meso-tetrakis(4-carboxyphenyl)porphyrin, have been prepared by Adler 
synthesis with ester-substituted benzaldehydes followed by saponification of the esters.42 
Tetracarboxylated palladium porphyrin 62 was prepared by this approach (Scheme 1-22).90 
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Scheme 1-22. Carboxylated meso-aryl porphyrins, as described by the group of Skondra.90 
An introduction of esters to the β-positions of a porphyrin from ester-substituted building 
blocks is also possible, as illustrated by the synthesis of carboxylated benzoporphyrins starting 
from an ester-functionalized isoindole (Scheme 1-23).91 A retro-Diels-Alder reaction of 63 with 
concomitant saponification of the methyl esters afforded octacarboxylate 64. Protonation 
provided the octaacid 65 that also precipitated under these conditions. The water-solubility of 
the sodium salt 64 was determined to be 0.111 M.91 
 
Scheme 1-23. Carboxylated benzoporphyrins, as described by the group of Sugimoto.91 
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Water-soluble acetylene-linked bis(imidazolylporphyrins) were prepared from starting 
materials bearing protected acid functionalities. Thus, ester-functionalized aldehyde and 
dipyrromethane were condensed and oxidized to synthesize porphyrin 66 bearing ester-
terminated alkyl chains in the meso-positions. The ester moieties were carried through the 
entire synthesis of the porphyrin dimer, and the carboxylates were only deprotected in the last 
step (Scheme 1-24).92 Using this strategy, bulky bis(carboxylethyl)methyl substituents could 
also be introduced to the meso-positions early in the synthesis to furnish dimers of type 68 and 
trimers of type 69, which showed less aggregation in water.93 
 
Scheme 1-24. Porphyrin dimers and trimers bearing carboxylate groups in the meso-positions, as described by the 
group of Kobuke.92-93 
Lindsey and co-workers prepared carboxylated trans-AB porphyrins using a 2+2 
dipyrromethane condensation strategy, using dipyrromethane 70 carrying a protected 2,4,6-
triester-subsituted meso-phenyl group (Scheme 1-25).94 The condensation of 70 and 
counterpart 71 in the presence of zinc afforded the zinc-porphyrin triester 72, which could be 
saponified and protonated to afford the tricarboxylic acid 73a. Along an analogous route, trans-
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AB porphyrins 73b and 73c bearing bioconjugatable groups at the meso-position opposite the 
solubilizing groups were prepared. 
 
Scheme 1-25. Carboxylated trans-AB porphyrins, as described by the group of Lindsey.94 
To maximize the number of carboxylic acid groups introduced, carboxylic acid ester-
terminated dendritic components can be utilized, often bound to the porphyrin through amide 
linkages. For instance, treatment of tetrarylporphyrin acid chloride 74 with dimethyl 
iminodiacetate or its second generation dendrimer analogue, followed by saponfication of the 
esters, afforded the polyacid porphyrins 75a or 75b, respectively (Scheme 1-26).95 They were 
purified by precipitation and filtration. 
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Scheme 1-26. Dendritic carboxylated porphyrins, as described by the group of Mukhtar.95 
meso-Tetrakis(4-hydroxyphenyl)porphyrin (76) is a versatile starting material for the 
synthesis of hydrophilic derivatives since the p-phenolic oxygens can react with a variety of 
solubilizing groups. A4-Porphyrin 76 is synthesized through the Adler procedure, generally as its 
4-methoxy derivative, that can be purified and handled easily. It is subsequently deprotected 
using BBr331e (see also below, Scheme 1-28 and Scheme 1-52). 
Using tetraphenol 76, Chen and co-workers also synthesized porphyrins bearing dendritic 
carboxylate groups, albeit their synthesis was less convergent than that of Mukhtar and co-
workers,96 since the dendrimer generations were built up on the porphyrin core. Thus, 76 was 
converted to polyamine-derivatized porphyrin 77 in three steps. Reaction of the amines in 77 
with bromoacetic acid ethyl ester provided the protected porphyrin 78; hydrolysis with TFA gave 
the free acid 79 (Scheme 1-27)96 that was isolated by precipitation (addition of a MeOH solution 
of 79 to Et2O).  
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Scheme 1-27. Dendritic polycarboxylated porphyrins, as described by the group of Chen.96 
Alkylation strategies have also been employed for the introduction of carboxylates. For 
instance, various carboxylated core-modified porphyrins were prepared by O-alkylation of the 
phenolic oxygens of a meso-4-hydroxyphenyl-substituted core-modified dithiaporphyrin. Like 
their aza-analogues, the requisite core-modified porphyrins were synthesized with a methyl-
ether protecting group in the p-position of one or more phenyl groups and deprotected using the 
standard BBr3 method. The phenolic oxygens were then alkylated with ethylbromoacetate. 
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Saponification of the installed esters furnished the dithiaporphyrin 81 bearing carboxylic acid 
functional groups (Scheme 1-28).97 
 
Scheme 1-28. Core-modified carboxylated porphyrin, as described by the group of Detty.97 
Prato and co-workers also used an alkylation strategy to synthesize octacarboxylated 
porphyrin 84, starting from a tetrabromomethyl-substituted porphyrin. Alkylation of porphyrin 82 
with diethyl malonate afforded the tetramalonic ester-derivatized porphyrin 83, which was 
saponified to free the eight carboxylate moieties (Scheme 1-29).84 Octacarboxylate 84 
precipitated under the saponification conditions and was isolated by filtration to afford the pure 
product. 
 
Scheme 1-29. Octacarboxylated porphyrin 84, as described by the group of Prato.84 
Carboxyphenyl substituents can also be directly introduced to the meso-positions of 
synthetic chlorins and bacteriochlorins by Suzuki coupling of suitable meso-bromo-substituted 
N
SN
S
OCH3
OCH3
H3CO
OCH3
1. BBr3, CH2Cl2
2. K2CO3, Acetone
3. NaOH/ THF
OEt
O
Br
N
SN
S
O
O
O
80 81
CO2H
CO2H
O
CO2H
HO2C
N
N N
N
Zn
O
O
R
R
R
OR
O
O
R
R
O
O
RO
R
N
N N
N
Zn
Br
Br
Br
Br
EtO OEt
OO
KH, DMF
NaOH, EtOH83: R = OEt84: R = O–Na+
,
82
1. Introduction 
 
36 
 
porphyrins with boronic esters derived from benzoic acid. Using the same Suzuki coupling 
approach that was used to introduce pyridyl substituents to the meso-position (cf. Scheme 
1-17), chlorins 85, 86 and the bacteriochlorin 87 were prepared.81 The carboxylate functionality 
was introduced in the free acid form, eliminating the need for the utilization of protecting groups. 
 
Starting from meso-brominated precursors, the group of Anderson used a Sonogashira 
coupling strategy to functionalize the meso-positions of a PEGylated porphyrin dimer with 
carboxylate groups. meso-Dibromoporphyrin dimer 49 was coupled with 5-ethynyl-1,3-
benzenedicarboxylic acid to form the tetracarboxylated water-soluble porphyrin dimer 88 
(Scheme 1-30).63 Again, it is noteworthy that the acid functionality was introduced in 
unprotected form.  
 
Scheme 1-30. Carboxylated bis-acetylene linked porphyrin dimers, as described by the group of Anderson.63 dba = 
dibenzylacetone. 
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carboxylates.98 Thus, β-dibromoporphyrin 89 was functionalized using the boronic ester of the t-
butyl ester-protected 3,5-carboxyphenyl substituents (Scheme 1-31). The protecting groups 
were removed at the last step of the synthesis by acid treatment. Furthermore, the option for 
bioconjugation was demonstrated in these systems by Suzuki coupling of a meso-
bromobacteriochlorin, generated by regioselective bromination of the parent bacteriochlorin, to 
produce hydrophilic tetracarboxylbacteriochlorin 94.98 
 
Scheme 1-31. Tetracarboxybacteriochlorins, as described by the group of Lindsey.98 
1.4.2.2 Sulfonated Porphyrins 
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arylporphyrins.42 A number of sulfonated A4 porphyrins were prepared by direct sulfonation 
methods42 and are commercially available.52 However, this solubilization strategy has draw-
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sulfonation readily leads to the solubilization of porphyrins in aqueous media. Interestingly, the 
porphyrin is protonated during the sulfonation step and is thus protected by the dicationic 
charge from getting sulfonated at the β-positions.100 
One particular challenge faced by using sulfonation procedures is the incorporation of other 
functional groups since they may be incompatible with the harsh sulfonation conditions. The 
sulfonation step is often employed directly after porphyrin formation; then, subsequent 
modification of the porphyrin is performed. The drawback of this strategy is the difficulty in 
handling and purification of the sulfonated porphyrins. 
Despite these disadvantages, the traditional direct sulfonation method was employed by 
Pillai and co-workers to regioselectively introduce sulfonate groups to the meso-p-phenyl 
positions of N-confused porphyrins (Scheme 1-32).101 Sulfonation of N-confused porphyrin 95 
by treatment with H2SO4 at elevated temperature over several hours afforded tetrasulfonated 
porphyrin 96 that was tested as a photosensitizer for PDT.101 The product was purified by 
precipitation and continuous Soxhlet extraction with MeOH. No further functionalizations of this 
porphyrin derivative were reported. 
 
Scheme 1-32. Sulfonated N-confused porphyrin, as described by the group of Pillai.101 
Likewise, asymmetric meso-aryl porphyrins were also subjected to sulfonation reactions. For 
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condensation, could be trisulfonated using oleum at 80 °C.102 The pure product was obtained by 
precipitation and centrifugation after neutralization of the acid. The pyridyl moiety could then be 
functionalized with a platinum complex for study as a tumor targeting photosensitizer. The 
Lippard group prepared the A3B porphyrin meso-trisphenyl-(2,6-nitrophenyl)porphyrin 97 
(Scheme 1-33). Reduction of the nitro group afforded 2,6-diaminophenyl porphyrin 98 that was 
subjected to sulfonation. The water-soluble product 99 was purified and isolated by reverse 
phase chromatography (RP-18). The purified free amine could then be functionalized with DPA 
for its use as a Zn2+ chemosensor.103 Furthermore, the manganese complex of 100 was 
prepared and used as a dual function contrast agent for the fluorescence imaging of Zn2 and 
MRI in biological contexts.103 
 
Scheme 1-33. Sulfonated A3B porphyrin bearing DPA substituents for fluorescence sensing of Zn2+, as described by 
the group of Lippard.103 
As the previous examples have shown, some functionalities tolerate the sulfonation 
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porphyrin 101. The three phenyl substituents could be sulfonated by treatment with H2SO4 with 
retention of the isoindoline nitroxide (Scheme 1-34); albeit the yield for the water-soluble final 
product 102 was low (~ 30%).104 
 
Scheme 1-34. Sulfonated isoindoline nitroxide-functionalized A3B porphyrin, as described by the group of Yang.104 
A chlorosulfonation method has been used for the introduction of sulfonic acid groups to a 
number of halogenated meso-aryl porphyrins by the group of Wyatt and co-workers (Scheme 
1-35).105 Treatment of chlorinated porphyrin 103, for example, with chlorosulfonic acid afforded 
chlorosulfonation product 104 that was hydrolyzed by suspension in H2O to provide the 
corresponding sulfonic acid product 105. Alternatively, the chlorosulfonate could be converted to 
sulfonamide derivatives by reaction with amines.105 The corresponding chlorin and 
bacteriochlorin 106 and 107, respectively, were made by diimide reduction of sulfonated 
porphyrin 105, and were tested as photosensitizers for the PDT of tumors (Scheme 1-35).106  
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Scheme 1-35. Chlorosulfonated porphyrins and their hydrolysis and reduction products, as described by the group of 
Wyatt.105 DBO = 1,4-diazobicyclo[2.2.2]octane. 
The attachment of sulfonated groups to the β-positions of a tetrapyrrolic macrocycle is an 
alternative method toward the generation of hydrophilic sulfonated derivatives. This approach 
was applied to the generation of alkylsulfonated bacteriochlorins.107 For example, sulfonated 
bacteriochlorophyll derivatives were prepared by reaction of Pd-bacteriopheophorbide (108) 
with homotaurine (Scheme 1-36).107 Treatment of either 109 or the sulfo-NHS ester 110 with a 
second equivalent of homotaurine also yielded the bis-sulfonated product 111 (with the trisulfo-
nated compound arising from imine formation with the β-acetyl group as a minor product). 
Bacteriochlorin 112M could also prepared using a similar procedure using taurine as the 
nucleophile. All the sulfonated derivatives were found to possess high solubility in water (up to 
40 mg/mL).108 The products were either purified by HPLC (MeOH/phosphate-buffer solvent 
systems) or by silica gel chromatography (4:1 CHCl3:MeOH). 
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Scheme 1-36. Sulfonated Pd-bacteriopheophorbide, as described by the group of Scherz.108 EDC = 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide. 
Sulfonate functionalities may also be introduced at a late stage in the porphyrin synthesis by 
transition metal-mediated cross-coupling strategies. For instance, Anderson and co-workers 
introduced sulfonate groups to the meso-positions of a meso-brominated PEGylated conjugated 
porphyrin dimer using a Suzuki coupling with a sulfonated arylboronic acid, a strategy similar to 
the introduction of pyridine functionalities described above (cf. Scheme 1-18).63 The tetra-
sulfonated porphyrin dimer 113 was purified using semi-preparative reverse-phase HPLC. 
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1.4.2.3 Porphyrins With Phosphate/Phosphonate Functional Groups 
The introduction of alkylphosphonate functional groups to the periphery of a porphyrin is 
another strategy to impart hydrophilicity to porphyrins and hydroporphyrins. Phosphate groups 
have also been employed, but because of the increased hydrolytic lability of the phosphate 
group, only rarely. Alkyl phosphonates have been introduced to the porphyrin by modification of 
a porphyrin or by the synthesis of the porphyrin macrocycle with protected phosphonate/phos-
phate or alcohol building blocks. Deprotection and subsequent modification of the porphyrin 
furnished the water-soluble phosphonated derivatives.  
One of the first examples of porphyrins bearing phosphonate groups was introduced by the 
Montforts group.109 They prepared water-soluble metalloporphyrins by phosphonation of the 
primary alkyl alcohols in deuteroporphyrin derivative 114M (Scheme 1-37).109 Their strategy 
involved the conversion of the alcohols in 114M to brominated derivative 115M, followed by 
reaction with P(OSiMe3)3, and subsequent hydrolysis of the intermediate with MeOH/H2O to 
afford phosphonate 116M. The free phosphonate functional groups were used to attach these 
derivatives to electrode surfaces.109 Using a similar strategy, diphosphonated chlorin derivatives 
rac-117 and rac-118 were also prepared (Scheme 1-37). 
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Scheme 1-37. Phosphonated β-alkyl porphyrin derivatives, as described the group of Montforts.109 
 
Scheme 1-38. trans-AB Porphyrins bearing swallowtail phosphonate motifs, as described by the group of Lindsey.110 
While the requisite alkyl alcohols for phosphonation in 114M were generated by functional 
group manipulation of the propionic acid side chains present in the natural product precursors, 
the requisite alcohols can also be introduced (in free or protected form) at the porphyrin 
synthesis stage. For instance, Lindsey and co-workers prepared trans-AB porphyrin 119 by 
N
N N
N
CH3
OHHO
H3C
H3C CH3
M
1. TsCl, NEt3, 
CH2Cl2, 0 °C
2. KBr, 
18-crown-6,
 acetone
N
N N
N
CH3
BrBr
H3C
H3C CH3
M
1. P(OSiMe3)3,
Δ
2. MeOH/H2O N
N N
N
CH3
PO(OH)2(HO)2OP
H3C
H3C CH3
M
114M
deuteroporphyrin
M = 2H, Ni, Zn
115M 116M
N
N N
N
H3C
PO(OH)2(HO)2OP
H3C
H3C CH3
Ni
CON(CH3)2
CH3
rac-118
N
NN
N
(HO)2OP PO(OH)2
CH3H3C
Ni
(H3C)2NOC
rac-117
CH3
H3C
CH3
NN
N N
Zn
R
TBDMSO OTBDMS
1. TBAF, THF
2. Zn(OAc)2, CH2Cl2
3. CBr4, PPh3, CH2Cl2
4. P(OCH3)3, Ar, Δ
119a: R = OCH2CO2tBu
119b: R = Br
NN
N N
R
(H3CO)2OP
H
H
120a: R = OCH2CO2tBu
120b: R = Br
NN
N N
R
M
1. TMS-Br, CHCl3, Ar
2. dil aq. NaOH
121a: R = CH2CO2H
121b: R = Br
PO(OCH3)2 (HO)2OP PO(OH)2
NN
N N
(HO)2OP
R
121c: R = NH2
121d: R = NHCOCH3
121e: R = NHCOCH2I
PO(OH)2
H
H
1. Introduction 
 
45 
 
using a dipyrromethane precursor bearing two t-butyldimethylsilyl (TBDMS) protected hydroxyl 
groups (Scheme 1-38).110a After removal of the protecting groups, the hydroxyl groups could be 
derivatized in a similar manner as described by Montforts109 to provide the protected 
phosphonate ester 120. Ester hydrolysis revealed the free phosphonate groups, conferring 
water-solubility. The corresponding zinc complexes were also prepared.  
Along analogous pathways, trans-AB porphyrins bearing amino (121c), acetamido (121d), 
and iodoacetamido (121e) bioconjugatable tethers at the meso-phenyl position opposite the 
solubilizing group also became accessible (Scheme 1-38).110b This approach is suitable for the 
synthesis of phosphonated chlorins, synthesized by using dipyrromethane building block 123, 
bearing two protected alcohols (Scheme 1-39).110b After condensation of 122 and 123, the 
benzyl ether protecting groups in 124 were removed, and the alcohols were brominated and 
phosphonated. The phosphonate ester was then treated with TMS-Br to furnish the free 
phosphonates 125.  
 
Scheme 1-39. Synthetic chlorins bearing phosphonate swallowtail motifs, as described by the group of Lindsey.111  
Lindsey and co-workers also prepared trans-AB porphyrins incorporating phosphate groups, 
though in this instance they started with a dipyrromethane precursor already bearing phosphate 
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esters (Scheme 1-40).110a In the last steps, the protected phosphate groups were subjected to 
hydrolysis to afford the free phosphate groups.  
 
Scheme 1-40. trans-AB porphyrins bearing phosphate swallowtail motifs, as described by the group of Lindsey.110a 
Phosphonate groups can also be introduced to the porphyrin by starting with 
dipyrromethane precursors bearing protected phosphonate functional groups. Using this 
strategy, trans-AB porphyrin 130 was synthesized by condensation using a dipyrromethane 
precursor carrying a 2,6-diphosphonated aryl ring that projects the solubilizing groups above 
and below the plane of the macrocycle target (cf. Scheme 1-40).112 Hydrolysis of the phospho-
nate esters and saponification affords the trans-AB porphyrin bearing both the phosphonate 
solubilization groups and a carboxylic acid bioconjugatable tether. Using a similar strategy as for 
chlorin 125, this 2,6-aryl-phosphonate motif was also incorporated into chlorin 131.111 Again, the 
Suzuki coupling strategy of β-dibromobacteriochlorins proved versatile enough to be applicable 
to the introduction of β-aryl-phosphonate groups (cf. Scheme 1-11). Lindsey and co-workers 
coupled two aryl-diposphonate esters by a Suzuki coupling strategy to afford, after hydrolysis of 
the phosphonate esters, water-soluble bacteriochlorin 132. 
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1.4.3 Water-Soluble Porphyrins with Neutral Groups 
1.4.3.1 PEGylated porphyrins  
PEGylation has emerged as a strategy for the preparation of neutral water-soluble 
porphyrins and hydroporphyrins. It has many benefits over traditional means using ionic groups. 
For instance, PEGylation strategies are more flexible with respect to where in the synthetic 
sequence they are introduced. This is because the PEG functional group is not very reactive 
once installed. Unwanted reactivity to form oligomeric species is also suppressed by using 
heterobifunctional PEG chains, in which one end of the PEG chain often has a methyl cap. 
PEGylated porphyrins are also much more amenable to traditional aqueous work-up conditions, 
as they may partition favorably in organic solvents such as CH2Cl2 and EtOAc.113 Often times 
PEGylated porphyrins can be purified by normal silica-gel chromatography.31e,114 
Porphyrinoid Macrocycle Total Synthesis Using PEGylated Building Blocks 
Despite these advantages, the multistep manipulation of porphyrins with PEG-groups 
present throughout the synthesis is relatively rare. For instance, Brunner and co-workers 
presented such an example. They synthesized the A3B porphyrin 133 by mixed condensation of 
two arylaldehydes and pyrrole, with one of the aryl aldehydes carrying a PEG chain (n = 2, 3 or 
17) (Scheme 1-41).115 The resulting A3B PEGylated porphyrins 133a-133c were purified using 
ordinary silica gel chromatography (CH2Cl2/MeOH mixtures). 
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Scheme 1-41. A3B porphyrin carrying three short PEG chains, as described by the group of Brunner.115 
Another example for the early introduction of PEGylated building blocks was reported by the 
Anderson group.63 Using a PEGylated benzaldehyde, porphyrin 26 bearing two methyl-capped 
tetraethylene glycol (TEG) groups on opposite meso-phenylgroups was prepared. Leaving the 
PEG chains intact, it was converted to the bis-acetylene linked porphyrin dimer 134. Porphyrin 
dimer 134 was found not to be sufficiently soluble in aqueous media for biological application. 
Therefore, these materials were further derivatized with additional solubilizing groups, all while 
the PEG functional groups remained intact (Scheme 1-42).63 
Starting from meso-dibromo dimer 49, cationic (pyridinium; cf. Scheme 1-18), anionic 
(sulfonate) and carboxlyate (cf. Scheme 1-30) groups were introduced using either Suzuki or 
Sonogashira coupling strategies. The Senge-arylation method was also used to introduce 
ammonium and pyridyl solubilizing groups (cf. Scheme 1-12). The dimers were separated by 
either recrystallization (DMF, Et2O) or by semi-preparative reverse phase HPLC. Due to 
insufficient solubility of the compounds in regular reverse-phase HPLC solvents (such as 
CH3CN, MeOH, water), DMF, DMSO, or THF were used. Also due to solubility issues, the 
authors could not measure logP values for these compounds in octanol:water. However, they 
did compare the relative polarity of some derivatives by means of their retention times under 
reverse-phase HPLC conditions (Table 1-1). 
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Table 1-1. Comparison of the retention times of hydrophilic porphyrin dimers63 
Porphyrin dimer Retention time/min 
51 6.2 
29 6.8 
135 7.6 
136 15.6 
88 18.0 
HPLC Conditions: C8 column (5 µm, 3.9 × 150 mm) , 1 mL/ min flow rate, solvent A: 1% aqueous 
acetic acid, solvent B: THF, linear gradient 
 
 
Scheme 1-42. Hydrophilic bis-acetylene linked porphyrin dimers carrying PEG chains and various other solubilizing 
motifs, as described by the group of Anderson.63 
PEG-substituted dipyrromethanes also found use in the early introduction of solubilizing 
groups. The Lindsey group was able to synthesize chlorins from a PEGylated dipyrromethane 
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precursor (Scheme 1-43).113b This strategy also incorporated a bioconjugatable tether at another 
meso-position, the precursor of which was also introduced at the dipyrromethane stage. 
 
Scheme 1-43. PEGylated synthetic chlorins using PEGylated building blocks, as described by the group of 
Lindsey.113b 
PEGylation of meso-aryl Porphyrins 
A number of meso-tetrarylporphyrins bearing PEG groups have been synthesized by 
PEGylation of porphyrins incorporating suitable linker functionalities on the aryl groups. These 
porphyrins are usually prepared via Adler or Lindsey methods, and the PEG groups can be 
linked by various methods, including etherification, amidation or esterification reactions. 
Particularly popular linking groups for the PEGylation of porphyrins are meso-phenol 
substituents. PEGylation of various meso-tetrahydroxyphenyl porphyrin derivatives with a 
suitably functionalized PEG precursor yields water-soluble porphyrins, with activation of the 
PEG group often required. 
For example, meso-tetrakis(3-hydroxyphenyl)chlorin (141) was rendered water-soluble by 
introducing PEG groups through two different etherification strategies. Tetraphenolporphyrin 
141 was treated with methoxypolyethylene glycol-p-nitrophenylcarbonate or cyanuric chloride-
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activated methoxypolyethyleneglycol to afford the water-soluble PEGylated porphyrins 142 or 
143, respectively (Scheme 1-44. PEGylated derivatives of meso-tetrakis(3-
hydroxyphenyl)chlorin, as described by the group of Sinn.116).116 
 
Scheme 1-44. PEGylated derivatives of meso-tetrakis(3-hydroxyphenyl)chlorin, as described by the group of Sinn.116 
meso-Tetrakis(4-hydroxyphenyl)porphyrin (76) can also be alkylated using various activated 
PEGs. For instance, this procedure has been employed to alkylate 76 by treatment with PEG-
mesylates to form 144. (Scheme 1-45).114a Under similar conditions, single PEG chains or PEG-
dendrimers (Scheme 1-46)117 can also be introduced into asymmetric meso-hydroxyphenyl-
porphyrins.118 Vitalini and co-workers prepared PEGylated derivatives of 76 by alkylation of the 
phenolic oxygens with a chlorinated PEG.119 The PEG-functionalized porphyrins could be 
purified by adding a solution of the compound in CH2Cl2 to a cold solution of Et2O to induce 
precipitation (for larger PEGs);114a,118a porphyrins bearing smaller PEG-chains could also be 
purified by column chromatography (CH2Cl2-acetone-MeOH or CH2Cl2/EtOH mixtures).114a,117 
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Scheme 1-45. PEGylated derivatives of meso-tetra(4-hydroxyphenyl)porphyrin, as described by the group of 
Pozzi.114a 
 
Scheme 1-46. Amphiphilic porphyrin with a PEG-dendrimer, as described by the group of Dumoulin.117 
PEGylation of meso-arylporphyrins was also achieved by inversion of the Williamson ether 
synthesis reaction partners, i.e., involving a halogenated porphyrin precursors and PEGs 
bearing a free alcohol. An example is the PEGylation of tetra(p-bromomethylphenyl)porphyrin 
(147) with a methyl-capped PEG alcohol (Mn = 550) that afforded the tetra-PEGylated porphyrin 
148 as the main product, along with partially PEGylated porphyrins (Scheme 1-47). The 
porphyrin starting material was prepared by Lindsey porphyrin synthesis from 4-(bromomethyl)-
benzaldehyde and pyrrole.120 The PEGylated products were amenable to aqueous work-up 
(extraction with CH2Cl2) and were purified by HPLC. 
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Scheme 1-47. PEGylated meso-aryl porphyrins by benzylation of a PEG with tetra(p-bromomethylphenyl)porphyrin, 
as described by the group of Lee.120 
meso-Aryl porphyrins bearing peripheral carboxylic acid functional groups can be PEGylated 
by amide formation using an amine-terminated PEG. For instance, Scolaro and co-workers 
prepared PEGylated derivatives of meso-tetrakis(4-carboxyphenyl)porphyrin (149) by treatment 
with Jeffamine M-600 (n = 7-9) (Scheme 1-48).121  
 
Scheme 1-48. PEGylated porphyrins derived from meso-tetrakis(4-carboxyphenyl)porphyrin using a PEG-amine, as 
described by the group of Scolaro.121 
Also starting from tetraacid 149, Lovell and co-workers reacted it with a variety of homobi-
functional PEG-diamines (average Mw ranging from 150 Da to 10 kDa) to synthesize a PEG-
linked porphyrin mesh 151.122 This reaction illustrates the complex cross-linked structure formed 
when using PEGs capable of reacting at both ends. The porphyrin-PEG-mesh was purified by 
dialysis, followed by addition of citric acid to precipitate unreacted porphyrin. 
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PEGylated porphyrins and hydroporphyrins with amide linkages can also be prepared 
starting with aminophenyl porphyrins. For instance, Peng et al. functionalized a chlorin with a 
poly(ε-caprolactone)-polyethyleneglycol) diblock copolymer.123 Introduction of the PEG-polymer 
was achieved by treatment of meso-tetrakis(4-aminophenyl)chlorin with the acid-chloride of the 
diblock copolymer. The polymer-functionalized porphyrin was purifed by precipitation with Et2O, 
followed by a dialysis step in acetone. Vicente and co-workers prepared water-soluble 
porphyrin-peptide conjugates with a PEG linker on one meso-aryl group starting from an AB3 
porphyrin 152 bearing one p-aminophenyl group. The amine functionality in 152 was reacted 
with diglycolic anhydride, followed by amidecoupling using a PEG-amine and Boc-deprotection 
(Scheme 1-49). A peptidyl resin can be coupled to the hydroxybenzotriazole (HOBt) ester of the 
porphyrin 154.124 More hydrophilic PEGylated A3B porphyrins bearing three carboxyphenyl 
groups were also prepared in a similar manner.124 
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Scheme 1-49. PEGylated AB3 porphyrin with carboxylic acid bioconjugation handle, as described by the group of 
Vicente.124  
Oligoethylene glycol amide-linkages have also been utilized as hydrophilic spacers in 
instances that require designed structures on the periphery of a hydrophilic porphyrin. Using this 
strategy, Alessio and co-workers have prepared ruthenium-porphyrin conjugates with oligo-
ethylene glycol spacers.125 This methodology has also been used to develop Rhenium (I)-
porphyrin conjugates in a similar manner.126 Lastly, PEGylation of meso-hydroxyphenyl-
porphyrins can be achieved utilizing ester linkages. Thus, Diederich and co-workers prepared 
dendritic porphyrin 156 by esterification of porphyrin tetraol 155 (Scheme 1-50).127 
 
Scheme 1-50. Porphyrin-PEG dendrimer conjugates, as described by the group of Diederich.127 TMAD = N,N,N’,N’-
tetramethylazodicarboxamide. 
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The extension of the reactive alcohol site from the phenolic position using an alkyl chain was 
employed to accomodate the bulky PEG-dendrimer substituents. The resulting porphyrin-
dendrimers were purified by preparative gel permeation chromatography and were soluble in 
phosphate buffer at pH 7. Alternatively, the PEGylation of a meso-hydroxphenyl A2B2 porphyrin 
by DCC/DMAP-mediated esterification with a PEG-carboxylic acid (1000 Da) was reported 
(Scheme 1-51).128 
 
Scheme 1-51. PEGylated A2B2 porphyrin, as described by the group of Nawaz.128 DCC = dicyclohexylcarbodiimide, 
DMAP = 4-dimethylaminopyridine. 
π-Extended porphyrin derivatives may also be subject to the same PEGylation strategies as 
seen for regular porphyrins. For instance, PEGylation of the phenolic oxygens in quinoline-
annulated porphyrin 160 was reported by Luciano et al. (Scheme 1-52)31e using a similar O-
alkylation method as described for regular porphyrins (Scheme 1-45).  
Precursor porphyrin 159 was prepared from meso-tetrakis(4-methoxyphenyl)porphyrin. A 
BBr3-mediated deprotection was employed to deprotect the phenolic oxygens as the 
penultimate step of the synthesis. The phenol could then be PEGylated using either a short (n = 
4) or long chain (avg. MW 550, n ≈ 12) PEG-mesylate.31e The short PEG chain derivative 161a 
was found to be only slightly soluble in water. However, the derivative bearing long PEGs 
(161b) was soluble in PBS to form ~ 30 mM solutions and was used as photoacoustic imaging 
contrast agents for in vivo imaging of tumors in a mouse model.31e 
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Scheme 1-52. PEGylated quinoline-annulated porphyrins, as described by the group of Brückner.31e 
Brückner and co-workers were able to take advantage of the well-known SNAr reactivity of 
meso-pentafluorophenylporphyrins toward nucleophiles at the p-F positions to introduce PEG 
groups to pyrrole-modified porphyrins (PMPs) at a late stage of the synthetic sequence toward 
meso-arylmetalloporpholactones114b,114c,129 (Scheme 1-53). This allowed the preparation of a 
variety of PEGylated porpholactone metal complexes (163M) that were used as optical high pH 
or cyanide sensors in water.114c The PEGylated derivatives were purified by silica gel 
chromatography (CH2Cl2/5% MeOH). Similarly, thiol-functionalized sugars were introduced into 
meso-pentafluorophenylporphyrins using the SNAr reaction, also resulting in their solubilization 
in aqueous solutions.130 
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Scheme 1-53. PEGylated porpholactone derived from meso-tetrakis(pentafluorophenyl)porphyrin derivatives, as 
described by the group of Brückner.114c 
Building on previous efforts for the solubilization of antimony porphyrins by axial ligand 
exchange with alcohols (cf. Scheme 1-16), Yasuda and co-workers prepared hydrophilic 
PEGylated phosphorus porphyrins, such as tetraphenylporphyrin derivative 164, by introduction 
of short PEGs as axial ligands. Incorporation of the axial-PEGs furnished highly water-soluble 
derivatives. Porphyrin 164, for example, has a water-solubility of 17.3 mM.80  
 
Porphyrins PEGylated at their  β-Positions 
A number of PEGylated β-alkyl-porphyrins and chlorins were prepared. Representative of 
these are a number of PEGylated chlorin e6 derivatives, prepared first by Hamblin et al.131 The 
PEGylation increased tumor targeting of the photosensitizer. Mono-(165a), di-(165b), and tri-
(165c) PEGylated derivatives of chlorin e6 were also prepared in which the PEG groups were 
introduced by esterification at one to three of its carboxylic acids using a short methyl-capped 
PEG (Scheme 1-54).132 Longer reaction times were needed to increase the yield of the tri-
PEGylated product 165c. The authors also measured the solubility of the compounds to be 1.8 
± 1.3 mM for 11, 2.3 ± 1.0 mM for 165a, 3.3 ± 0.9 mM for 165b, and 3.9 ± 0.8 mM for 165c in 
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1% (v/v) DMSO/water, indicating the increased aqueous solubility with the increase of the 
number of PEG chains. 
 
Scheme 1-54. PEGylated derivatives of chlorin e6, as described by the group of Greer.132 EDC = 1-ethyl3-(3-
dimethylaminopropyl)carbodiimide,  
The propionic side chains in protoporphyrin 166 could be functionalized with PEG-chains 
through amide linkages, whereby a short diamine established the requisite amine linkage sites. 
Amine intermediate 167 was then reacted with succinimidyl-PEG5000 to afford the water-soluble 
PEGylated protoporphyrin derivative 168 (Scheme 1-55), and its zinc complex.133 
 
Scheme 1-55. PEGylated protoporphyrin and its zinc complex, as described by the group of Maeda.133a 
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Other PEGylated porphyrins were prepared using ether linkages. For example, brominated 
hematoporphyrin derivative 169 was converted to the corresponding PEGylated compounds 
170a-170f by treatment with a stoichiometric excess of a methyl-capped PEG (Scheme 1-56).134 
Concomitantly, the propionic acid side chains were also derivatized with PEG chains. After 
hydrolysis of the propionic ester side chains, platinum-conjugates were prepared and evaluated 
for their antitumor phototoxicity and cytotoxicity.134 The PEGylated derivatives were amenable to 
aqueous work-up and purified by alumina chromatography. 
 
Scheme 1-56. PEGylated hematoporphyrin, as described by Brunner and Sohn.134 
Etherification conditions were also applied to cycloimide-bacteriochlorin alcohol derivative 
171 (Scheme 1-57).135 Activation of the hydroxyethyl substituent on bacteriochlorin 171 with 
trifluoroacetic anhydride, followed by treatment with hydroxyl-terminated short PEGs and diols 
of varying length, gave the corresponding derivatives 172a-172d. The products were insoluble 
in water, but aqueous solutions were prepared with the help of 10% Cremophore EL, a 
PEGylated castor oil formulation vehicle. 
 
Scheme 1-57. Hydrophilic bacteriochlorin cycloimides, as described by the group of Feofanov.135 
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The meso-Suzuki coupling method developed by Lindsey and co-workers was utilized for 
the introduction of PEG groups to bacteriochlorin 173 (Scheme 1-58).136 Bacteriochlorin 173 
was prepared by Suzuki coupling of the corresponding meso-bromo bacteriochlorin with an aryl-
boronic ester bearing two unprotectted aldehyde functional groups. The aldehyde functionalities 
were PEGylated by reductive amination with an amine-terminated PEG to afford water-soluble 
PEGylated bacteriochlorin 174.  
 
Scheme 1-58. PEGylated bacteriochlorins formed by reductive amination, as described by the group of Lindsey.136 
Another representative example for the introduction of PEG groups via Suzuki coupling of 
dibromobacteriochlorin 19 with a Boc-protected amine-derivatized boronic ester, followed by 
Boc-deprotection under standard conditions, afforded diaryl bacteriochlorin 175 carrying two 
amine groups. The amines were PEGylated by amide formation with a PEG-NHS ester to afford 
bacteriochlorin 176 (Scheme 1-59).113a Derivatives bearing bioconjugtable tethers (177) and 
(178) were also prepared using a regioselective meso-bromination strategy, followed by similar 
coupling sequences.113a 
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Scheme 1-59. β-Substituted PEGylated synthetic bacteriochlorins via Suzuki coupling, as described by the group of 
Lindsey.113a 
Due to the versatility of the 3,13-dibromobacteriochlorin building block (19), various 
solubilization motifs could be introduced to this scaffold. Thus, ammonium (22 and 23), 
carboxylate (92), phosphonate (132) and PEG (176) solubilizing motifs were introduced by 
coupling with suitable aryl-boronic esters as shown in Scheme 1-59. The products were 
compared by Lindsey and co-workers according to several notable parameters59 (Table 1-2): 
The method of purification of the water-soluble adducts, the solubility of the compounds (as 
measured by the change in UV-vis absorption spectra over a 1000-fold concentration range), 
the full width at half-maximum (fwhm) of the longest wavelength of absorption and emission, 
and the stability of the chromophores in the light and dark. Overall, it was found that either the 
cationic ammonium or neutral-PEGylated species were the most promising derivatives because 
of their facile purification (precipitation), their amenability to further bioconjugation reactions, and 
good dark and light stabilities. The PEGylated derivatives were also shown to display very little 
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aggregation, as demonstrated by the sharp absorbance and emission peaks in their optical 
spectra over a 1000-fold concentration range. 
 
Table 1-2. Comparison of relevant properties concerning hydrophilicity of a series of structurally similar synthetic 
bacteriochlorins, as described by the group of Lindsey.59 
Compound Purification 
methoda 
Water-Solubilityb fwhm (abs, fl) 
(nm)c 
Stability in 
light (%)d 
Stability in 
dark (%)e 
132 reverse phase 
chromatography 
0.46 µM – 460 µM 26, 30 85 > 95 
92 ppt, washing with 
hexanes/MeOH (49:1) 
0.32 µM – 320 µM 26, 26 96 > 95 
22 ppt, washing with 
Et2O/ THF (1:1) 
0.24 µM – 240 µM 26, 26 82 > 95 
23 ppt.,washing with 
Et2O/ THF (1:1) 
0.18 µM – 180 µM 40, 26 96 > 95 
176 ppt, washing with 
hexanes/CH2Cl2 (19:1) 
0.43 µM – 430 µM 22, 23 95 > 95 
a For the final step of the synthesis. b measured in aqueous media (PBs except 176, water) by the absorption upon 
reciprocal change in concentration and pathlength. c 1 µM in PBS. fwhm = full width at half maximum of the longest 
wavelength band of absorption or emission, an indicator of aggregation. d The % remaining of a 1 µM solution in PBS 
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after several hours of absorption and fluorescence studies. e The % remaining of a, 1 µM solution in PBS allowed to 
stand in the dark at 4 °C for 48 h (as determined by absorption intensity of Qy band. 
With the PEGylated derivatives appearing to be among the most promising motifs for 
solubilization, Lindsey and co-workers set out to prepare a series of PEGylated chlorins and 
bacteriochlorins (with options for bioconjugation) using a range of synthetic methodologies.113 
One such example for the direct, late-stage PEGylation of chlorin derivatives was the azide-
alkyne Huisgen-cycloaddition (click) reaction between an alkyne-substituted porphyrin or chlorin 
and an azide-terminated PEG. This strategy was employed to perform a direct PEGylation of 
trans-AB porphyrin 179 (Scheme 1-60) to afford the PEGylated porphyrin 180.137 Along 
analogous routes, synthetic chlorins 181 and 182 were prepared from alkyne-substituted meso-
aryl groups and subsequent reactions with PEG-azides.113b 
 
Scheme 1-60. PEGylated porphyrins and chlorins prepared through click chemistry, as described by the group of 
Lindsey.113b 
In addition, an aldol condensation method was developed to directly introduce an aryl group 
bearing three PEG chains to the β-positions of a β-diacetyl-substituted chlorin 183. Reaction of 
183 with a PEG-substituted aryl aldehyde formed the porphyrin-chalcone 184 (Scheme 
1-61).113b The absorption spectrum of the PEGylated chlorin-chalcone 184 was broadened in 
pure water, indicating its aggregation. 
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Scheme 1-61. PEGylated chlorins prepared by Aldol-condensation of β-diformyl chlorin, as described by the group of 
Lindsey.113b 
Lindsey and co-workers also used an amide coupling of an alkyl-amine substituted 
bacteriochlorin with a PEG-NHS ester to produce PEGylated bacteriochlorin 186 (Scheme 
1-62).113a The β-functionalized bacteriochlorin 185 was prepared by Sonogashira coupling and 
subsequent reduction of the alkynes. Boc-deprotection was followed by saponficiation to furnish 
the amine and acid-derivatized intermediate, which was reacted with a PEG-NHS ester to 
provide the PEGylated bacteriochlorin 186. The carboxylic acid functionality on this 
chromophore is available for bioconjugation. 
 
Scheme 1-62. PEGylated bacteriochlorins bearing a bioconjugatable tether prepared by amide coupling, as 
described by the group of Lindsey.113a 
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1.4.4 Summary and Outlook 
In summary, significant progress has been made in the past decades toward the preparation 
of water-soluble porphyrins and hydroporphyrins. A wide range of options is available for their 
solubilization in aqueous media. Cationic, anionic or neutral groups may be introduced in regio- 
and chemoselective fashion. Their number and positioning has major influences on the solubility 
of the derivatized porphyrin, whereby swallowtail approaches stand out as seemingly 
particularly effective in mediating water-solubility with a moderate concomitant increase in 
molecular weight. All solubilizing functionalities can be introduced at early stages of the 
synthesis of the target compound – generally in protected form – or at late stages. The late-
state introduction of the solubilizing motif(s) reduces the number of difficult chromatographic 
steps needed in the synthetic sequence; these polar moieties and/or their water-solubility 
generally complicate their isolation and purification. Irrespective of the timing of the introduction 
of the solubilizing groups, multiple linking strategies are available. As far as flexibility and ease 
of implementation, PEGylation strategies stand out because they generate neutral 
chromophores of good solubility, the PEG chains are chemically stable, the versatility of the 
linking moieties can be used to link PEG chains to the chromophore, and the facility of the work-
up conditions once the PEG chains are established. A combined approach using both ionic and 
PEG groups may also have its merits in cases where the introduction of short PEGs was not 
enough to solubilize the macrocycle. Even though the toolbox for the synthetic chemist to effect 
water-solubility is already extensive, the continued development of solubilizing strategies that 
are mild, selective, and introduce chemically robust solubilization motifs to porphyrins is vital to 
the field for these versatile chromophores to realize their full potential in the many technical and 
biomedical applications that take place in aqueous media. 
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2 Quinoline-Annulated Chlorins and Chlorin Analogues 
Hydroporphyrins (chlorins and bacteriochlorins) possess bathochromically hyperspectra 
compared to porphyrins, making them desirable targets for synthesis, either via total synthesis 
pathways or the reduction of porphyrins.1 Examples of recently reported synthetic chlorins are 
12 and 2,3 made by conversion of a porphyrin and total synthesis, respectively. The particular β-
substituent patterns employed impart high chemical stabilities on these chlorins, whereas many 
‘simple’ chlorins are frequently sensitive toward oxidations back to the parent porphyrin. 
Exceptions notwithstanding,4 derivatization of the phenyl-groups in meso-phenylporphyrins 
generally have no major effect on the optical properties of the porphyrin.5 A generally more 
significant effect is observed when the phenyl group is replaced by sterically smaller aryl group 
that allow a larger co-planar arrangement – and thus π-overlap – of the π-system of the aryl 
group and the porphyrinoid, as in the case of meso-thienyl-substituted porphyrinoids, such as 
3.6 Substituents that are conjugated to the chromophore also modulate the electronic properties 
of the chromophore.1f,7 
 
One related approach is to extend the porphyrinic π-systems through annulation reactions. 
Multiple examples were reported, including porphyrins 4,8 5,9 and 6.10 The distortion from 
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planarity of the chromophores is yet another synthetic approach to red-shift the spectra of 
porphyrins.11 Incidentally, annulations also often introduce non-planarity.9-10,12 Indachlorindione 
5, for example, combines π-extension, non-planarity, and the presence of conjugated β-
substituents to achieve a panchromatic absorption spectrum between 300 and >900 nm.9 
Reported by us recently,12-13 quinoline-annulated porphyrins 10 and 11 are available in two 
steps from well-known 2,3-dioxochlorin 8, itself accessible along a number of pathways from the 
ultimate porphyrinic starting material, meso-tetraphenylporphyrin 7 (Scheme 2-1).14 Depending 
on the reaction conditions, ring-closure of oxime 9 using either acidic or oxidative conditions 
yields 10 or 11, respectively.12-13 A repeat of the reaction sequence on 10 generates a bis-
quinoline-annulated porphyrin 20.12 An alternative reaction pathway to the bis-quinoline-
annulated macrocycle was reported by Jeandon and Ruppert.15 
 
Scheme 2-1.  Synthesis of quinoline-annulated porphyrin 10 and its quinoline-N-oxide 11. 
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All quinoline-annulated porphyrins possess unusually broadened and red-shifted optical 
spectra.12-13 They are also low emitting and are poor singlet oxygen sensitizers.16 Quinoline-
annulated porphyrin 10 in particular has gained additional interest as a very attractive 
photoacoustic imaging (PAI) agent.16 PAI is a non-invasive biomedical imaging modality that 
combines optical and ultrasound imaging in such a way that its key characteristics are superior 
to each of the component imaging techniques. NIR absorbers displaying a strong photoacoustic 
effect are much sought-after,17 particularly if they are also non-phototoxic. 
With the intriguing quinoline-annulated porphyrins at hand, the question arises whether the 
corresponding hydroporphyrin analogues can be formed. We also indented to expand the pool 
of quinoline-annulated porphyrin derivatives to screen them in PAI assays to help us better 
define structural motifs that lead to high PAI signals. In this contribution, we will show that the 
quinoline-annulated dihydroxychlorin can indeed be generated. Moreover, using our ‘porphyrin 
breaking and mending’ strategy, this dihydroxychlorin can also be converted to quinoline-
annulated porphyrin and chlorin analogues in which a pyrroline moiety was formally replaced by 
a pyrroledione and oxazolone moiety, respectively. We will describe the dramatic effects these 
modifications have on the NIR absorbance properties of some of the derivatives.  
2.1 Results and Discussion 
2.1.1 OsO4-Mediated dihydroxylation of quinoline-annulated porphyrins 10 and 11.  
Reaction of quinoline-annulated porphyrin 10 or its quinoline N-oxide 11 with stoichiometric 
amounts of OsO4 under the standard porphyrin dihydroxylation conditions18 generated an 
identical product in high yields that, on account of its diagnostic signals in the 1H NMR spectum 
(inter alia, the signals for pyrroline hydrogens, d at 6.61 and 6.80 ppm), can be identified as the 
expected osmate ester 12 (Scheme 2-2). We observed the facile loss of the quinoline-N-oxide 
oxygen atom before, even under oxidizing conditions.19 Reduction of osmate ester 12 using H2S 
generated the corresponding quinoline-annulated dihydroxychlorin 13.18 All signals expected for 
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the quinoline and the pyrroline moiety can be identified. As commonly observed in the non-
planar quinoline-annulated porphyrins, the signals for the inner NH protons are low-field shifted 
compared to regular porphyrins or chlorins, to 0.1 and 0.5 ppm, likely an effect of their non-
planarity.12-13 
 
Scheme 2-2.  OsO4-Mediated dihydroxylation of quinoline-annulated porphyrins 10 and 11. 
The absence of symmetry in diol ester 12 and diol 13 did not allow a direct confirmation of 
the site of dihydroxylation, by for instance, an inspection of the number and coupling patterns of 
the β-proton signals. However, we deduced that the connectivity of 12 and 13 was the result of 
a dihydroxylation of the β,β’-bond opposite the quinoline-annulated pyrrole based on other 
spectroscopic evidence, combined with correlations to precedent reactions of the related 
dioxochlorins. Considering, for example, the two tautomeric possibilities for isomer A and 
isomer B, all resulting from the reaction of one of the pyrroles adjacent to the quinoline-
annulated pyrrole: This forces the inner NH protons into a high-energy adjacent 
isobacteriochlorin-type arrangement.20 Any tautomer (like A-I) that places a proton on the 
quinoline-annulated pyrrole also interrupts ring aromaticity and is therefore highly unlikely. In 
addition, the pyrroline β-proton signals can be clearly made out in the 1H NMR spectra of 12 and 
13, as can all the signals for the quinoline-annulated meso-phenyl group. Since in isomer B, one 
pyrroline β-proton is located very closely to a quinoline proton, a strong coupling between these 
protons should be seen in a NOESY spectrum of 13, but no such correlation could be detected. 
On the other hand, the NOESY spectrum of 13 indicates a correlation between the pyrroline 
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hydrogens and two non-annulated phenyl groups (see experimental section), confirming the 
connectivity of the quinolone-annulated diol 13 as shown. Oxidation reactions of free base 
dioxochlorin 8 are also directed toward the pyrrole opposite the dioxopyrroline,21 and reductions 
of the somewhat related porpholactones and porpholactams also take place at the pyrrole 
opposite the oxazolone moiety.22 Thus, in its regioselective dihydroxylation, quinoline-annulated 
porphyrin 10 resemble chlorins.23 
 
Figure 2-1. Two other theoretical isomers of diol 13, highlighting the arguments against their existence, and the 
observed NOe correlation seen in 12. 
The UV-vis spectrum of the parent quinoline-annulated porphyrin 10 is, as described 
previously,12-13 much broadened and red-shifted (λmax = 750 nm) compared to that of a regular 
porphyrin (λmax ~ 650 nm) (Figure 2-2). In comparison, the spectrum of its dihydroxylated 
derivative 13 is nearly 100 nm red-shifted (λmax = 842 nm), with a slight enhancement of the λmax 
band. These are the hallmarks of chlorins vs. porphyrins.24 Thus, compound 13 can be referred 
to as a quinoline-annulated dihydroxychlorin. 
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Figure 2-2. UV-vis spectra (CH2Cl2) of the compounds indicated. 
2.1.2 Periodinane-mediated oxidation of quinoline-annulated dihydroxychlorin 13 
The oxidation of the vic-cis-diol moiety in dihydroxychlorins, tetrahydroxybacteriochlorins, or 
dihydroxypyrroline-bearing pyrrole-modified porphyrins to the corresponding diones and 
tetraones using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or 2-iodoxybenzoic acid 
(IBX) is well known.9,14a,25 We found that the hypervalent iodine-based oxidant Dess-Martin 
periodinane (DMP) is also well suited to accomplish this reaction on diol 13, generating the 
corresponding quinoline-annulated dione 14. The product shows all the expected analytical data 
(e.g., absence of the pyrroline-hydrogen signals in its 1H NMR, appearance of two new ketone 
signals in its 13C NMR at 186 and 187 ppm, and exhibiting a composition indicating the loss of 
four hydrogens, as per ESI+ HR-MS). 
 
Scheme 2-3. Oxidations of quinoline-annulated dihydroxychlorin 13. 
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The UV-vis spectrum of dione 14 shows the spectral broadening also observed for dione 
814a (Figure 2-3), attributed to the conjugated dione moiety.26 Otherwise, the spectrum 
resembles more that of porphyrin 10 than chlorin 13. An equivalent diol-to-dione conversion in 
an indachlorin led to significant red-shifts,9 not observed here, perhaps reflecting the spectral 
differences between dione-modified porphyrins and chlorin analogues. 
 
Figure 2-3. UV-vis spectra (CH2Cl2) of the compounds indicated. 
The direct conversion of a pyrrole β,β’-bond to a lactone moiety under a number of oxidation 
conditions is well established,14b,27 whereby the two-step process via the diolchlorins is 
characterized by mild reaction conditions and high selectivity.19,28 This reaction could also be 
translated to pyrrole-modified porphyrins.9,29 Application of the standard cetyltrimethyl-
ammonium permanganate (CTAP) oxidation protocol to quinoline-annulated chlorin diol 13, 
generates the low-polarity product 15 that showed all the expected spectroscopic signatures for 
its quinoline-annulated porpholactone structure. Its ESI+ HR-MS indicates the loss of a carbon 
and four hydrogen atoms and its IR spectrum shows the appearance of an additional, lactone-
type, carbonyl group (at 1756 cm-1). The 1H NMR spectrum of 15 shows the expected 
disappearance of the pyrroline hydrogens and also reveals the presence of an inseparable 1:5 
mixture of the two possible regioisomers 15-I and 15-II. We were, however, not able to assign 
which isomer is the major isomer. We,29 and others,7 have observed before that the introduction 
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of a lactone moiety into non-symmetric pyrrole-modified porphyrins exhibits some degree of 
regioselectivity. 
The UV-vis spectrum of quinoline-annulated porpholactone 15 is clearly different from that of 
the starting chlorin 13 and resembles that of quinoline-annulated porphyrin 10 (Figure 2-4). The 
ability of a lactone moiety to mimic a β,β’-bond was rationalized before.28b 
 
Figure 2-4. UV-vis spectra (CH2Cl2) of the compounds indicated. 
2.2 Conclusions 
In conclusion, quinoline-annulated porphyrin 10 can be dihydroxylated using OsO4 like 
regular porphyrins or chlorins, with the regiochemical selectivity of a chlorin (dihydroxylation 
opposite the annulated dione moiety).23 The dihydroxypyrroline moiety in quinoline-annulated 
dihydroxychlorin 13 is susceptible to the same conversions we previously demonstrated for 
dihydroxychlorins14a,28,30 and dihydroxychlorin analogues.9,29 Oxidations to the corresponding 
dione 14 and lactone 15 were also carried out. Likewise, the same general trends in the 
changes of their optical spectra are observed. Comparing the absolute λmax values of the parent 
compounds (644 nm for dihydroxychlorin 17;18 very broad Q-bands in dioxochlorin 8,14a Figure 
2-3 and 640 nm for porpholactone 18,28b Figure 2-4 with those of the quinoline-annulated 
analogues, the large shifts induced by the quinoline-annulation become apparent. The 
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absorption maximum in all of the annulated chromophores was pushed well into the NIR, and all 
possess longer wavelengths absorptions than, for example, bisquinoline-annulated porphyrin 
20,12,15 though these are more readily accessible. Annulation causes a ~200 nm shift in diol 13 
(Figure 2-2), a ~150 nm shift in dione 14 (Figure 2-3) and a ~130 nm shift in lactone 15 (Figure 
2-4). This compares to the ~100 nm annulated porphyrin 10 is shifted compared to porphyrin 
7.12 The magnitude of the shifts correlates with the flexibility of the frameworks, with the 
porphyrins tending to be more rigid and planar than hydroporphyrins.31 Evidently, the annulation 
introduces some strain into the macrocyle that can be alleviated through the adoption of non-
planar conformation modes the more flexible the parent framework is. We attribute the general 
reduction in the extinction coefficient induced by the annulation also to their non-planarity. We 
are currently investigating the detailed photophysical properties of these intriguing NIR-
absorbing chromophores, including their efficacy as PAI contrast agents.  
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2.3 Experimental Section 
2.3.1 Materials and Instruments 
Monoquinoline annulated porphyrin 10 was prepared according to the previously reported 
preparation.12-13 Aluminum-backed, silica gel 60, 250 µm thickness analytical plates were used 
for analytical TLC; 20 × 20 cm, glass-backed, silica gel 60, 500 µm thickness preparative TLC 
plates, and standard grade, 60 Å, 32−63 µm flash column silica gel were used for preparative 
chromatography. 
1H and 13C NMR spectra were recorded on a Bruker 400 MHz instrument in the solvents 
indicated, and were referenced to residual solvent peaks. High and low resolution mass spectra 
were provided by the Mass Spectrometry Facility, Department of Chemistry, University of 
Connecticut. The microwave synthesizer used was a discover microwave reactor. 
2.3.2 Synthesis and Characterization 
Quinoline-annulated osmate ester 12. Quinoline-annulated porphyrin 10 (250 mg, 3.83 × 
10-5 mol) was dissolved in mixture of freshly distilled pyridine and EtOH-stabilized CHCl3 (12 mL 
of CHCl3/30% pyridine) in a round-bottom flask equipped with a magnetic stir bar. The mixture 
was treated with OsO4 (400 mg, 1.57 × 10-3 mol, 4 equiv; 4 mL of a stock solution prepared by 
dissolving a 1 g OsO4 ampule in 10 mL pyridine) and the reaction flask was stoppered, shielded 
with aluminum foil from ambient light, and stirred at r.t. for four days. Once no further changes of 
the reaction mixture was detectable and the starting material was 95%+ consumed (by TLC), 
the solvent was removed by rotary evaporation and the residue was thoroughly dried under a 
gentle stream of N2. The crude material was loaded onto a silica gel column with a fine sand 
layer and eluted with CH2Cl2/3% MeOH. The first fraction was a trace amount of unreacted 
starting material. The second olive-green fraction was collected, the solvent volume was 
reduced and solvent-exchanged with MeOH on the rotary evaporator. The precipitate was 
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collected and dried under vacuum to provide quinoline-fused dihydroxychlorin osmate ester 12 
(339 mg, 3.21 × 10-4 mol, 82% yield) as a dark green, micro-crystalline material. Rf (silica-
CH2Cl2/2% MeOH) = 0.21; 1H NMR (400 MHz, CDCl3): δ 8.98–8.92 (m, 3H), 8.66 (br s 2H), 8.58 
(br s 2H), 8.18 (dd, 3J = 4.9, 4J = 1.7 Hz, 1H), 8.10 (dd, 3J = 4.9, 4J = 1.8 Hz, 2H), 8.03 (dd, 3J = 
4.9, 4J = 1.9 Hz, 1H), 7.90–7.86 (m, 4H), 7.79 (br s, 3H), 7.70 (t, 2H), 7.64 (br s, 4H), 7.55–7.53 
(d, 3J = 5.0 Hz, 3H), 7.44 (br s, 3H), 7.36 (br s, 3H), 6.79 (d, 3J = 5.9 Hz, 1H), 6.62 (d, 3J = 5.6 
Hz, 1H), -0.08 (s, 1H, exchangeable with D2O), -0.25 (s, 1H, exchangeable with D2O) ppm; 13C 
NMR: This compound possesses limited solubility, even at elevated temperature. UV-vis 
(CH2Cl2) λmax (Rel. I.) 402 (1), 692 (0.14), 844 (0.12) nm; FT-IR (neat, diamond ATR): νC=O = 
1715 cm-1; for full spectrum, see Figure S2; HR-MS (ESI+, 100% CH3CN, 30 V cone voltage): 
The molecular peak of this compound could not, like that of other osmate esters,32 not be 
detected. 
 
Figure 2-5. UV-vis spectrum (CH2Cl2) of 12. 
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Quinoline-annulated dihydroxychlorin 13. Quinoline osmate ester 12 (378 mg) was 
dissolved in CHCl3/10% MeOH (50 ml) in a 100 ml round bottom flask equipped with a magnetic 
stir bar and a gas in- and outlet. A gentle stream of H2S was passed into the flask for ~2 min (no 
bubbling through the solution! Caution: fume hood and bleach-filled H2S scrubber!). Once TLC 
control indicated the consumption of all the starting material, the reaction mixture was 
thoroughly purged with nitrogen (fume hood and H2S scrubber!), and then evaporated to 
dryness by rotary evaporation (air outlet of rotary evaporator vacuum pump in the fume hood!). 
The residue was separated by automated flash chromatography (silica gel–solvent gradient 
from 100% CH2Cl2 to CH2Cl2/2% MeOH) to obtain 13 in 44% yield (~96 mg): Rf (silica-
CH2Cl2/2% MeOH) 0.38; 1H NMR (400 MHz, CDCl3): δ 8.78 (d, 3J = 7.1 Hz, 1H), 8.69 (br s, 1H), 
8.24 (d, 3J = 7.1 Hz , 2H), 8.05 (dd, 3J = 5.0, 4J = 1.8 Hz, 1H), 8.00 (dd, 3J = 5.0, 4J = 2.0 Hz, 
1H), 7.99 (d, 3J = 4.4 Hz, 2H), 7.77 (two overlapping dd, 3J = 5.0, 4J = 1.8 Hz, 2H), 7.68–7.60 
(m, 13H), 6.07 (d, 3J = 6.3 Hz, 1H), 5.91 (d, 3J = 6.3 Hz, 1H), 3.54 (s, 1H), 3.32 (s 1H), 0.48 (s, 
1H, exchangeable with D2O), 0.08 (s, 1H, exchangeable with D2O) ppm; 13C NMR (100 MHz, 
CDCl3): δ 193.9, 162.7, 158.3, 149.7, 147.0, 145.0, 141.8, 140.9, 140.8, 140.3, 140.0, 138.2, 
136.8, 133.7, 132.8, 132.5, 131.9, 130.7, 129.5, 128.5, 128.2, 128.0, 127.9, 127.8, 127.6, 127.5, 
127.0, 122.2, 122.1, 120.9, 118.7, 114.6, 111.0, 74.5, 74.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 
397 (5.23), 543 (3.93), 682 (4.33), 773 (4.14), 842 (4.32) nm; FT-IR (neat, diamond ATR): νC=O 
= 1710 cm-1; for full spectrum, see Figure S6; HR-MS (ESI+, cone voltage = 30 V, 100% CH3CN) 
m/e calcd for C44H30N5O3 ([M·H]+) 676.2309, found 676.2322. 
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Figure 2-6. 1H NMR spectrum (400 MHz, CDCl3) of 13. 
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Figure 2-7. 13C NMR (100 MHz, CDCl3) of 13. 
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Figure 2-8. 1H-1H NOESY spectrum (CDCl3) of 13. 
2. Quinoline-Annulated Chlorins and Chlorin Analogues 
 
92 
 
Quinoline-annulated dioxoporphyrin 14. Diol 13 (10.6 mg, 1.6 × 10-5 mol) was dissolved 
in CH2Cl2 (9.0 mL) in a round-bottom flask equipped with a magnetic stir bar. Dess-Martin 
periodinane (DMP) (13.7 mg, 3.2 × 10-5 mol, 2 equiv) was added and the reaction mixture 
stirred at ambient temperature for 10 min. When TLC and UV-vis indicated the consumption of 
the starting material, a saturated Na2S2O3 solution (5 mL) was added to the reaction mixture and 
vigorously stirred. After a few minutes, the mixture was extracted with CH2Cl2 (3 × ~10 mL). The 
combined organic layers were washed with saturated Na2CO3, followed by brine, then dried 
over Na2SO4, and reduced to dryness. The residue was separated by preparative TLC (silica-
CH2Cl2) to afford the dark green dioxoporphyrin 14 in 42% yield (4.4 mg): Rf (silica-CH2Cl2) = 
0.32; 1H NMR (400 MHz, CDCl3): δ 9.02–8.98 (m, 2H), 8.53–8.51 (dd, 3J = 8, 4J = 1.2 Hz, 1H), 
8.22 (m, 3H), 7.92–7.64 (m, 19H), 0.71 (s, 1H, exchangeable with D2O), 0.52 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): δ 193.8, 187.1, 185.7, 149.8, 149.3, 
145.8, 144.4, 143.5, 142.6, 140.8, 138.3, 137.9, 137.5, 137.2, 135.5, 134.3, 133.3, 132.71, 
132.55, 132.43, 130.45, 130.39, 128.89, 128.81, 128.62, 128.43, 127.84, 127.69, 127.64, 127.3, 
123.3, 122.9, 117.1, 115.5, 111.7 ppm; UV-vis (CH2Cl2) λmax (log ε) 395 (4.8), 463 (sh), 686 
(3.8), 757 (sh), 825 (3.8) nm; FT-IR (neat, diamond ATR): νC=O = 1719 cm-1; for full spectrum, 
see Figure S10; HR-MS (ESI+, 100% CH3CN, cone voltage = 30 V) m/e calcd for C44H26N5O3 
([M·H]+) 672.2056, found 672.2064. 
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Figure 2-9. 1H NMR (400 MHz, CDCl3) of 14 
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Figure 2-10. 13C NMR spectrum (100 MHz, CDCl3) of 14. 
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Quinoline-annulated porpholactone 15: To a solution of diol 13 (10.0 mg, 1.51 × 10-5 mol) 
in CHCl3 (5 mL) in a round-bottom flask equipped with a stir bar was added cetyltrimethyl-
ammonium permanganate (CTAP,33 6.1 mg, 1.51 × 10-5 mol, ~5 equiv) and the mixture was 
stirred for 1 h at ambient temperature. The reaction was monitored by TLC for the 
disappearance of the starting material. If needed, additional oxidant was added after 1 h and 
until all starting material was consumed. The solution was then filtered through a short plug of 
silica gel, and the filter cake washed with CHCl3 until the filtrate was colorless. The combined 
filtrates were evaporated to dryness by rotary evaporation. The residue was purified by 
preparative TLC (silica-CH2Cl2/10% pet ether 30-60), followed by precipitation of the product by 
slow solvent exchange with pet ether 30-60 on the rotary evaporator to afford the 1:5 mixture of 
the two lactone isomers: Rf (silica-CH2Cl2) 0.47; 1H NMR (400 MHz, CDCl3): δ 9.20 (d, 3J = 8.3 
Hz, 1H), 8.90 (two overlapping dd, 3J = 4.5, 4J = 2.2 Hz, 1H), 8.60 (dd, 3J = 8.0, 4J = 1.1 Hz, 1H), 
8.22 (dd, 3J = 5.2, 4J = 1.7 Hz, 1H), 8.11 (dd, 3J = 5.2, 4J = 1.7 Hz, 1H), 8.04 (dd, 3J = 4.6, 3J = 
2.3 Hz, 1H), 7.97–7.83 (m, 6H), 7.75–7.63 (m, 10H), 1.17 (s, 1H, exchangeable with D2O), 1.60 
(s, 1H, exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): This compound possesses 
limited solubility even at elevated temperature, not allowing the recording of a well-resolved 13C 
NMR spectrum; UV-vis (CH2Cl2) λmax (log ε) 404 (5.09), 668 (4.05), 726 (4.00), 772 (3.89) nm; 
FT-IR (neat, diamond ATR): νC=O = 1756, 1724 cm-1; for full spectrum, see Figure S13; HR-MS 
(ESI+, 100% CH3CN, cone voltage = 30 V) m/e calcd for C43H26N5O3 ([M·H]+) 660.2036, found 
660.2048. 
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Figure 2-11. 1H NMR spectrum (400 MHz, CDCl3) of 15. 
2. Quinoline-Annulated Chlorins and Chlorin Analogues 
 
97 
 
2.4 References 
(1) a) Flitsch, W. Adv. Heterocycl. Chem. 1988, 43, 73; b) Montforts, F.-P.; Gerlach, B.; 
Hoeper, F. Chem. Rev. 1994, 94, 327; c) Montforts, F.-P.; Glasenapp-Breiling, M. Prog. 
Heterocycl. Chem. 1998, 10, 1; d) Galezowski, M.; Gryko, D. T. Curr. Org. Chem. 2007, 
11, 1310; e) Brückner, C.; Samankumara, L.; Ogikubo, J. In Handbook of Porphyrin 
Science; Kadish, K. M., Smith, K. M., Guilard, R., Eds.; World Scientific: River Edge, NY, 
2012; Vol. 17 (Synthetic Developments, Part II; Chapter 76), p 1; f) Lindsey, J. S. Chem. 
Rev. 2015, 115, 6534. 
(2) Silva, A. M. G.; Tome, A. C.; Neves, M. G. P. M. S.; Silva, A. M. S.; Cavaleiro, J. A. S. J. 
Org. Chem. 2005, 70, 2306. 
(3) Laha, J. K.; Muthiah, C.; Taniguchi, M.; McDowell, B. E.; Ptaszek, M.; Lindsey, J. S. J. 
Org. Chem. 2006, 71, 4092. 
(4) Vitasovic, M.; Gouterman, M.; Linschitz, H. J. Porphyrins Phthalocyanines 2001, 5, 191. 
(5) Lindsey, J. S. In The Porphyrin Handbook; Kadish, K. M., Smith, K. M., Guilard, R., Eds.; 
Academic Press: San Diego, 2000; Vol. 1, p 45. 
(6) a) Gupta, I.; Hung, C.-H.; Ravikanth, M. Eur. J. Org. Chem. 2003, 4392; b) Gupta, I.; 
Ravikanth, M. J. Photochem. Photobiol., A 2006, 177, 156; c) Brückner, C.; Foss, P. C. 
D.; Sullivan, J. O.; Pelto, R.; Zeller, M.; Birge, R. R.; Crundwell, G. Phys. Chem. Chem. 
Phys. 2006, 8, 2402; d) Greco, J. A.; Rossi, A.; Birge, R. R.; Brückner, C. Photochem. 
Photobiol. 2014, 90, 402. 
(7) Ke, X.-S.; Chang, Y.; Chen, J.-Z.; Tian, J.; Mack, J.; Cheng, X.; Shen, Z.; Zhang, J.-L. J. 
Am. Chem. Soc. 2014, 136, 9598. 
(8) a) Davis, N. K. S.; Thompson, A. L.; Anderson, H. L. Org. Lett. 2010, 12, 2124; b) Davis, 
N. K. S.; Thompson, A. L.; Anderson, H. L. J. Am. Chem. Soc. 2011, 133, 30. 
(9) Samankumara, L. P.; Dorazio, S. J.; Akhigbe, J.; Li, R.; Nimthong-Roldán, A.; Zeller, M.; 
Brückner, C. Chem. – Eur. J. 2015, 21, 11118. 
(10) Hyland, M. A.; Morton, M. D.; Brückner, C. J. Org. Chem. 2012, 77, 3038. 
(11) a) Ravikanth, M.; Chandrashekar, T. K. Struct. Bonding (Berlin) 1995, 82, 105; b) 
Shelnutt, J. A.; Song, X.-Z.; Ma, J.-G.; Jentzen, W.; Medforth, C. J. Chem. Soc. Rev. 
1998, 27, 31; c) Ryeng, H.; Ghosh, A. J. Am. Chem. Soc. 2002, 124, 8099. 
(12) Akhigbe, J.; Luciano, M.; Zeller, M.; Brückner, C. J. Org. Chem. 2015, 80, 499. 
(13) Akhigbe, J.; Zeller, M.; Brückner, C. Org. Lett. 2011, 13, 1322. 
2. Quinoline-Annulated Chlorins and Chlorin Analogues 
 
98 
 
(14) a) Daniell, H. W.; Williams, S. C.; Jenkins, H. A.; Brückner, C. Tetrahedron Lett. 2003, 
44, 4045; b) Crossley, M. J.; King, L. G. Journal of the Chemical Society, Chemical 
Communications 1984, 920; c) Crossley, M. J.; Burn, P. L.; Langford, S. J.; Pyke, S. M.; 
Stark, A. G. J. Chem. Soc., Chem. Commun. 1991, 1567; d) Starnes, S. D.; 
Arungundram, S.; Saunders, C. H. Tetrahedron Lett. 2002, 43, 7785. 
(15) Jeandon, C.; Ruppert, R. Eur. J. Org. Chem. 2011, 4098. 
(16) Abuteen, A.; Zanganeh, S.; Akhigbe, J.; Samankumara, L. P.; Aguirre, A.; Biswal, N.; 
Braune, M.; Vollertsen, A.; Röder, B.; Brückner, C.; Zhu, Q. Phys. Chem. Chem. Phys. 
2013, 15, 18502. 
(17) a) Kim, C.; Favazza, C.; Wang, L. V. Chem. Rev. 2010, 110, 2756; b) Wang, L. V. 
Nature Photonics 2009, 3, 503. 
(18) Brückner, C.; Rettig, S. J.; Dolphin, D. J. Org. Chem. 1998, 63, 2094. 
(19) Banerjee, S.; Zeller, M.; Brückner, C. J. Org. Chem. 2010, 75, 1179. 
(20) a) Wu, Y.-D.; Chan, K. W. K.; Yip, C.-P.; Vogel, E.; Plattner, D. A.; Houk, K. N. J. Org. 
Chem. 1997, 62, 9240; b) Stepien, M.; Latos-Grazynski, L. Top. Heterocycl. Chem. 
2009, 19, 83. 
(21) Imahori, H.; Iijima, H.; Hayashi, H.; Toude, Y.; Umeyama, T.; Matano, Y.; Ito, S. 
ChemSusChem 2011, 4, 797. 
(22) Akhigbe, J.; Haskoor, J. P.; Krause, J. A.; Zeller, M.; Brückner, C. Org. Biomol. Chem. 
2013, 11, 3616. 
(23) Bruhn, T.; Brückner, C. J. Org. Chem. 2015, 80, 4861. 
(24) Gouterman, M. In The Porphyrins; Dolphin, D., Ed.; Academic Press: New York, 1978; 
Vol. 3, p 1. 
(25) Starnes, S. D.; Rudkevich, D. M.; Rebek Jr., J. J. Am. Chem. Soc. 2001, 123, 4659. 
(26) Brückner, C.; McCarthy, J. R.; Daniell, H. W.; Pendon, Z. D.; Ilagan, R. P.; Francis, T. 
M.; Ren, L.; Birge, R. R.; Frank, H. A. Chem. Phys. 2003, 294, 285. 
(27) a) Gouterman, M.; Hall, R. J.; Khalil, G. E.; Martin, P. C.; Shankland, E. G.; Cerny, R. L. 
J. Am. Chem. Soc. 1989, 111, 3702; b) Jayaraj, K.; Gold, A.; Austin, R. N.; Ball, L. M.; 
Terner, J.; Mandon, D.; Weiss, R.; Fischer, J.; DeCian, A.; Bill, E.; Müther, M.; 
Schünemann, V.; Trautwein, A. X. Inorg. Chem. 1997, 36, 4555; c) Lv, H.; Yang, B.; 
Jing, J.; Yu, Y.; Zhang, J.; Zhang, J.-L. Dalton Trans. 2012, 41, 3116; d) Yu, Y.; Lv, H.; 
Ke, X.; Yang, B.; Zhang, J.-L. Adv. Synth. Catal. 2012, 354, 3509. 
(28) a) McCarthy, J. R.; Jenkins, H. A.; Brückner, C. Org. Lett. 2003, 5, 19; b) Brückner, C.; 
Ogikubo, J.; McCarthy, J. R.; Akhigbe, J.; Hyland, M. A.; Daddario, P.; Worlinsky, J. L.; 
2. Quinoline-Annulated Chlorins and Chlorin Analogues 
 
99 
 
Zeller, M.; Engle, J. T.; Ziegler, C. J.; Ranaghan, M. J.; Sandberg, M. N.; Birge, R. R. J. 
Org. Chem. 2012, 77, 6480. 
(29) Ogikubo, J.; Meehan, E.; Engle, J. T.; Ziegler, C. J.; Brückner, C. J. Org. Chem. 2013, 
78, 2840. 
(30) Akhigbe, J.; Ryppa, C.; Zeller, M.; Brückner, C. J. Org. Chem. 2009, 74, 4927. 
(31) Kratky, C.; Waditschatka, R.; Angst, C.; Johansen, J. E.; Plaquevent, J. C.; Schreiber, J.; 
Eschenmoser, A. Helv. Chim. Acta 1985, 68, 1312. 
(32) Samankumara, L. P.; Zeller, M.; Krause, J. A.; Brückner, C. Org. Biomol. Chem. 2010, 8, 
1951. 
(33) Furniss, B.S.; Hannaford, A.J; Smith, P.W.G.; Tatchell, A.R. Vogel’s Textbook of 
Practical Organic Chemistry, Longman: Essex, GB, 5th Edition, 1989, p. 549. 
 
3. Platinum Complexes of Quinoline-Annulated Porphyrins as NIR Emitters 
 
100 
 
3 Platinum Complexes of Quinoline-Annulated Porphyrins as NIR Emitters 
Dyes with pO2-dependent emission are desirable for a number of applications such as 
luminophores in pressure-sensitive paints and as optical O2 sensors in biomedical applications.1 
The Stern-Volmer relationship describes the underlying mechanism of function of these dyes: If 
a triplet-state dye collides with a triplet state oxygen molecule (3O2), singlet oxygen (1O2) is 
generated, and the regular phosphorescence of the dye is quenched. Platinum and palladium 
porphyrins in particular show promise as dyes to measure any O2 tension due to their efficient 
intersystem crossing (ISC) quantum yields into the triplet state, long triplet excited state lifetimes 
and high quantum yields of phosphorescence.2  
For a metalloporphyrin-based O2 sensor to find use in biomedical applications in vivo it must 
absorb light within the optical window of tissue (i.e. > 700 nm), have emission in the NIR and 
have an excited-state that is quenched by O2. Toward this end, various Pt and Pd tetrabenzo- 
and tetranaphtholporphyrin derivatives have been prepared.3 However, difficult syntheses and 
poor solubility largely prevented the further evaluation of these types of chromophores.  
We found that the platinum complexes of our own quinoline annulated porphyrins, which are 
prepared in two steps from the well-known dioxoporphyrin 5,4 possess strong NIR emission (at 
77 K). We report here the synthesis, characterization and photophysics for the quinoline-
annulated porphyrin-Pt complexes as NIR emitters with the potential for use as novel O2 
sensors. 
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3.1 Results and Discussion 
3.1.1 Synthesis 
Insertion of platinum(II) into the known free bases tetraphenyl-2,3-dioxochlorin 5 and mono- 
and bisquinoline-annulated porphyrins 9 and 10, all synthetized along established pathways,4 
and using standard reaction conditions,5 generated the corresponding platinum complexes 5Pt, 
9Pt, and 10Pt, respectively (Scheme 1).  
 
Scheme 3-1. Synthesis of quinoline-annulated porphyrin Pt-complexes. 
Metal insertion was generally facile, likely assisted by the pronounced non-planarity of the 
chromophores.4b When subjected to platinum(II) insertion conditions (or the insertion of nickel(II) 
or even zinc(II)), the N-oxide of the quinoline-annulated porphyrin N-oxide 7 is lost.4b,6 Hence, 
the synthesis of N-oxide platinum complex 7Pt required a synthetic path that involved an early 
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insertion of platinum. Thus, [tetraphenyl-2,3-dioxochlorinato]platinum(II) 5Pt served as the 
starting material. This metallodione was then manipulated along an established reaction 
sequence: Formation of oxime 6Pt, followed by DDQ-induced oxidative ring-closure to form 
quinoline-annulated porphyrin N-oxide platinum(II) complex 7Pt. The platinum complexes 
possessed all the expected spectroscopic properties. Most 1H NMR spectroscopic data of the 
platinum complexes are very similar to those of the corresponding nickel(II) or palladium(II) 
complexes, also suggesting that the platinum complexes assume the non-planar conformations 
of their congeners. 
3.1.2 Optical Properties and Photophysics 
Similar to the observation for the free base species, the quinoline-annulated porphyrin 
platinum complexes 7Pt, 8Pt, 10Pt all possess bathochromically shifted UV-vis spectra, which 
we attribute to the increase in π-conjugation of the chromophores, as well as their inferred non-
planarity. Compared with the other previously prepared group 10 metal complexes (Ni, Pd) as 
well as the free base 8, the UV-vis spectrum of 8Pt is also relatively unchanged upon metal 
insertion, with no observed shift in the soret band and side bands. On the other hand, the bis-
quinoline fused 10Pt exhibits the expected reduction in the number of side bands, as well as a 
split soret band, similar to other group 10 metal complexes of 10.4b 
Table 3-1. Photophysical data for dione 5Pt  and the quinoline-annulated porphyrin Pt complexes. 
Compound λmax,abs/nma log ε at 
 λmax/cm -1 M -1a 
λmax,em/nmb φPh/%b τT1/µsc 
5Pt ~524-815d -e 733  55 71 
7Pt 702 4.33 1000 1 0.43 
8Pt 720 4.05 945, 1062 2 0.53 
10Pt 717 3.99 944, 1073 7 1.7 
a in CH2Cl2,  b λexcitation = λsoret  c EtOH, glass, 77K d broad, featureless absorption e not measured 
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Key photophysical properties for the platinum complexes are listed in Table 3-1. All of the 
quinoline-annulated porphyrin Pt complexes possess the NIR emission expected for Pt 
porphyrins,2 with λemission values well into the NIR region for quinoline-annulated porphyrin 
platinum complexes 7Pt, 8Pt and 10Pt.  
The φPh and τT1 were also determined for the Pt complexes. Of the quinoline-annulated 
porphyrin platinum complexes, 10Pt stands out as a potentially useful luminophor for O2 
sensing applications due to its bight emission in the NIR with a phosphorescence quantum yield 
(φPh) of 7%, and a long excitated-state triplet lifetime (τT1) of 1.7 µs. 
3.2 Conclusions 
In conclusion, the platinum complexes of the NIR absorbing quinoline-annulated porphyrins 
were prepared using standard conditions. Like their free base counterparts, they possess long 
wavelength absorption within the optical window of tissue, and similar UV-vis spectra as the 
other previously prepared group 10 metal complexes. However, unlike their free base 
counterparts, they exhibit emission well into the NIR region. Particularly bis-quinoline-fused 
porphyrin 10Pt possesses bright NIR emission and relatively long excited-state lifetime, 
suggesting it as a potentially most useful chromophore. The preparation of a water-soluble 
derivative of 10Pt is currently underway for the biological testing of this novel NIR emitting and 
oxygen partial pressure-sensitive dye. 
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3.3 Experimental Section 
3.3.1 Materials and Instruments 
All reagents and solvents were from commercial sources and used without prior purification. 
Platinum dione 5Pt and oxime 6Pt7, free-base dione 58, and free-base annulated quinolines 8 
and 94b were prepared as described previously (Scheme 1). Aluminum-backed, silica gel 60, 
250 µm thickness analytical plates were used for analytical TLC; 20 × 20 cm, glass-backed, 
silica gel 60, 500 µm thickness preparative TLC plates, and standard grade, 60 Å, 32−63 µm 
flash column silica gel were used for preparative chromatography. 
1H and 13C NMR spectra were recorded on a Bruker 400 MHz instrument in the solvents 
indicated, and were referenced to residual solvent peaks. High and low resolution mass spectra 
were provided by the Mass Spectrometry Facility, Department of Chemistry, University of 
Connecticut. The microwave synthesizer used was a discover microwave reactor. 
3.3.2 Synthesis and Characterization 
[meso-Triphenyl-monoquinoline-annulated oxo-porphyrinato-N-oxide]platinum(II) (7Pt). 
Monooxime 6Pt (20.2 mg, 2.37 × 10-5 mol) was dissolved in CH2Cl2 (10.0 mL) in a round-bottom 
flask equipped with a magnetic stirring bar. DDQ (11 mg, 4.7 × 10-5 mol, 2 equiv) was added 
and the mixture was stirred for 30 min. When the starting material was consumed (reaction 
control by TLC), the reaction mixture was filtered through a short plug of silica gel to removed 
excess DDQ/the corresponding hydroquinone. The filtrate was washed with water (2 × 10 mL), 
dried over anhyd Na2SO4, evaporated to dryness by rotary evaporation, and the residue was 
purified by preparative TLC (CH2Cl2/2% MeOH). After solvent exchange of the extracted main 
green band with MeOH, 7Pt was isolated by filtration in 82% yield as a green powder: Rf (silica-
CH2Cl2/5% MeOH) = 0.55; 1H NMR (400 MHz, CDCl3): δ 9.09 (d, 3J = 5.2 Hz, 1H), 8.88, (d, 3J = 
8.5 Hz, 1H), 8.70 (d, 3J = 8.1 Hz, 1H), 8.57 (d, 3J = 5.0 Hz, 1H), 8.36, 8.33, 8.31 (three 
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overlapping d, 3J = 5.0 Hz, 3H), 8.21 (d, 3J = 5.0 Hz, 1H), 8.04 (dd, 3J = 6.3 Hz, 4J = 1.5 Hz, 2H), 
7.99 (dd, 3J = 6.2 Hz, 4J = 1.6 Hz, 2H), 7.83 (t, 3J = 7.8 Hz, 1H) 7.77 – 7.66 (m, 12H) ppm; 13C 
NMR (100 MHz, CDCl3): δ 180.7, 147.5, 141.4, 141.0, 140.1, 140.0, 139.9, 138.2, 137.5, 136.2, 
134.9, 134.6, 133.6, 133.4, 133.1, 131.9, 131.7, 130.9, 130.0, 129.9, 129.7, 129.5, 129.0, 128.7, 
128.6, 128.4, 128.0, 127.9, 127.7, 127.5, 125.9, 121.6, 118.4, 103.3 ppm; UV-vis (CHCl2) λmax 
(log ε) 408 (5.33), 475 (4.59), 650 (sh), 702 (4.33) nm; FT-IR (neat, diamond ATR): 1695.4 
(νC=O) cm-1; MS (DART+, orifice voltage = 20 V, 100% CH3CN) m/e calcd for C44H25N5O2Pt 
851.1738 ([M.H]+), found 851.1719. 
 
Figure 3-1. UV-vis spectrum (CH2Cl2) of 7Pt. 
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Figure 3-2. 1H NMR spectrum (400 MHz, CDCl3) of 7Pt. 
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Figure 3-3. 13C NMR spectrum (100 MHz, CDCl3) of 7Pt. 
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[meso-Triphenyl-monoquinoline-fused oxoporphyrinato]platinum(II) (8Pt). Free base 
mono-quinoline-fused oxo-porphyrin 8 (17.7 mg, 2.76 × 10-5 mol) was dissolved in PhCN (5 mL) 
and added to a hot solution of PhCN (15 mL) and platinum(II) chloride (PtCl2, 29.3 mg, 1.10 × 
10-4 mol, 4.0 equiv) in a round-bottom flask equipped with a magnetic stir bar and N2 gas inlet. 
The mixture was heated to reflux for 2 h. When the starting material was consumed (reaction 
control by UV-vis and TLC), the resulting mixture was allowed to cool to room temperature, the 
solvent was removed in vacuo and taken up in CH2Cl2. The main product was isolated and 
purified by a flash column chromatography (CH2Cl2/0.5% MeOH), followed by recrystallized by 
solvent exchange into MeOH to provide 8Pt as a light green powder in 93% yield. Rf (silica-
CH2Cl2) 0.30; 1H NMR (400 MHz, CDCl3): δ 8.98 (d, 3J = 4.7 Hz, 1H), 8.65 (d, 3J = 8.2 Hz, 1H), 
8.42 (t, 2H), 8.24 – 8.19 (overlapping s and d, 3J = 5.0 Hz, 3H), 8.10 (d, 3J = 5.0 Hz, 1H), 8.00 
(d, 3J = 7.0 Hz, 2H), 7.93 (d, 3J = 6.7 Hz, 2H), 7.74 – 7.60 (m, 13H) ppm; 13C NMR (100 MHz, 
CDCl3): δ 190.5, 150.0, 148.6, 145.2, 141.4, 140.5, 140.0, 139.9, 139.5, 138.0, 137.3, 135.5, 
134.5, 134.1, 133.9, 133.3, 133.2, 133.1, 132.9, 132.8, 132.1, 131.8, 129.8, 129.3, 129.3, 129.1, 
128.7, 128.6, 128.3, 128.1, 127.9, 127.8, 127.5, 127.3, 127.1, 125.3, 117.3, 110.8 ppm; UV-vis 
(CHCl2) λmax (log ε) 399 (5.07), 462 (4.38), 492 (4.24), 668 (sh), 720 (4.05) nm; FT-IR (neat, 
diamond ATR): 1714.7 (νC=O) cm-1; MS (DART+, orifice voltage = 20 V, 100% CH3CN) m/e calcd 
for C44H25N5OPt 835.1788 ([M.H]+), found 835.1779. 
 
Figure 3-4. UV-vis spectrum (CH2Cl2) of 8Pt. 
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Figure 3-5. 1H NMR spectrum (400 MHz, CDCl3) of 8Pt. 
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Figure 3-6. 13C NMR spectrum (100 MHz, CDCl3) of 8Pt. 
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[meso-Diphenyl-bis-quinoline-fused porphyrinato]platinum(II) (10Pt). Free base 
bisquinoline-annulated porphyrin 10 (11.6 mg, 1.8 × 10-5 mol) was dissolved in PhCN (2.7 mL) in 
a thick-walled glass tube equipped with a magnetic stir bar. Pt(acac)2 (22 mg, 5.4 x 10-5 mol, 3 
equiv) was added, and the vessel was sealed and placed in a microwave cavity. Using an initial 
microwave power of 300 W, the contents of the reaction vessel were heated to 250 °C where it 
was held for 20 min. Upon completion, the vessel was cooled to ambient temperature. The 
solvent was evaporated and the residue was separated on a preparative TLC plate (CH2Cl2/5% 
MeOH) to provide 10Pt as a bright green solid in 60% yield (9.1 mg). Rf (silica-CH2Cl2/5% 
MeOH) = 0.51; (400 MHz; CD2Cl2): δ 8.29 (d, 3J = 4.0 Hz, 1H), 8.21 (two overlapping d, 3J = 6.7 
Hz, 2H), 7.83 (s, 1H), 7.76-7.61 (m, 8H) ppm; 13C NMR (100 MHz, CD2Cl2): δ 149.6, 143.89, 
143.73, 139.3, 139.0, 134.27, 134.10, 133.0, 132.0, 131.4, 129.8, 129.0, 128.1, 127.5, 127.0, 
126.9, 125.7, 124.3, 124.2, 108.6 ppm; UV-vis (CH2Cl2) λmax (log ε) 399 (4.46), 455 (4.20), 658 
(3.66), 717 (3.99) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C44H25N6Pt ([M·H]+), 
832.1792 found 832.1769. 
 
Figure 3-7. UV-vis spectrum (CH2Cl2) of 10Pt. 
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Figure 3-8. 1H NMR spectrum (400 MHz, CDCl3) of 10Pt. 
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Figure 3-9. 13C NMR spectrum (100 MHz, CD2Cl2) of 10Pt. 
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4 in vivo Photoacoustic Tumor Tomography Using a Quinoline-Annulated 
Porphyrin as NIR Molecular Contrast Agent  
The development of new—or the refinement of existing—imaging techniques of 
biological processes and tissue is arguably one of the leading driving forces in 
contemporary biomedical chemistry.1 Photoacoustic imaging (PAI) is a rapid and non-
invasive imaging modality that combines optical and ultrasound imaging.2 Photoacoustic 
signals are optically generated and ultrasonically detected. PAI thus can take advantage 
of the optical window of tissue and provides the deep probing depth (multiple cm) and 
spatial resolution (sub-mm) of ultrasound. 
PAI is the consequence of a number of physical effects:2c The absorption of a light pulse by 
a chromophore causes it to enter an excited state. Good PAI chromophores relax rapidly 
primarily along non-radiative pathways, causing a transient rise in temperature (in the mK 
regime) around the closest vicinity of the absorbing dye, leading to a localized thermal-elastic 
expansion. Thus, if the light source is a pulsed laser, light absorption generates a wideband 
ultrasonic wave. This signal can be acquired with standard ultrasonic transducers known from 
traditional ultrasound imaging. Furthermore, using wavelengths within the optical window of 
tissue (~700-1100 nm; the wavelength of maximum penetration of breast tissue is ~725 nm; 
whole blood has an absorption minimum at ~710 nm),3 dyes many centimeters deep within 
tissue can be probed. If such a NIR laser beam is scanned across an object, the photoacoustic 
data can be used to reconstruct 2D or 3D photoacoustic maps. The laser light energy used for 
in vivo imaging experiments is generally well below the standard thresholds above which tissue 
damages can be expected. Variants of PAI are photoacoustic tomography (PAT)2a for large-
scale imaging and photoacoustic microscopy (PAM)4 for small scale, high-resolution image 
generation.  
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Endogenous chromophores, primarily hemoglobin, can be used as PAI dyes.5 This allowed 
for the imaging of the blood content of the vascular network in rodent brains4 or cancer in 
breast6 and ovary tissues,7 the mapping of mesoscopic biological objects or whole animals.2a 
However, particularly cancers in their early stages, cannot be detected by their intrinsic vascular 
contrast. Therefore, the use of exogenous contrast agents is required to achieve a suitable 
signal to noise ratio and to allow the PAI of deeply-seated organs or lesions.5 
A number of nano- or micro-scale agents have been introduced as PAI or multimodal 
contrast agents in recent years, with some showing good in vivo imaging results.8 Among them 
are metal-based nanoparticles, combined with and without organic dyes, and nanotubes. 
However, the use of nanoparticles is not without problems with respect to biodistribution, 
toxicity, or homogeneity.9 Alternative approaches have been the use of molecular dyes 
assembled into vesicles, most prominent among them porphysomes made from chlorins or 
bacteriochlorins, such as pyropheophyrin derivative 1,8b,10 microbubbles,8c,8d or nanodroplets.8e 
Also developed were photoacoustic probes that are generated in tissue.11 
Conspicuously rare in the contemporary literature are small molecular contrast agents 
designed for PAI.5 One example is 2, shown to be a suitable contrast agent for imaging 
dissolved oxygen using photoacoustic lifetime imaging.12 One of the oldest and best studied PAI 
contrast agents is the FDA-approved ocular angiographic dye indocyanine green (ICG, 3), and 
related derivatives.13 ICG possesses NIR absorption (λmax ~ 800 nm) properties but is otherwise 
far from ideal. For instance, ICG is fluorescent. Thus, a portion of the absorbed light is not 
translated into a photoacoustic signal, diminishing its effectiveness as a PAI contrast agent. ICG 
is confined to the vasculature space, and it clears rapidly (t1/2 < 4 min),14 complicating longi-
tudinal in vivo studies. Irrespective of these shortcomings, the broad utilization of ICG suggests 
its use as a benchmark dye. The absence of the development of many molecular contrast 
agents highlights the fact that reliable structure-function relationships that might guide the 
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rational development of photoacoustic dyes suitable for their use in biological contexts has not 
been derived. 
 
We recently reported the synthesis of meso-tetraphenylporphyrin-derived quinoline-annulated 
porphyrins, such as 4a or 5a.15 As a consequence of the extended π-conjugation and their 
annulation-induced non-planarity of the porphyrinic chromophore, the photophysical properties 
of quinoline-annulated porphyrins are significantly altered when compared to those of the parent 
porphyrin. While regular porphyrins generally do not absorb much past 650 nm, quinoline-annu-
lated porphyrins possess λmax bands in the 750 nm range. We have further shown that the bis-
annulated systems and quinoline-annulated chlorins (in which another pyrrole was modified by a 
non-pyrrole heterocycle) are accessible by step-wise conversion of 5a, further manipulating the 
optical properties of this family of porphyrinoids.15 Complementary syntheses of some of these 
derivatives and related chromophores are also known.16 
Crucially, quinoline-annulated porphyrins 4a and 5a were shown to be primarily relaxing 
rapidly non-radiatively, making them very good photoacoustic dyes.17 We demonstrated a ~ 2.5-
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fold PAI contrast enhancement for 4a over pure blood or ICG in phantom tissue experiments. 
The realization of a NIR-absorbing chromophores showing good photoacoustic signal 
generation efficiency is difficult, as the direct comparison of a number of NIR dyes absorbing in 
the same wavelength range has shown.17 Despite the promise of 4a or 5a as PAI contrast 
agents, however, their insolubility in aqueous solutions (in the absence of a formulation vehicle 
like Cremophore EL®) prevented their in vivo assessment. 
We report here the development of a quinoline-annulated porphyrin-based single-molecule, 
serum-soluble PAI contrast agent and the evaluation of its efficacy as an in vivo PAI contrast 
agent for the detection of implanted tumors in a mouse model. A multi-fold contrast 
enhancement when compared to ICG was found, a finding that could be traced to its 
photophysical properties. Its nontoxicity and renal clearance rates will be demonstrated. We 
also prepared a water-soluble quinoline-annulated derivative of the quinoline annulated 
porphyrin carrying a small fluorescent tag designed to facilitate the biodistribution studies of this 
intrinsically non-fluorescent chromophore. It was, however not fluorescent enough to be of 
utility. Nonetheless, the experiment demonstrated a facile and general conjugation strategy for 
these chromophores. 
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4.1 Results and Discussion 
4.1.1 Synthesis of a Freely Water-Soluble Quinoline-Annulated Porphyrin 
A number of strategies were established to render meso-arylporphyrins water-soluble.18 
Among them are their functionalization with anionic (carboxylate, sulfonate, phosphonate) or 
cationic (pyridinium) groups or their decoration with (multiple) polyethylene glycol (PEG) chains. 
We chose the PEG-strategy for the charge neutrality of the final products and previous reports 
indicating their suitability for tumor targeting.18e,19 We found that quinoline-annulated porphyrin 
4a is chemically stable under the classic acidic methoxy deprotection conditions (BBr3) but not 
to, for example, classic basic saponification reaction conditions (NaOH, wet THF). We thus 
chose the phenol-protected meso-tetrakis(p-methoxyphenyl)porphyrin 6b as the basis for the 
formation of the quinoline-annulated porphyrin chromophore,15a with the intent to deprotect and 
PEG-ylate the phenolic oxygens using standard Williamson alkylation strategies at the last 
stages of the dye synthesis pathway. This strategy was successful as demonstrated by the 
synthesis of the waters-soluble dyes 4d and 4e (Scheme 4-1). 
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Scheme 4-1. Synthesis of water-soluble quinoline-annulated porphyrins. Reaction conditions: (i) 1. 1 equiv. OsO4, 
30% pyridine/CHCl3, r.t.; 2. H2S (ii) 4 equiv. DMP, CH2Cl2, r.t. (iii) 100 equiv. NH2OH·HCl, pyridine, N2 atmosphere, 
r.t. (iv) DDQ, CH2Cl2, r.t. (v) pyridine, Δ (vi) 1. BBr3, CH2Cl2 (vii) Me(OCH2CH2)nOMs, Cs2CO3, DMF, 90 °C. 
p-Methoxy-derivatized quinoline-annulated porphyrin 4b was synthesized from meso-
tetrakis(p-methoxyphenyl)porphyrin 6b using the dihydroxylation → oxidation → oximation → 
annulation route established earlier for this chromophore class;15a all intermediates showed the 
expected spectroscopic and analytical properties (see ESI). However, some notable deviations 
from the established protocols were implemented. The oxidation of diolchlorin 7 required the 
use of Dess-Martin Periodinane (DMP) for its smooth conversion to the corresponding 2,3-
dioxochlorin 8.20 The generally used oxidant DDQ failed to produce this dione;21 instead 
dehydration to the corresponding enol was observed (the reaction was not further investigated). 
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Oxime 9 formed smoothly; its treatment with p-TSA under forcing conditions (toluene, reflux) 
produced the quinoline annulated porphyrin 4b in acceptable yields, but this product was 
contaminated with the corresponding N-oxide 5b. Because their separation was tedious, we 
treated oxime 9 with DDQ, thus forming N-oxide 5b as the exclusive product in near-quantitative 
yields. We attribute the facile annulation and oxidationto the electron-rich nature of the p-OMe-
substituted oxime. N-Oxide 5b could be readily reduced to quinoline annulated porphyrin 4b by 
heating to reflux in pyridine. Similar ready losses of the N-oxide were observed previously.15a 
Quinoline-annulated porphyrin N-oxide 5b was also susceptible to a BBr3-mediated deprotection 
of the methoxy groups and concomitant reduction of the N-oxide, without any noticeable 
degradation of the macrocycle, generating the phenolic quinoline-annulated porphyrin 4c in five 
linear steps from porphyrin 6b. 
Phenol-derivatized quinoline-annulated porphyrin 4c could be PEG-ylated with a methoxy-
capped PEG-mesylate using a short PEG chain (n = 4), forming 4d, as well as a longer chain 
(avg. MW 550, n ~ 12), forming 4e. ESI+ MS and 1H NMR spectra of 4d and 4e confirmed that 
all four non-equivalent phenolic OH-groups were PEG-ylated. The mass spectra of 4e reflect the 
chain length inhomogeneity of the longer PEG-chain (see experimental section). Because of the 
homogeneity of the shorter PEG derivative, we used this derivative for the determination of the 
photophysical properties of the water-soluble quinoline-annulated porphyrins. 
4.1.2 Photophysical Properties and Solubility of PEGylated Quinoline-Annulated 
Porphyrins 4d and 4e 
The presence of the four p-methoxy groups in 4b (or the four p-OH groups in its deprotected 
derivative 4c) is reflected in a slight red-shift of its optical spectrum (λmax = 762 nm for 4b,  λmax 
= 748 nm for 4c) when compared to the spectrum of 4a (λmax = 728 nm), but the overall 
characteristics of the quinoline-annulated porphyrins are not altered (Figure 4-1A).17 
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Figure 4-1. UV-vis spectra (A: CH2Cl2, B: H2O) of the compounds indicated. 
The shorter PEG derivative 4d is highly soluble in CH2Cl2 as well as alcoholic solvents, but 
is only slightly soluble in pure water. The PEG-ylated quinoline-annulated porphyrin 4e is freely 
soluble in alcohols, water, serum, and PBS buffer. As expected, the PEGylated derivatives 4d 
and 4e possess a λmax value of 764 nm in CH2Cl2. Both compounds exhibit some modest 
degree of solvatochromism. The spectrum of 4e in water, for example, is slightly blue-shifted 
and overall broadened (Figure 4-1B). 
The dissolution of 100 mg 4e/mL PBS was readily possible, forming a 33.3 mM solution. 
The solubility is therefore ~ 2 orders of magnitude higher than the reported value for ICG in 
water.22 The Lambert-Beer law is maintained for aqueous concentrations up to 0.03 mM (the 
upper limit we could measure in a 1 mm path length cell) but the addition of the surfactant 
TritonTM X-100 to dilute solutions slightly blue-shifts and enhances the Soret band (see 
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experimental), suggesting that 4e is somewhat aggregated in aqueous solution. The solutions 
are stable; no significant changes were observed in the UV-vis spectra of the solutions over 
many hours, and with only the onset of minor shifts after two weeks (in the dark at 4 °C). 
The fluorescence quantum yield φ for 4e in CH2Cl2 as well as H2O were determined to be 
significantly below 0.1%. Transient absorption spectra (in the range from 450 to 900 nm) for 4e 
in both solvents with pump-probe delay times from 0 to 15000 ps delivered no reliable ISC-
quantum yield or S1-lifetime data. Correspondingly, 4e in CH2Cl2, H2O, as well as H2O-TritonTM 
X-100 solutions showed no sign for the generation of singlet oxygen (1O2), as measured by the 
time-resolved NIR luminescence spectra of solutions of 4e (at O.D. = 0.1 at the excitation λ of 
532 nm) at 1270 and 1210 nm. 
Thus, PEGylated quinoline-annulated porphyrin 4e, like its parent compound,17 absorbs 
strongly within the spectroscopic window of tissue, is non-emissive, and does not generate 1O2. 
These are excellent properties for a photoacoustic imaging agent. 
4.1.3 ex vivo	 Photoacoustic Signal Generation of Water-Soluble Quinoline-Annulated 
Porphyrin 4e 
The strength of a photoacoustic (PA) signal generated by an irradiated sample is dependent 
upon the excitation source, absorption coefficient of the sample, solvent, and its Grüneisen 
parameter that represents the efficiency of the photoacoustic signal generation.3b The 2.5-fold 
increased PAI signal of quinoline-annulated porphyrin 4a (dissolved in PBS–1% DMF–1% 
Cremophore EL®) over the signal resulting from blood at identical absorbance values in tissue 
phantom studies was demonstrated.17 Water-soluble quinoline-annulated porphyrin 4e dissolved 
in water exhibits a similarly excellent performance: The relative ex vivo photoacoustic signal 
generation efficiency of the dye 4e placed in a translucent polyethylene tube submerged in a 
water bath was compared against that of day-old rat blood in the same setup and otherwise 
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identical irradiation and detection conditions. The concentration of 4e was adjusted so as to 
possess the identical absorbance value of the blood sample at 790 nm, the wavelength of the 
laser used to excite the dye. The co-registered pulse-echo and photoacoustic tomography (PE-
PAT) images clearly show that the tube filled with 4e generated a 4-fold stronger signal, thus 
generating a much higher contrast image than the blood sample (Figure 4-2A and Figure 4-2B). 
 
Figure 4-2. Co-registered PE-PAT images of polyethylene tubes (inner/outer Ø = 0.58/0.96 mm) filled with (A and C) 
one-day-old rat blood and (B and D) with a solution of PEG-ylated quinoline-annulated porphyrin 4e at a 
concentration in which the sample possessed the identical absolute absorbance value at 790 nm as the undiluted 
blood (see ESI). In each image pair (A-B and C-D) the PAT signal was normalized to the maximum value recorded 
from the tube filled with 4e. Samples immersed in water (A and B, PA signal dynamic range of -12 dB, the threshold 
is 25% of maximum) and Intralipid® (C and D, dynamic range of -15 dB, the threshold is 18% of maximum) at 1 cm 
(A and B) and 2.5 cm (C and D) scan depths, respectively. Vertical image axis is approximately parallel to the tube 
length and horizontal axis represents imaging depth. 
In tissue, light is significantly scattered and absorbed. The fat emulsion Intralipid® provides 
a strongly scattering medium for light.23 Thus, at 2.5 cm depth, only a small fraction of the light 
energy is delivered to the targets.3b In fact, at the light level used in the experiment, the blood 
sample could not provide any PA signal higher than the noise level (Figure 4-2C), while the tube 
filled with 4e still delivered well-resolved and high-contrast images (Figure 4-2D), demonstrating 
its potential as a PAI contrast agent. 
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4.1.4 Toxicity of PEGylated Quinoline-Annulated Porphyrin 4e 
Anesthetized 6 week old BALB/c mice were treated with 100 µL of a 33.3 mM PBS solution 
of 4e via retro-orbital injection, and their heart rates were monitored for 3 h after injection. No 
signs of distress of the mice were observed. They also lived for several weeks after the injection 
with normal weight gain and showed no abnormal behavior. The majority of the dye is excreted 
via the renal pathway within the first hour after injection (see also below). These are all 
promising preliminary indications for the absence of any acute toxicity of the PEG-ylated 
quinoline-annulated porphyrin 4e. 
4.1.5 The Use of Quinoline-Annulated Porphyrin 4e as an in vivo	PAI Contrast Agent 
As a result of the solubility, apparent non-toxicity, and high PA signal generation efficiency 
of the PEG-ylated dye 4e, we tested the efficacy of this dye as an in vivo PAT contrast agent in 
a mouse model. The dye 4e (100 µL of a 33.3 mM of 4e in PBS) was administered via retro-
orbital injection24 to anesthetized BALB/c mice with tumors (7-10 mm) implanted in their flanks, 
and the PE and co-registered PE-PAT images were recorded, beginning 1 min after injection 
(Figure 4-3A and B). The PE image shows the outline of the tumor and serves as backdrop to 
the PA image. Before injection, only few pixels of the PA image possess high enough signal 
strength to exceed a threshold value (25% of the maximum PA signal after injection). 
Proximately after injection (1 min), a ~ 4-fold increase in the PAT signal strengths originating 
from the tumor site were recorded. The enhancement of the PA signal was monitored for 45 min 
after injection, seeing a gradual loss of the signal strength, but even after 45 min, an at least 2-
fold PA signal enhancement was still achieved (Figure 4-4). The effect of PEG-ylation on 
increasing the blood circulation time of small molecules has been described.19,25 
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Figure 4-3. Co-registered PE-PAT images before injection of the contrast agent (A) and ICG (C) and after the 
systemic injection of 4e (B) and ICG (D). In each image pair (A-B and C-D) the PAT signals were normalized to the 
same maximum value recorded after the injection; a similar dynamic range of -12 dB is applied to all images (the 
threshold is 25% of the maximum value). The vertical axis is approximately parallel to the surface of the mouse body 
and the horizontal axis represents the depth inside the body. 
In comparison, injection of 100 µL ICG solution of identical absorbance at 780 nm as 4e at 
790 nm ([ICG] = 1.33 mM) provided a significantly lower PA signal strength enhancement (~1.6-
fold) (Figures 3C-D), with no enhancement after less than 30 min (Figure 4-4). Thus, the rate at 
which dye 4e is excreted (via renal pathways, see below) is significantly slower than the rapid 
excretion rate of ICG.14 
 
Figure 4-4. Time-dependence of the relative enhancement of the PAT max value following the injection of 100 µL of 
the dye 4e (~33.3 mM, λexcitation = 790 nm) and ICG (1.33 mM, λexcitation = 780 nm) at identical absorbance value. 
 4. in vivo PAI Using a Quinoline-Annulated Porphyrin as NIR Molecular Contrast Agent  
 
127 
 
4.1.6 Renal Filtration of Quinoline-Annulated Porphyrin 4e 
An early indication for the biodistribution of dye 4e was the observation of the color of the 
urine excreted by the mice immediately after the imaging experiments (after ~45 min) to the 
color of the dye (Figure 4-5). This suggested a very efficient renal filtration of the dye. Using UV-
vis spectroscopic and HPLC-MS analyses of the urine extracts, we were able to show that 4e 
was excreted in unaltered form. 
 
Figure 4-5. A. PEG-ylated quinoline-annulated dye 4e dissolved in PBS (~33.3 mM) in a microcuvette. B. Mouse 
urine collected after ~45 min after injection of 4e in a capillary tube. 
4.1.7 Fluorescent-Tagging of Quinoline-Annulated Porphyrin 4e 
Quinoline-annulated porphyrin 4e is non-fluorescent. However, the recording of fluorescent 
images of organs or the measurement of the dye-specific fluorescence of organ or biofluid 
extracts are convenient methodologies to track the biodistribution of any fluorophore. Thus, we 
opted to prepare a fluorophore-tagged derivative of quinoline-annulated porphyrin 4e. 
Recognizing that FRET processes might be operative that quench the fluorescence of the tag at 
the absorption maxima of quinoline-annulated porphyrins, we looked for fluorophores that emit 
in an area of relative minor absorption of these chromophores (Figure 4-1). 
BODIPYs are well-established low molecular weight fluorophores of high brightness and 
multiple options to adjust their optical spectra.26 Furthermore, a recent report describing the 
reaction of meso-mercapto-BODIPY derivative 10 with phenols to generate the meso-phenoxy-
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BODIPY derivative 11 (Scheme 4-2)27 seemed most suitable for our task of tagging a tetra-
phenol-derived quinoline-annulated porphyrin. Moreover, the emission λmax of 495 nm for 11 lies 
within the target range, and the attachment of the fluorophore at the most distal position to the 
porphyrinic chromophore would also reduce the chances for any FRET. 
 
Scheme 4-2. Synthesis of meso-phenoxy BODIPY derivative 11. Reaction Conditions: (i) Na2CO3, MeCN, 55 °C. 
Thus, we chose to attach a single BODIPY moiety to one of the four phenolic oxygens of 
tetraol 4c, followed by exhaustive PEG-ylation of the remaining three phenol functionalities 
(Scheme 4-3).  
 
Scheme 4-3. Synthesis of BODIPY-tagged water-soluble quinoline-annulated porphyrin 4g. Reaction conditions: (i) 1. 
Zn(OAc)2·2H2O, CH2Cl2/MeOH, Δ; 2. 1 equiv 10, Na2CO3, CuTC, CH3CN, 50 °C; 3. aq. HCl. (ii) Me(OCH2CH2)12OMs, 
Cs2CO3, DMF, 90 °C. 
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In anticipation of the copper-catalyzed reaction chosen for the conjugation of the fluorescent 
tag to quinoline-annulated porphyrin 4c, its central cavity was protected by insertion of zinc(II). A 
Cu(I) thiophene-carboxylate (CuTC)-mediated reaction of meso-mercapto-BODIPY 10,27 
followed by an acid-mediated removal of the zinc protecting group using a mineral acid wash, 
generated quinoline-annulated porphyrin 4f in which one of the phenolic oxygens was 
derivatized with the BODIPY group, while the other three groups remained unmodified (as per 
ESI+ MS). The lack of regioselectivity of this reaction is reflected in the complex 1H NMR 
spectrum of this compound (see experimental section). The three phenolic oxygens of 4f were 
then PEG-ylated using the long PEG mesylate as described above. Product 4g, a deep yellow 
oil, shows the expected composition (as per MALDI MS). It is freely water-soluble. The 
presence of the BODIPY is seen in the (complex) 1H NMR spectrum of 4g by the observation of 
the diagnostic peaks for the α- and β-protons of the BODIPY moiety (at δ = 6.5-7.0 ppm). Its 
19F NMR spectrum indicates the presence of fluorine atoms at δ = -146.4 to -146.6 ppm, the 
typical range for BODIPY fluorine atoms. 
The UV-vis spectrum of non-PEGylated derivative 4f is derived from a linear addition of the 
spectrum of tetraol 4c and BODIPY 11 (Figure 4-6A), with only some minor shifts and 
broadening, likely derived from the presence of four regioisomers. Upon PEGylation of 4f, the 
UV-vis spectrum is further broadened, with retention of the overall character of the quinoline-
annulated derivatives (Figure 4-6B). 
When dyad 4g is excited at the λmax value of the BODIPY moiety (at 441 nm), the molecule 
emits at 485 nm, this emission can be attributed to the BODIPY portion of 4g.27 However, the 
fluorescence yield φ for 4g is estimated to lie below 0.3%, i.e., much lower than the fluorescence 
yield φ for 11.27  
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Figure 4-6. A. UV-vis spectra of 4f (black) and 11 (red) (solid lines), and fluorescence emission (red broken line; 
λexcitation = 441 nm) for phenoxy-BODIPY 11 (all MeOH). B. UV-vis (solid line) and fluorescence emission (broken line; 
λexcitation = 441 nm) spectra of quinoline-annulated porphyrin-BODIPY dyad 4g (MeOH)). 
This suggests that some FRET (or other quenching) mechanisms are operative in 4g, but 
that this quenching is not efficient enough to entirely switch off the fluorescence of the BODIPY 
moiety. The low fluorescence yield questions the possibility of tracking dyad 4g in tissue using a 
fluorescence scanner. 
4.1.8 Biodistribution Study of BODIPY-Tagged Quinoline-Annulated Porphyrin 4g 
The biodistribution of the BODIPY-labeled derivative 4g in the tumor and other organs was 
studied by ex vivo fluorescent imaging, following the injection of 4g into 4 BALB/c mice as 
described for 4e. The mice were sacrificed 15 or 120 min after injection, the organs extracted, 
and their radiant efficiency fluorescent images recorded (λexc = 465 nm; GFP emission filter). 
Unfortunately, the high amount of tissue auto-fluorescence in that wavelength, did not allow the 
recording of high-contrast images. We note, however, that the tumor was yellow stained, 
suggesting an accumulation of the dye 4g in the tumor. 
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4.2 Conclusions 
In conclusion, we have demonstrated the in vivo efficacy of freely serum-soluble quinoline-
annulated porphyrin derivative 4e as a molecular contrast agent for photoacoustic tomography. 
The solubilization of the quinoline-annulated porphyrin followed a straight-forward PEGylation 
strategy, with the lengths of the PEG chains determining the solubility of the final product. The 
product appeared to be low acute toxicity, accumulated in the tumor site, and was rapidly 
excreted in unaltered fashion via renal pathways. The solubilisation strategy is conceivably also 
suitable to other quinoline-annulated porphyrin derivatives. Conjugation of the non-fluorescent 
PEGylated quinoline-annulated porphyrin to a fluorophore was also demonstrated, but the 
hopes to utilize this derivative for the tracking of the biodistribution of the contrast agent using 
fluorescence imaging was not fulfilled. Nonetheless, the flexible derivatization strategy points 
the way toward the conjugation to other molecules. 
4.3 Experimental Section 
4.3.1 Materials and Instruments 
All solvents (Aldrich, Acros) and reagents MeO-PEG4-OMs (Aldrich) and MeO-PEG12-OMs 
(Creative Peg Works), CuTC (Aldrich) were reagent grade, or better, and were used as 
received. meso-Tetrakis(p-methoxyphenyl)-2,3-dihydroxychlorin (7)28 and BODIPYs 10 and 11 
were prepared as described previously.27 
Analytical (aluminum backed, silica gel 60, 250 µm thickness) and preparative (20 × 20 cm, 
glass backed, silica gel 60, 500 µm thickness) TLC plates, and the flash column silica gel 
(standard grade, 60 Å, 32-63 µm) used were provided by Sorbent Technologies, Atlanta, GA.  
1H and 13C NMR spectra were recorded on Bruker Avance II 400 and Bruker Avance I 500 
instruments in the solvents indicated, and were referenced to residual solvent peaks. High and 
low resolution ESI mass spectra were provided by the Mass Spectrometry Facilities at the 
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Department of Chemistry, University of Connecticut. MALDI MS Spectra were provided by the 
Mass Spectrometry & Proteomics Facility at the University of Notre Dame. UV-vis and 
fluorescence spectra were recorded on Cary 50 and Cary Eclipse photospectrometers, Varian 
Inc, respectively, and IR spectra on a Bruker Alpha-P FT-IR spectrometer using a diamond ATR 
unit. 
4.3.2 Synthesis and Characterization 
meso-Tetrakis(p-methoxyphenyl)-2,3-dioxoporphyrin (8). Diol 7 (270 mg, 3.51 × 10-4 
mol) was dissolved in CH2Cl2 (60.0 mL) in a round-bottom flask equipped with a magnetic stir 
bar. To the stirring solution was added Dess-Martin periodinane (590 mg, 1.39 × 10-3 mol, 4 
equiv) in portions at ambient temperature. When the starting material was consumed (reaction 
control by UV-vis and TLC), the reaction was quenched by addition of a sat’d aq NaHCO3 
solution. The organic layer was isolated and washed with H2O (3 × 30 mL). The organic layer 
was dried over anhyd Na2SO4 and evaporated to dryness by rotary evaporation, and the residue 
purified by column chromatography (silica-CH2Cl2) to yield 8 as a dark blue powder in yields 
ranging from 65 to 90% (243 mg): Rf (CH2Cl2-silica) = 0.52; 1H NMR (400 MHz, CD2Cl2) δ 8.81 
(d, 3J = 4.9 Hz, 1H), 8.65 (d, 3J = 4.9 Hz, 1H), 8.61 (s, 1H), 8.06 (d, 3J = 8.6 Hz, 2H), 7.84 (d, 3J 
= 8.6 Hz, 2H), 7.31-7.24 (m, 4H), 4.07 (two overlapping s, 6H), -1.90 (br s, 1H, exchangeable 
with D2O); 13C NMR (100 MHz, CD2Cl2): δ 188.2, 159.9, 159.6, 155.64, 155.62, 155.59, 140.9, 
140.2, 138.4, 135.3, 134.1, 133.8, 133.4, 131.8, 128.4, 128.0, 123.9, 113.4, 112.65, 112.54, 
112.47, 55.5, 55.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 410 (5.26), 477 (4.26) nm; FT-IR (neat, 
diamond ATR) 1730 (νC=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for C48H37N4O6 
([M·H]+) 765.2713, found 765.2726. 
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Figure 4-7. 1H NMR spectrum (400 MHz, CD2Cl2) of 8. 
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Figure 4-8. 13C NMR spectrum (100 MHz, CD2Cl2) of 8. 
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Figure 4-9. UV-vis spectrum (CH2Cl2) of 8. 
 
 
Figure 4-10. FT-IR spectrum (neat, diamond ATR) of 8. 
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meso-Tetrakis(p-methoxyphenyl)-2-hydroxyimino-3-oxoporphyrin (9). Dione 8 (94 mg, 
1.2 × 10-4 mol) was dissolved in pyridine (30.0 mL) in a round bottom flask equipped with a 
magnetic stir bar and N2 inlet. Hydroxylamine hydrochloride (NH2OH·HCl, 850 mg, ~100 equiv) 
was added, and the mixture was stirred at ambient temperature. When the starting material was 
consumed (after about 24 h; reaction control by TLC), the reaction mixture was evaporated to 
dryness by rotary evaporation. The residue was taken up in CH2Cl2 and filtered through a glass 
frit (M). The volume of the filtrate was reduced and submitted to column chromatography (silica-
CH2Cl2/1% MeOH) to afford the olive-green product 9 in 60% yield, (58 mg): Rf (silica-
CH2Cl2/1% MeOH) = 0.65; 1H NMR (400 MHz, CD2Cl2) δ 15.78 (br s, 1H, exchangeable with 
D2O), 8.81 (d, 3J = 5.7 Hz, 2H), 8.62 (t, 3J = 8.4 Hz, 4H), 8.03 (dd, 3J = 8.4, 4J = 2.0 Hz, 4H), 
7.85 (dd, 3J = 8.4 Hz, 4H), 7.27-7.19 (m, 8H), 4.05 (s, 12H), -2.23 (br s, 1H exchangeable with 
D2O), -2.36 (br s, 1H exchangeable with D2O) ppm; 13C NMR (100 MHz, CD2Cl2) δ 188.2, 
159.82, 159.75, 159.6, 156.4, 154.9, 151.9, 145.4, 141.1, 139.8, 138.9, 138.80, 137.98, 135.4, 
134.4, 133.6, 133.50, 133.47, 132.1, 128.6, 128.4, 127.63, 127.57, 123.8, 121.8, 115.8, 113.0, 
112.7, 112.4, 112.2, 55.5, 55.42, 55.39, 53.8 ppm; UV-vis (CH2Cl2) λmax (log ε) 410 (5.44), 465 
(sh), 613 (4.04), 670 (sh) nm; FT-IR (neat, diamond ATR): 1732 (νC=O) cm-1; HR-MS (ESI+, 
100% CH3CN, TOF) m/z calcd for C48H38N5O6 ([M·H]+) 780.2822, found 780.2801. 
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Figure 4-11. 1H NMR spectrum (400 MHz, CD2Cl2) of 9. 
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Figure 4-12. 13C NMR spectrum (100 MHz, CD2Cl2) of 9. 
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Figure 4-13. UV-vis spectrum (CH2Cl2) of 9. 
 
Figure 4-14. FT-IR spectrum (neat, diamond ATR) of 9. 
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meso-Tris(p-methoxyphenyl)(p-methoxy)quinoline-annulated porphyrin N-Oxide (5b). 
Oxime 9 (14.7 mg, 1.88 × 10-5 mol) was dissolved in CH2Cl2 (10.0 mL) in a round bottom flask 
equipped with a magnetic stir bar. To the stirring solution was added 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ, 9 mg, 2 equiv) and the mixture was stirred at ambient temperature. 
When the starting material was consumed (after 0.5 h; reaction control by UV-vis and TLC), the 
reaction mixture was filtered through a plug of silica gel. The filtrate was washed with water (2 × 
10 mL), dried over anhyd Na2SO4, and evaporated to dryness by rotary evaporation. The 
resulting residue was purified by column chromatography (silica-CH2Cl2/1% MeOH) to afford the 
brown product 5b in 97% yield (14 mg): Rf (silica-CH2Cl2/2% MeOH) = 0.22; 1H NMR (400 MHz, 
CDCl3) δ 8.54 (d, 3J = 4.2 Hz, 1H), 8.41 (d, 3J = 4.9 Hz, 1H), 8.35-8.28 (m, 3H), 8.19 (dd, 3J = 
4.3 Hz, 2H), 8.03 (d, 3J = 2.0 Hz, 1H), 7.86-7.80 (m, 4H), 7.68-7.65 (m, 2H), 7.23-7.20 (m, 4H), 
7.16-7.10 (m, 3H), 4.08-4.04 (m, 10H), 3.89 (s, 3H), -0.32 (br s, 2H, exchangeable with D2O) 
ppm; 13C NMR (100 MHz, CDCl3) δ 185.0, 159.9, 159.6, 159.3, 159.0, 155.9, 153.6, 145.9, 
143.7, 143.5, 141.6, 138.2, 135.6, 135.5, 135.2, 134.9, 134.3, 133.7, 133.4, 133.3, 133.10, 
132.98, 132.94, 131.0, 129.3, 127.7, 127.4, 127.3, 124.5, 123.8, 122.7, 120.9, 113.2, 113.1, 
112.6, 112.5, 102.1, 101.9, 56.0, 55.6, 55.54, 55.47 ppm; UV-vis (CH2Cl2) λmax (log ε) 422 
(5.02), 504 (4.27), 543 (4.16), 751 (4.09) nm; FT-IR (neat, diamond ATR): 1686 (νC=O) cm-1; HR-
MS (ESI+, 100% CH3CN, TOF) m/z calcd for C48H36N5O6 ([M·H]+), 778.2666, found 778.2693. 
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Figure 4-15. 1H NMR spectrum (400 MHz, CDCl3) of 5b. 
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Figure 4-16. 13C NMR spectrum (100 MHz, CDCl3) of 5b. 
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Figure 4-17. UV-vis spectrum (CH2Cl2) of 5b. 
 
 
Figure 4-18. FT-IR spectrum (neat, diamond ATR) of 5b. 
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meso-Tris(p-methoxyphenyl)(p-methoxy)quinoline-annulated porphyrin (4b). Quinoline 
N-oxide 5b (23.7 mg, 3.05 × 10-5 mol) was dissolved in pyridine (25.0 mL) and heated to reflux. 
When the starting material was consumed (after 48 h; reaction control by TLC and UV-vis), the 
solvent was evaporated and the remaining residue was purified by preparative TLC (silica-
CH2Cl2/2% MeOH) and solvent exchanged from CH2Cl2 to MeOH to afford the brown powder 4b 
in 44% yield (10 mg): Rf (silica-CH2Cl2/2% MeOH) = 0.54; 1H NMR (400 MHz, CD2Cl2): δ 8.97 
(two overlapping d, 3J = 7.5 Hz, 2H), 8.37 (dd, 3J = 7.9, 4J = 4.9 Hz, 2H), 8.22 (d, 3J = 4.6 Hz, 
1H), 8.16 (d, 3J = 4.4 Hz, 2H), 8.00-7.97 (m, 3H), 7.89 (d, 3J = 8.5 Hz, 2H), 7.73 (d, 3J = 8.4 Hz, 
2H), 7.54 (dd, 3J = 9.1, 4J = 2.7 Hz, 1H), 7.28 (d, 3J = 8.5 Hz, 2H), 7.22 (dt, 3J = 5.3, 4J = 3.3 Hz, 
4H), 4.09 (s, 3H), 4.06 (two overlapping singlets, 6H), 4.03 (s, 3H), 1.07 (s, 2H, exchangeable 
with D2O); 13C NMR (100 MHz, CD2Cl2): δ 202.2, 180.4, 160.2, 159.8, 159.4, 159.0, 148.96, 
148.85, 148.29, 148.21, 146.8, 146.56, 146.54, 145.7, 135.5, 134.7, 134.3, 133.5, 133.2, 132.9, 
132.3, 131.0, 129.9, 127.5, 127.2, 122.9, 120.5, 113.0, 112.9, 112.8, 112.7, 112.6, 112.3, 110.0, 
55.8, 55.6, 55.5, 55.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 418 (5.0), 490 (4.23), 529 (4.23), 701 
(sh), 762 (4.12) nm; FT-IR (neat, diamond ATR): 1716 (νC=O) cm-1; HR-MS (ESI+, 100% CH3CN, 
TOF) m/z calcd for C48H36N5O5 ([M·H]+) 762.2716, found 762.2738. 
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Figure 4-19. 1H NMR spectrum (400 MHz, CD2Cl2) of 4b. 
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Figure 4-20. 13C NMR spectrum (100 MHz, CD2Cl2) of 4b (the compound has limited solubility). 
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Figure 4-21. UV-vis spectrum (CH2Cl2) of 4b. 
 
 
Figure 4-22. FT-IR spectrum (neat, diamond ATR) of 4b. 
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meso-Tris(p-hydroxyphenyl)(p-hydroxy)quinoline-annulated porphyrin (4c). Quinoline 
N-oxide 5b (26 mg, 3.3 × 10-5 mol) was dissolved in dry CH2Cl2 (5.5 mL) in a round bottom flask 
equipped with a magnetic stir bar and N2 inlet. A 1.0 M solution of BBr3 in CH2Cl2 (1.35 mL, ~40 
equiv) was added drop-wise to the flask and the reaction mixture was stirred. When the starting 
material was consumed (after 24-48 h; reaction control by TLC), the excess BBr3 was quenched 
by the careful addition of the reaction mixture to distilled water (10 mL). The resulting mixture 
was extracted with EtOAc (3 × 20 mL), washed with sat’d sodium bicarbonate solution and 
water (2 × 20 mL). The organic layer was then dried over anhydrous Na2SO4. The resulting 
residue was adsorbed onto silica gel and dry-loaded onto a silica gel column and purified by 
chromatography (silica-CH2Cl2/10% MeOH) to afford 4c in 65% yield (18 mg): Rf (silica-
CH2Cl2/10% MeOH) = 0.45; 1H NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H, exchangeable with 
D2O), 10.09 (s, 1H, exchangeable with D2O), 9.97 (s, 1H, exchangeable with D2O), 9.71 (s, 1H, 
exchangeable with D2O), 8.81 (s, 1H), 8.61 (s, 1H), 8.34 (s, 1H), 8.20 (s, 1H), 8.12 (d, 3J = 4.4 
Hz, 1H), 8.03 (d, 3J = 5.8 Hz, 1H), 7.75 (d, 3J = 7.5, 3H), 7.58 (d, 3J = 7.8 Hz, 2H), 7.34 (d, 3J = 
3.9 Hz, 1H), 7.16 (d, 3J = 7.9 Hz, 2H), 7.11 (d, 3J = 8.2 Hz, 2H), 7.04 (d, 3J = 8.4 Hz, 2H) ppm; 
13C NMR (100 MHz, DMSO-d6): δ 194.6, 158.6, 158.1, 157.5, 157.4, 150.51, 150.49, 150.47, 
146.12, 146.10, 142.03, 141.96, 138.92, 138.89, 136.1, 135.8, 135.43, 135.39, 135.2, 134.7, 
134.6, 134.03, 133.94, 133.4, 132.5, 131.4, 131.1, 130.6, 130.3, 130.10, 130.09, 129.4, 127.86, 
127.83, 127.80, 127.32, 127.30, 127.27, 127.26, 124.59, 124.57, 123.29, 123.26, 123.20, 
123.19, 120.98, 120.96, 120.95, 120.26, 120.25, 115.44, 115.41, 114.95, 114.92, 114.82, 
114.76, 114.68, 111.9, 109.4, 100.0 ppm; UV-vis (MeOH) λmax (log ε) 417 (5.15), 487 (sh), 531 
(4.31), 748 (4.24) nm; FT-IR (neat, diamond ATR): 1705 (νC=O) cm-1; HR-MS (ESI+, 100% 
CH3CN, TOF) m/z calcd for C44H28N5O5 ([M·H]+) 706.2090, found 706.2061. 
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Figure 4-23. 1H NMR spectrum (400 MHz, DMSO-d6) of 4c. 
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Figure 4-24. 13C NMR spectrum (100 MHz, DMSO-d6) of 4c. 
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Figure 4-25. UV-vis spectrum (MeOH) of 4c.  
 
Figure 4-26. FT-IR spectrum (neat, diamond ATR) of 4c. 
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meso-Tris(p-MeOPEG4Ophenyl)(p-MeOPEG4O)quinoline-annulated porphyrin (4d). 
Following a literature protocol for the PEGylation of a meso-(p-OH-phenyl)porphyrin,29 
quinoline--annulated porphyrin 4c (10 mg, 1.4 × 10-5 mol) was dissolved in dry DMF (4.0 mL) in 
a two-neck round bottom flask equipped with a magnetic stir bar. MeO-PEG4-OMs (25.0 mg, 8.9 
× 10-5 mol, 6 equiv.) and Cs2CO3 (24.2 mg, 7.4 × 10-5 mol, 5.2 equiv.) were added and the 
reaction mixture was immersed in a preheated oil bath at ~100 °C. After consumption of the 
starting material after ~3 h (reaction control by TLC) the solvent was evaporated and the 
residue was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic layer was 
washed with H2O (3 × 10 mL) and dried over Na2SO4. The brown residue was purified by column 
chromatography (silica-CH2Cl2/5% MeOH) to afford the tetra-PEGylated product 4d as a yellow-
brown oil in 56% yield (12 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.56; 1H NMR (500 MHz, 
CD2Cl2): δ 9.06-9.04 (m, 2H), 8.40 (d, 3J = 4.5 Hz, 1H), 8.36 (d, 3J = 5.0 Hz, 1H), 8.23 (d, 3J = 
4.5 Hz, 1H), 8.16 (d, 3J = 4.5 Hz, 2H), 7.99 (d, 3J = 8.5 Hz, 3H), 7.89 (d, 3J = 8.5 Hz, 2H), 7.71 
(d, 3J = 8.5 Hz, 2H), 7.63 (dd, 3J = 9.1, 4J = 2.5 Hz, 1H), 7.30 (d, 3J = 8.6 Hz, 2H), 7.23 (dd, 3J = 
8.5, 4J = 1.8 Hz, 4H), 4.44 (t, 3J = 4.5 Hz, 2H), 4.38 (two overlapping t, 3J = 4.7 Hz, 4H), 4.35 (t, 
3J = 4.6 Hz, 2H), 3.99 (dd, 3J = 8.8, 4J = 4.7 Hz, 6H), 3.82-3.77, (m, 8H), 3.72-3.57 (m, 34H), 
3.55-3.50 (m, 8H), 3.35 (s, 3H), 3.34 (s, 3H), 3.33 (s, 3H), 3.31 (s, 3H) ppm; UV-vis (CH2Cl2) 
λmax (log ε) 419 (5.2), 491 (4.5), 531 (4.4), 764 (4.3) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z 
calcd for C80H100N5O21 ([M·H]+), 1466.6911, found 1466.6891. 
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Figure 4-27. 1H NMR spectrum (500 MHz, CD2Cl2) of 4d. 
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Figure 4-28. 13C NMR spectrum (125 MHz, CD2Cl2) of 4d. 
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Figure 4-29. UV-vis spectrum (CH2Cl2) of 4d. 
meso-Tris(p-MeOPEG12Ophenyl)(p-MeOPEG12O)quinoline-annulated porphyrin (4e). 
Prepared from 4c (22 mg, 3.1 × 10-5 mol) in dry DMF (10.0 mL), Cs2CO3 (80 mg, 1.6 × 10-4 mol, 
5.2 equiv.), and MeO-PEG12-OMs (80 mg, 1.2 × 10-4 mol, 4 equiv.) as described for the 
preparation of 4d. Reaction time at 90 °C ~3 h. Purified by column chromatography (silica-
CH2Cl2/10% MeOH) to afford the tetra-PEGylated porphyrin 4e as a brown oil in 90-99 % yield 
(81 mg-89 mg): 1H NMR (400 MHz, CD2Cl2): δ 9.04 (s, 1H), 8.38 (two overlapping d, 2H), 8.19 
(d, 3H), 7.98 (t, 3J = 6.6 Hz, 3H), 7.89 (d, 3J = 8.3 Hz, 3H), 7.72 (d, 3J = 8.4 Hz, 2H), 7.63 (d, 3J = 
8.3 Hz, 1H), 7.31 (d, 3J = 8.5 Hz, 3H), 7.24 (dd, 3J = 8.6, 4J = 2.2 Hz, 4H), 3.34 (four overlapping 
s, 12H) ppm; UV-vis (CH2Cl2) λmax (rel I.) 422 (1.0) 529 (0.20) 763 (0.09) nm; HR-MS (ESI+, 
100% CH3CN, TOF) cluster of peaks corresponding to addition of four PEG groups, see ESI.  
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Figure 2-30. 1H NMR spectrum (400 MHz, CD2Cl2) of 4e. 
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Figure 4-31. UV-vis spectrum (H2O) of 4e. 
 
 
Figure 4-32. Absorption spectra of 4e (PQP) in CH2Cl2, H2O and H2O-Triton-X solutions. The change of the 
absorption spectrum of 4e in H2O after adding triton indicates that 4e is somewhat aggregated in pure aqueous 
solution. 
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Figure 4-33. HR-MS (ESI+, 100% CH3CN, TOF) of 4e. 
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[meso-Tris(p-hydroxyphenyl)(p-hydroxy)quinoline-annulated porphyrinato]Zinc(II) (4cZn). 
Quinoline-annulated porphyrin 4c (19 mg, 2.7 × 10-5 mol) was dissolved in CH2Cl2/10% MeOH 
(7.0 mL) in a round bottom flask equipped with a magnetic stir bar. Zn(OAc)2·2H2O (18 mg, 8.1 
x 10-5 mol, 3 equiv.) was added and the reaction was gently warmed. When the starting material 
was consumed (after 10 min; reaction control by TLC and UV-vis), the solvents were 
evaporated, and the residue was taken up in EtOAc and washed with water (3 × 20 mL). The 
organic layer was dried over anhydrous Na2SO4 and evaporated to dryness by rotary 
evaporation to afford 4cZn as an orange solid in near-quantitative yield (21 mg): Rf (silica-
CH2Cl2/10% MeOH) = 0.39; 1H NMR (400 MHz, DMSO-d6): δ 10.23 (s, 1H, exchangeable with 
D2O), 9.94 (s, 1H, exchangeable with D2O), 9.85 (s, 1H, exchangeable with D2O), 9.57 (s, 1H, 
exchangeable with D2O), 8.90 (t, 3J = 7.9 Hz, 2H), 8.19 (d, 3J = 4.5 Hz, 1H), 8.05 (d, 3J = 4.6 Hz, 
1H), 7.99 (dd, 3J = 12.1, 4J = 4.4 Hz, 2H), 7.76 (t, 3J = 6.4 Hz, 4H), 7.70 (d, 3J = 8.2 Hz, 2H), 
7.56 (dd, 3J = 9.0, 4J = 2.4 Hz, 1H), 7.47 (d, 3J = 8.2 Hz, 2H), 7.13 (d, 3J = 8.3 Hz, 2H), 7.07 (d, 
3J = 8.3 Hz, 2H), 7.00 (d, 3J = 8.2 Hz, 2H) ppm; 13C NMR (100 MHz CD2Cl2/10% MeOD): δ 
195.7, 159.8, 158.1, 157.8, 157.0, 156.6, 152.7, 152.1, 150.9, 150.5, 150.1, 148.0, 146.3, 143.3, 
142.7, 135.6, 135.4, 134.8, 134.6, 133.8, 133.7, 133.6, 133.52, 133.47, 133.2, 132.0, 131.2, 
131.06, 130.13, 130.0, 126.7, 123.7, 121.0, 115.6, 115.0, 114.7, 114.5, 111.9 ppm; UV-vis 
(MeOH) λmax (log ε) 420 (5.13), 484 (sh), 518 (sh), 737 (sh), 816 (4.25) nm; FT-IR (neat, 
diamond ATR): ~1750 (νC=O) cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z calcd for 
C44H26N5O5Zn ([M·H]+) 768.1225, found 768.1222. 
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Figure 4-34. 1H NMR spectrum (400 MHz, DMSO-d6) of 4cZn. 
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Figure 4-35. 13C NMR spectrum (100 MHz, CD2Cl2/10% MeOD) of 4cZn. 
N
N N
N
N
O
OH
OH
OH
HO Zn
 4. in vivo PAI Using a Quinoline-Annulated Porphyrin as NIR Molecular Contrast Agent  
 
162 
 
 
Figure 4-36. UV-vis spectrum (MeOH) of 4cZn. 
 
 
Figure 4-37. FT-IR spectrum (neat, diamond ATR) of 4cZn. 
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p-(BODIPY)-tris-p-(OH)-quinoline-annulated porphyrin, mixture of regioisomers (4f). 
meso-thiomethyl-4,4,-difluoro-4-bora-3a,4a-diaza-s-indacene 10 (6 mg, 2.7 × 10-5 mol) was 
dissolved in dry CH3CN (3.0 mL) in a round bottom flask equipped with a magnetic stir bar 
under N2 atmosphere. Tetraol 4cZn (21 mg, 2.7 × 10-5 mol, 1 equiv) was added and the mixture 
was stirred for 5 min under N2. Copper(I) thiophene-2-carboxylate (CuTC) (5 mg, 2.7 × 10-5 mol, 
1 equiv.) and Na2CO3 (3 mg, 2.7 × 10-5 mol, 1 equiv.) were added and the reaction mixture was 
immersed in a pre-heated oil bath at 50 °C and stirred.27 After 48 h, a saturated aqueous NH4Cl 
solution was added and the reaction mixture was stirred for several hours. The resulting 
biphasic mixture was extracted with EtOAc (3 × 10 mL), washed with H2O (2 × 10 mL), and 
dried over Na2SO4. The remaining residue was purified by column chromatography (silicia-
CH2Cl2/10% MeOH) to afford recovered 4cZn (6 mg) and the mono-BODIPY-tagged product 4f 
as a series of closely running yellow fractions. The combined yellow fractions were dissolved in 
EtOAc (5.0 mL) and treated with 3 M HCl (5.0 mL) until the UV-vis spectrum of a neutralized 
aliquot indicated full demetallation. The organic layer was then washed with a sat’d aq. NaHCO3 
solution and H2O, and was dried over anhyd. Na2SO4 to provide 4f as a yellow film in 30% yield 
(7 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.21; 1H-NMR (500 MHz, DMSO-d6): δ 10.09-10.07 (m, 
1H, exchangeable with D2O), 9.95-9.93 (m, 1H, exchangeable with D2O), 9.69-9.64 (m, 1H, 
exchangeable with D2O), 9.10 (br s, 1H), 8.45 (d, 3J = 4.4 Hz, 1H), 8.4-8.37 (m, 1H), 8.18 (d, 3J 
= 5.2 Hz, 2H), 8.13-8.10 (m, 2H) 8.08-7.95 (m, 3H), 7.92-7.88 (m, 3H), 7.80-7.77 (m, 4H), 7.60-
7.59 (m, 1H), 7.31 (s, 1H), 7.19 (d, J = 6.0 Hz, 2H), 7.12 (two overlapping d, 3J = 7.8 Hz, 2H), 
7.05-7.03 (m, 2H), 6.81 (d, J = 6.1 Hz, 2H), 6.76-6.72 (m, 1H) ppm; 19F NMR (470 MHz, DMSO-
d6): δ -142.1 to -142.2, (m) ppm; UV-vis (MeOH) λmax (rel I.) 400 (1.0), 443 (0.56), 510 (sh), 784 
(0.1) nm; Fl (MeOH, λexcitation = 441 nm) λmax 488 nm, φ (EtOAc) = 0.01; HR-MS (ESI+, 100% 
CH3CN, TOF) m/z calcd for C53H33BF2N7O5 ([M·H]+) 896.2613, found 896.2613. 
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Figure 4-38. 1H NMR spectrum (500 MHz, DMSO-d6) of 4f. 
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Figure 4-39. 19F NMR spectrum (470 MHz, DMSO-d6) of 4f. 
 
Figure 4-40. UV-vis and Fluorescence emission spectrum (MeOH, λexcitation = 441 nm) of 4f.  
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p-(BODIPY)-tris-p-(OPEG12)-quinoline-annulated porphyrin, mixture of regioisomers (4g). 
Prepared according to the procedure for 4e from 4d (10 mg, 1.1 × 10-5 mol), MeO-PEG550-OMs 
(22 mg, 3.4 × 10-5 mol, 3 equiv.), 14 mg of Cs2CO3 (4.4 × 10-5 mol, 3.9 equiv.) in DMF (2.0 mL) 
to afford 4g as a yellow oil in 56% yield (16 mg): 1H NMR (400 MHz, CD2Cl2): δ 9.14 (s, 1H), 
8.45 (s, 1H), 8.38 (d, 3J = 4.6 Hz, 1H), 8.21 (d, 4H), 8.01 (d, 3J = 6.8 Hz, 3H), 7.91 (d, 3J = 7.6 
Hz, 2H), 7.73 (d, 3J = 7.2 Hz, 3H), 7.52 (s, 1H), 7.31 (d, 3J = 8.0 Hz, 4H), 7.25 (d, 3J = 5.0 Hz, 
5H), 7.13-7.11 (m, 2H), 6.82 (d, 3J = 5.7 Hz, 1H), 6.46 (s, 1H), 3.35-3.3 (three overlapping s, 
9H) ppm; 19F NMR (470 MHz, CD2Cl2): δ -142.1 to -142.2, (m) ppm; UV-vis (MeOH) λmax (rel I.) 
402 (1.0), 473 (sh), 510, (sh), 769 (0.12) nm; Fl (MeOH, λexcitation = 441 nm) λmax 485 nm, φ 
(EtOAc) < 0.003; HR-MS (MALDI, 100% DHBA) cluster of peaks corresponding to addition of 
three PEG groups, see ESI. 
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Figure 4-41. 1H NMR spectrum (400 MHz, CD2Cl2, pre-saturated at 3.6 ppm) of 4g. 
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Figure 4-42. 19F NMR spectrum (376 MHz, CD2Cl2) of 4g. 
 
 
Figure 4-43. UV-vis and Fluorescence emission spectrum (MeOH, λexcitation = 441 nm) of 4g. 
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Figure 4-44. MALDI-TOF spectrum (100% DHBA) of 4g. 
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Figure 4-45. LC-MS of mouse urine extract (CH2Cl2), obtained after injection of 4e. 
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Figure 4-46. UV-vis spectrum (CH2Cl2) of mouse (diluted) urine obtained after injection of 4e. 
 
4.3.3 Co-registered pulse-echo-photoacoustic tomography 
The details to the 64 channel co-registered ultrasound pulse echo-photoacoustic 
tomography (PE-PAT) system is described elsewhere.29 Briefly, the system utilizes a unique 
field-programmable gate array (FPGA) technology that allows for real-time acquisition of 
ultrasound and photoacoustic signals. The photoacoustic signal is generated by a 15 Hz, 12 ns 
pulse width light of a tunable Ti-Sapphire laser (LT-2211, Symphotics TII Corp, Camarillo, CA) 
pumped by a second harmonic Nd:YAG laser (LS-2134, Symphotics TII Corp). Free space 
illumination is used for light delivery. The laser light is expanded by a combination of concave 
and convex lenses and shone on the sample using mirrors. A small portion of the beam is 
separated by a beam splitter (BSN11, Thorlabs) and is focused on a single element ultrasound 
transducer for monitoring the fluctuations in laser energy during the experiment.30 The pulse-
echo (PE) ultrasound signal is generated and received by the system in synchrony with the 
laser pulses. The PE and PAT images are formed by a beamforming algorithm. The data 
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sampling is performed at 40 MHz. A 64 channel ultrasound transducer with a center frequency 
of 3.5 MHz, a bandwidth of 80%, and a sector scan type is utilized for acquiring the co-
registered PE-PAT images. Ultrasound and PAT images are overlapped to form the co-
registered images. The effects of laser energy fluctuations are compensated for in the data 
analysis. 
The setup was also used for the phantom photoacoustic signal generation efficiency 
evaluation of the dyes, as described previously.17 
4.3.4 Animal protocols 
All experiments involving mice were performed as approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Connecticut under license #A15-047. The 
purity of contrast agents 4e and 4g was assessed by HPLC (see ESI). Solutions of 4e and 4g 
were also filtered through a syringe filter (nylon membrane, pore size 0.22 µm) prior to injection. 
4.3.5 Toxicity test 
100 µL of PBS based solution of 4e with 33.3 mM concentration was injected into 
anesthetized 6 week old BALB/c mice (n = 2). The heart rates of the mice were monitored by a 
pulse oximeter (MouseStat, Kent Scientific) before injection and during a 3 h period after 
injection. 
4.3.6 Tumor model 
Tumor cell preparation was adopted from the literature.31 Briefly, 4T1 Luc cells were cultured 
at 37 °C with 5% CO2 in a T75 flask (BD Biosciences, Bedford, MA); DMEM (Dulbecco's 
Modified Eagle's medium, Gibco, USA) medium supplemented with 10% FBS and 50 U/mL 
penicillin/streptomycin. After 3 passes, the cells were suspended in the DMEM and 1 × 105 cells 
were injected subcutaneously on top of the right leg of female BALB/c mice (6-8 weeks old, 
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body weight ~20 g). The mice were monitored for approximately two weeks post-inoculation 
until the tumor size was between 7-10 mm. 
4.3.7 In vivo	PAT of murine tumor 
Prior to the in vivo imaging, the mice were anaesthetized (1.5 L/min oxygen with 1.5% 
isoflurane) and the tumor area depilated. The position of the mouse was fixed. Ultrasound gel 
was applied on the tumor area and a bag of water was placed on top of the tumor for acoustic 
wave coupling. The pulsed laser at 790 nm of the pulse-echo-photoacoustic tomography (PE-
PAT) setup described above (780 nm for ICG) was shone on the tumor through the water bag; 
surface optical fluence on the tissue was always maintained below the maximum permissible 
exposure according to the ANSI safety standard.32 The transducer position was adjusted by a 
three-dimensional mechanical stage to reach a suitable imaging condition. The pre-injection 
PAT image of the tumor was acquired. Then 100 µL of the PBS based solution of the dye 4e 
(~33.3 mM concentration) or ICG was injected via retro-orbital injection.24 Care was taken to 
avoid any changes in the position of the mouse, transducer, and light beam as a result of the 
injection. The PAT images of the tumor were acquired during the 45 min period following 
injection. The PAT images and the maximum PA signal levels were compared before and after 
the injection. The p-values in a student t-test between the results obtained for the dye and ICG 
are less than 0.005 for all instances, indicating statistical significance. The schematic of the in 
vivo experiment setup is illustrated in Figure 4-47. 
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Figure 4-47. In vivo PAT experiment setup. N: Nd:YAG second harmonic laser, T: tunable Ti:sapphire laser, L1, L2, 
L3: lenses, BS: beam splitter, SE Tr: single element transducer for monitoring laser fluctuations, O: oscilloscope, M: 
mirror, WB: water bag, Tr: transducer, H: heater, NC: nose cone, A: anesthesia compound (1.5 L/min oxygen with 1.5 
% isoflurane), PE-PAT: the co-registered PE-PAT system, PC: computer. 
4.3.8 Ex vivo	fluorescent imaging 
100 µL of 4g (3 mM in PBS) was injected to three BALB/c mice of similar weight and similar 
tumor size. The mice were sacrificed 15 and 120 min after the injection. Tumor, liver, kidneys, 
heart, lung, and spleen were harvested, washed twice in PBS, and imaged using an IVIS® 
Lumina II fluorescent imaging system (Caliper Life Sciences, Hopkinton, MA); λexcitation = 465 nm, 
GFP emission filter. 
4.3.9 Photophysical measurements 
The photophysical measurements were performed as described previously.17 
  
 4. in vivo PAI Using a Quinoline-Annulated Porphyrin as NIR Molecular Contrast Agent  
 
175 
 
4.4 References 
(1) a) Weissleder, R.; Pittet, M. J. Nature 2008, 452, 580; b) Ethirajan, M.; Chen, Y.; Joshi, 
P.; Pandey, R. K. Chem. Soc. Rev. 2011, 40, 340; c) Schäferling, M. Angew. Chem. Int. 
Ed. 2012, 51, 3532; d) Stender, A. S.; Marchuk, K.; Liu, C.; Sander, S.; Meyer, M. W.; 
Smith, E. A.; Neupane, B.; Wang, G.; Li, J.; Cheng, J.-X.; Huang, B.; Fang, N. Chem. 
Rev. 2013, 113, 2469; e) Huang, H.; Song, W.; Rieffel, J.; Lovell, J. F. Frontiers Phys. 
2015, 3, Article #23; f) Chang, C. J.; Gunnlaugsson, T.; James, T. D. Chem. Soc. Rev. 
2015, 44, 4484. 
(2) a) Wang, L. V.; Hu, S. Science 2012, 335, 1458; b) Beard, P. Interface Focus 2011, 1, 
602; c) Zhou, Y.; Yao, J.; Wang, L. V. J. Biomed. Opt. 2016, 21, Article # 061007. 
(3) a) Cerussi, A. E.; Berger, A. J.; Bevilacqua, F.; Shah, N.; Jakubowski, D.; Butler, J.; 
Holcombe, R. F.; Tromberg, B. J. Acad. Radiol. 2001, 8, 211; b) Wang, L. V.; Wu, H.-i. 
Biomedical Optics: Principles and Imaging; John Wiley & Sons: Hoboken, NJ, 2012. 
(4) Yao, J.; Wang, L.; Yang, J. M.; Maslov, K. I.; Wong, T. T.; Li, L.; Huang, C. H.; Zou, J.; 
Wang, L. V. Nat. Methods 2015, 12, 407. 
(5) Weber, J.; Beard, P. C.; Bohndiek, S. E. Nat. Methods 2016, 13, 639. 
(6) Heijblom, M.; Piras, D.; Xia, W.; van Hespen, J. C. G.; Klaase, J. M.; van den Engh, F. 
M.; van Leeuwen, T. G.; Steenbergen, W.; Manohar, S. Opt. Express 2012, 20, 11582. 
(7) a) Salehi, H. S.; Li, H.; Merkulov, A.; Kumavor, P. D.; Vavadi, H.; Sanders, M.; Kueck, 
A.; Brewer, M. A.; Zhu, Q. J. Biomed. Opt. 2016, 21, Article # 046006; b) Wang, T.; 
Yang, Y.; Alqasemi, U.; Kumavor, P. D.; Wang, X.; Sanders, M.; Brewer, M.; Zhu, Q. 
Biomed. Opt. Express 2013, 4, 2763. 
(8) a) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nat. 
Nanotechnol. 2007, 2, 751; b) Wang, L.; Yang, P.-P.; Zhao, X.-X.; Wang, H. Nanoscale 
2016, 8, 2488; c) Huynh, E.; Lovell, J. F.; Helfield, B. L.; Jeon, M.; Kim, C.; Goertz, D. E.; 
Wilson, B. C.; Zheng, G. J. Am. Chem. Soc. 2012, 134, 16464; d) Huynh, E.; Jin, C. S.; 
Wilson, B. C.; Zheng, G. Bioconjugate Chem. 2014, 25, 796; e) Paproski, R. J.; Forbrich, 
A.; Huynh, E.; Chen, J.; Lewis, J. D.; Zheng, G.; Zemp, R. J. Small 2016, 12, 371; f) Ho, 
C. J. H.; Balasundaram, G.; Driessen, W.; McLaren, R.; Wong, C. L.; Dinish, U. S.; Attia, 
A. B. E.; Ntziachristos, V.; Olivo, M. Sci. Rep. 2014, 4, Article # 5342. 
(9) a) Lewinski, N.; Colvin, V.; Drezek, R. Small 2008, 4, 26; b) Gnach, A.; Lipinski, T.; 
Bednarkiewicz, A.; Rybka, J.; Capobianco, J. A. Chem. Soc. Rev. 2015, 44, 1561; c) 
Srivastava, V.; Gusain, D.; Sharma, Y. C. Ind. Eng. Chem. Res. 2015, 54, 6209. 
 4. in vivo PAI Using a Quinoline-Annulated Porphyrin as NIR Molecular Contrast Agent  
 
176 
 
(10) Lovell, J. F.; Jin, C. S.; Huynh, E.; Jin, H.; Kim, C.; Rubinstein, J. L.; Chan, W. C. W.; 
Cao, W.; Wang, L. V.; Zheng, G. Nat. Mater. 2011, 10, 324. 
(11) a) Filonov, G. S.; Krumholz, A.; Xia, J.; Yao, J.; Wang, L. V.; Verkhusha, V. V. Angew. 
Chem. Int. Ed. 2011, 51, 1448; b) Zhang, Y.; Cai, X.; Wang, Y.; Zhang, C.; Li, L.; Choi, 
S.-W.; Wang, L. V.; Xia, Y. Angew. Chem. Int. Ed. 2011, 50, 7359. 
(12) Ashkenazi, S. J. Biomed. Optics 2010, 15, Article # 040501. 
(13) a) Zanganeh, S.; Li, H.; Kumavor, P. D.; Alqasemi, U.; Aguirre, A.; Mohammad, I.; 
Stanford, C.; Smith, M. B.; Zhu, Q. J. Biomed. Opt. 2013, 18, Article # 096006; b) 
Abuteen, A.; Zanganeh, S.; Akhigbe, J.; Samankumara, L. P.; Aguirre, A.; Biswal, N.; 
Braune, M.; Vollertsen, A.; Röder, B.; Brückner, C.; Zhu, Q. Phys. Chem. Chem. Phys. 
2013, 15, 18502. 
(14) a) Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. FEBS Lett. 1990, 268, 235; 
b) Desmettre, T.; Devoisselle, J.; Mordon, S. Surv. Ophthalmol. 2000, 45, 15. 
(15) a) Akhigbe, J.; Luciano, M.; Zeller, M.; Brückner, C. J. Org. Chem. 2015, 80, 499; b) 
Akhigbe, J.; Yang, M.; Luciano, M.; Brückner, C. J. Porphyrins Phthalocyanines 2016, 
20, 265; c) Akhigbe, J.; Zeller, M.; Brückner, C. Org. Lett. 2011, 13, 1322. 
(16) a) Richeter, S.; Christophe, J.; Jean-Paul, G.; Romain, R. In Handbook of Porphyrin 
Science; Kadish, K. M., Smith, K. M., Guilard, R., Eds.; World Scientific Publishing 
Company: Hackensack, New Jersey, 2010; Vol. Volume 3, p 429; b) Jeandon, C.; 
Ruppert, R. Eur. J. Org. Chem. 2011, 4098. 
(17) Abuteen, A.; Zanganeh, S.; Akhigbe, J.; Samankumara, L. P.; Aguirre, A.; Biswal, N.; 
Braune, M.; Vollertsen, A.; Röder, B.; Brückner, C.; Zhu, Q. Phys. Chem. Chem. Phys. 
2013, 15, 18502. 
(18) a) Hambright, P. In The Porphyrin Handbook; Kadish, K. M., Smith, K. M., Guilard, R., 
Eds.; Academic Press: San Diego, 2000; Vol. 3, p 129; b) Brandis, A.; Mazor, O.; 
Neumark, E.; Rosenbach-Belkin, V.; Salomon, Y.; Scherz, A. Photochem. Photobiol. 
2005, 81, 983; c) Borbas, K. E.; Mroz, P.; Hamblin, M. R.; Lindsey, J. S. Bioconjugate 
Chem. 2006, 17, 638; d) Borbas, K. E.; Chandrashaker, V.; Muthiah, C.; Kee, H. L.; 
Holten, D.; Lindsey, J. S. J. Org. Chem. 2008, 73, 3145; e) Li, Y.; Wang, J.; Zhang, X.; 
Guo, W.; Li, F.; Yu, M.; Kong, X.; Wu, W.; Hong, Z. Org. Biomol. Chem. 2015, 13, 7681; 
f) Mandal, A. K.; Sahin, T.; Liu, M.; Lindsey, J. S.; Bocian, D. F.; Holten, D. New J. 
Chem. 2016, 40, 9648. 
(19) Veronese, F. M.; Pasut, G. Drug Discovery Today 2005, 10, 1451. 
(20) Starnes, S. D.; Rudkevich, D. M.; Rebek Jr., J. J. Am. Chem. Soc. 2001, 123, 4659. 
 4. in vivo PAI Using a Quinoline-Annulated Porphyrin as NIR Molecular Contrast Agent  
 
177 
 
(21) Daniell, H. W.; Williams, S. C.; Jenkins, H. A.; Brückner, C. Tetrahedron Lett. 2003, 44, 
4045. 
(22) Aldrich, S.  2003. 
(23) Flock, S. T.; Jacques, S. L.; Wilson, B. C.; Star, W. M.; van Gemert, M. J. C. Lasers 
Surg. Med. 1992, 12, 510. 
(24) Steel, C. D.; Stephens, A. L.; Hahto, S. M.; Singletary, S. J.; Ciavarra, R. P. Lab Animal 
2008, 37, 26. 
(25) Huang, H.; Wang, D.; Zhang, Y.; Zhou, Y.; Geng, J.; Chitgupi, U.; Cook, T. R.; Xia, J.; 
Lovell, J. F. Bioconjugate Chem. 2016, 27, 1574. 
(26) Boens, N.; Leen, V.; Dehaen, W. Chem. Soc. Rev. 2012, 41, 1130. 
(27) Flores-Rizo, J. O.; Esnal, I.; Osorio-Martinez, C. A.; Gomez-Duran, C. F.; Banuelos, J.; 
Lopez Arbeloa, I.; Pannell, K. H.; Metta-Magana, A. J.; Pena-Cabrera, E. J. Org. Chem. 
2013, 78, 5867. 
(28) a) MacAlpine, J. K.; Boch, R.; Dolphin, D. Journal of Porphyrins and Phthalocyanines 
2002, 6, 146; b) Brückner, C.; Ogikubo, J.; McCarthy, J. R.; Akhigbe, J.; Hyland, M. A.; 
Daddario, P.; Worlinsky, J. L.; Zeller, M.; Engle, J. T.; Ziegler, C. J.; Ranaghan, M. J.; 
Sandberg, M. N.; Birge, R. R. J. Org. Chem. 2012, 77, 6480. 
(29) Alqasemi, U.; Li, H.; Aguirre, A.; Zhu, Q. IEEE Trans. Sonics Ultrason. 2012, 59, 1344. 
(30) Salehi, H. S.; Wang, T.; Kumavor, P. D.; Li, H.; Zhu, Q. Biomed. Opt. Express 2014, 5, 
Article # 3074. 
(31) a) Xu, Y.; Zanganeh, S.; Mohammad, I.; Aguirre, A.; Wang, T.; Yang, Y.; Kuhn, L.; 
Smith, M. B.; Zhu, Q. J. Biomed. Opt. 2013, 18, Article # 066009; b) Zhou, F.; Zanganeh, 
S.; Mohammad, I.; Dietz, C.; Abuteen, A.; Smith, M. B.; Zhu, Q. Org. Biomol. Chem. 
2015, 13, 11220. 
(32) ANSI Z136.1-2007: American National Standard for Safe Use of Lasers, American 
National Standards Institute Inc. 2007. 
 
5. Supersizing Pyrrole-Modified Porphyrins 
 
178 
 
5 Supersizing Pyrrole-Modified Porphyrins by Reversal of the Breaking and 
Mending Strategy  
The synthesis of porphyrin analogues has contributed to the understanding of the concept of 
aromaticity,1 provided macrocycles with valuable molecular recognition or catalytic properties,2 
and has provided a large number of dyes with optical properties that are inaccessible with 
regular porphyrins or hydroporphyrins.3 The majority of porphyrin analogues were prepared by 
total synthesis.4 In an approach we dubbed ‘the breaking and mending of porphyrins’, we,5 and 
others,4e prepared a wide variety of porphyrin analogues containing one or two non-pyrrolic 
heterocycles by step-wise conversion of a porphyrin. To illustrate the approach, meso-tetra-
phenylporphyrin 1, for example, was dihydroxylated; the diol functionality was then used as a 
synthetic handle for further functionalizations (Scheme 5-1).5 Diol cleavage in the ‘breaking’ step 
resulted in the formation of a secochlorin 3 that could be cyclized in the ‘mending’ step to, e.g., 
provide a morpholinochlorin incorporating a 6-membered morpholine moiety.6 Attempts to 
generate 7-membered rings (1,4,5-triazaazepines or 1,3-diaza-5-oxaazepines) by cyclization of 
3 with hydrazine or hydroxylamine, respectively, failed.7 In all likelihood, the analogues formed 
but then rapidly extruded a small molecule (N2 or CO2, respectively), regenerating the porphyrin 
or a porphyrin-like arrangement of four five-membered rings. This highlights the large stability of 
the natural porphyrinic architecture, but also identifies a limitation of our ‘breaking and mending’ 
approach toward pyrrole-modified porphyrins containing medium-sized rings. 
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Scheme 5-1. Example for the ‘breaking and mending of porphyrins’ approach toward porphyrinoids containing non-
pyrrolic building blocks. 
Albeit rare, porphyrinoids prepared by total synthesis containing 7-membered rings are 
stable.4e The best investigated systems are the tropiporphyrins, a family of carbaporphyrins.4d 
Azepiphthalocyanines were also reported.8 Medium-sized rings can, in principle, be accessed 
by the cleavage of the linkage between two annulated smaller rings.9 In the realm of 
porphyrinoid chemistry, a single such example was provided in 2003 by the groups of Barrett 
and Hoffman (Scheme 5-2).10 
 
Scheme 5-2. Synthesis of pyrrole-expanded porphyrazine 6 described by the groups of Barrett and Hoffman. 
Reaction conditions: (i) KMnO4, CH2Cl2 (44% yield).10 
Diazapine-annulated porphyrazine 5 was prepared by total synthesis. Subsequently, the 
β,β’-bond linking the two heterocycles was cleaved, forming the pyrrole-expanded porphyrazine 
6 containing a 10-membered heterocycle.10 
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With this precedent in mind, we set out to test whether a reversal of our traditional 
methodology, i.e., a ‘mending and breaking’ approach can be developed into a possibly general 
approach toward the synthesis of pyrrole-modified porphyrins with medium-sized heterocyclic 
rings that can also take advantage of some of the reaction types well established by us. This 
contribution will demonstrate that this is indeed the case, but it will also point at some limitations 
to this approach. 
5.1 Results and Discussion 
5.1.1 Formation of a Novel Pyrrole-modified Porphyrin by Replacement of a Pyrrole with 
a 1,3,6-Triazocine-2,4,8-Trione Ring 
meso-Tetraarylporphyrin diones, such as 7, are accessible from TPP (1) along a number of 
complimentary routes.11 The regular ketone reactivity of the diones was previously 
demonstrated,11b including in reactions generating pyrrole-modified porphyrins.12 It is well-known 
that reaction of dione 7 with diamines generates diimines,13 but we found that the reaction of 7 
with urea or N,N’-dimethylurea generated dihydroxychlorins 8 and 9, respectively, containing 
imidazolidinone moieties annulated at the β,β’-positions. Diagnostic for the formation of the 
dihydroxychlorin structure are the preservation of the two-fold symmetry of the adducts as seen 
in their NMR spectra, the pyrroline carbon signals in their 13C NMR spectra (found at δ = 158.5 
ppm for 8), their regular chlorin-like spectra compared to the much broadened spectra for dione 
714 (Figure 5-1A), and their expected composition (as per HR-MS). The presence of the lactam 
moieties in the annulated ring are indicated in the 13C NMR spectra of the products (for 8 at δ = 
159.5 and 161.5 ppm for 9) and IR spectra (νC=O at 1715 cm-1 for 8). 
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Scheme 5-3. Synthesis of urea chlorindiol adducts 8 and 9, and the outcomes of the oxidative diol cleavage. 
Reaction conditions: (i) 20 equiv. urea derivative, pyridine, Δ (85% yield for 8; 54% yield for 9; 75% yield for 8Ni; 68% 
yield for 9Ni); (ii) 1-1.7 equiv. Pb(OAc)4, THF, (Et3N for preparation of 10 and 10Ni), r.t., (69% yield for 10; 71% yield 
for 11; 45% yield for 10Ni; 71% yield for 11Ni). 
We previously reported multiple methods for the oxidative cleavage of the pyrroline β,β’-
bond of dihydroxychlorins.15 Thus, treatment of the polar magenta diol 8 under classic diol 
cleavage reaction conditions (Pb(OAc)4)15b,16 resulted in the formation of a red non-polar 
compound in good yields (69%). Its porphyrin-like UV-vis spectrum (Figure 5-1B), NMR spectra, 
and its composition as determined by HR-MS identified it to be the known porpholactam 10.17 
Once again, the expulsion of smaller fragments from the putative medium-ring derivative 
establishing a stable ‘tetrapyrrolic’ architecture thwarted the formation of the target medium-
sized ring-expanded compound. On the bright side, this 3-step pathway toward 10 is more 
convenient and significantly higher yielding (overall 29% from diol 2 at a 50 mg scale) than the 
previously described 3-step synthesis (~13%).17 Performing the same dione 7 → diol 8 → 
lactam 9 synthetic sequence after inserting Ni to the dione 7 results also in the fragmentation to 
the lactam 9Ni from 8Ni. The Ni complexes show the expected spectroscopic properties for 
metal-inserted species. 
While we did not know the fragmentation mechanism of the putative intermediate resulting 
from the oxidative cleavage of 8 or 8Ni, we suspected that the replacement of the amide 
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protons might hinder the fragmentation by, for instance, blocking amide-iminol-type equilibria. 
Indeed, oxidative diol cleavage of dimethylurea adduct 9 generated a compound in good yields 
possessing a composition of two hydrogen atoms less than the starting material (as per HR-
MS). Moreover, it was characterized by a significantly red-shifted chlorin-type optical spectrum 
(Figure 5-1B). The general red-shift of the spectrum and particularly the much reduced 
extinction coefficient of its Soret band observed suggest the increase in non-planarity of the 
chromophore, while its general broadening suggest an increase of conformational flexibility.18  
 
Figure 5-1. UV-vis spectra (CH2Cl2) of the compounds indicated. 
Its NMR spectra retained the two-fold symmetry of the starting material with an upfield shift 
of the inner protons ( δ = 1.88 ppm) suggestive of a non-planar chromophore, and the presence 
of two lactam carbon atoms in different environments ( δ = 173.1 and 155.1 ppm). Thus all 
spectroscopic evidence point toward the successful formation of the target expanded pyrrole-
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modified porphyrin 11. Oxidative cleavage of diol 9Ni also generated the corresponding 
supersized pryrrole-modified porphyrin 11Ni, showing the expected analytical properties. 
A single crystal X-ray structure analysis of 11 provided the final proof for the unique 
connectivity of this porphyrinoid (Figure 5-2). The pyrroline β,β’-bond was, as designed, 
oxidatively cleaved, and both β-carbons were converted in due process to lactam moieties that 
are incorporated into an 1,3,6-triazocine-2,4,8-trione ring. This 8-membered ring is, as 
designed, the result of a fusion of the three annulated dimethylurea atoms with the five pyrroline 
atoms. The non-pyrrolic moiety assumes a significantly non-planar conformation with an almost 
90° twist along its long axis. This twist translates into the porphyrinic framework, leading to a 
mildly ruffled conformation.  
 
 
Figure 5-2. Stick representation of the single crystal X-ray structure of 11 (top) and 11Ni (bottom). All disorder, 
solvent molecules, and sp2-CH hydrogens were omitted for clarity. For details, see experimental section. 
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The corresponding Ni complex 11Ni could also be crystallized (Figure 5-2), and also exhibits 
a non-planar conformation of the non-pyrrolic moiety with an overall ruffled conformation of the 
chromophore. The solid-state conformation of 11Ni also translates to a red-shifted 
metallochlorin-like UV-vis spectrum of this compound (see experimental section). 
The structures rationalize all spectroscopic findings, but the question is also raised whether 
a larger than 8-membered ring will assume a figure-eight conformation that then will have a 
much weaker conformational effect on the remainder of the chromophore. This might rationalize 
why, for example, pyrrole-expanded porphyrazine 6 possesses a surprisingly regular chlorin-like 
optical spectrum (its solid state structure was not reported).10 
5.1.2 Synthesis of Thiono-Supersized Pyrrole-modified Porphyrin 14 
Treatment of 7 with thiourea smoothly produced a polar red product with all the hallmarks of 
an annulated-chlorin (chlorin-like UV-vis spectrum, 2-fold symmetric 1H NMR spectrum with 
exchangeable O-H and N-H protons) (Scheme 5-4). However, isolation of a pure sample of this 
compound proved difficult due to its preferential reversion back to the dione starting material 7. 
Treatment of a crude sample of imidazolidinethione-annulated chlorin 12 under the same 
oxidative cleavage conditions (Pb(OAc)4, Et3N, dry THF) afforded again the known 
porpholactam 10 as the major product, along with some of the reversion product dione 7. This 
reaction allows two conclusions to be made: The use of thiourea does not lead to the 
stabilization of the adduct of the putative eight-membered ring. It further suggests that the 
lactam oxygen in porpholactam 10 was unlikely to have been derived from the urea moiety, 
unless a rapid thionolactam-to-lactam conversion took place under the reaction conditions. 
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Scheme 5-4. Synthesis of thiono derivatives of the supersized pyrrole-modified porphyrins. Reaction conditions: (i) 
thiourea or N,N’-dimethylthiourea, pyridine, Δ (ii) Pb(OAc)4, THF, Et3N. 
Exchange of thiourea with N,N’-dimethylthiourea furnished the corresponding chlorin diol 13 
in very good yields (89%), and this was much more stable to work-up and chromatographic 
separation. Pb(OAc)4 cleavage of 13 in dry THF led mostly to a reversion of the addition 
reaction, and diketone 7 was observed as the major product. However, traces of a less-polar 
green product were also isolated, and we suspected it to be the desired supersized pyrrole-
modified porphyrin 14. The extensive reversion of the addition reaction is likely due to the 
instability of diol-chlorin 13 toward the residual acid in Pb(OAc)4. Thus, the reaction was 
repeated with Et3N in the reaction mixture to suppress the (presumably acid-catalyzed) 
reversion back to dione 7. This suppression was indeed observed and the nonpolar green 
fraction (Rf = 0.59, silica-CH2Cl2) was now isolated as the main product in good yield. The HR-
MS (ESI+, TOF) of this product indicated the loss of four hydrogen atoms, suggesting 
successful oxidative cleavage to supersized PMP 14 had taken place. The 1H NMR spectrum of 
14 is similar to that of the corresponding triazocine-trione-modified porphyrin 11, but with some 
slight shifting in the aromatic region. As expected, the thionolactam carbon is significantly 
downfield shifted (187 ppm) with respect to the amide version 11 (173 ppm). 
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A single crystal suitable for X-ray analysis could be grown by slow vapor diffusion of MeOH 
into a solution of 14 in CH2Cl2, ultimately confirming the connectivity of the pyrrole-modified 
porphyrin with an 8-membered 1,3,6-triazocine-2-thione-4,8-dione moiety.  
 
Figure 5-3. A: UV-vis spectra (CH2Cl2) of 11 (green trace) and thioxo-derivative 14 (blue trace). B: X-ray crystal 
structure and measured Cβ-Cα-Cα-Cβ dihedral angles of 11 and 14. 
Surprisingly, swapping out the oxygen atom for a sulfur atom has a rather drastic effect on 
the solid-state configuration of the pyrrole-modified porphyrin 14. The modified pyrrole is much 
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less twisted with respect to the porphyrin axis as compared to 11, translating into a milder 
ruffling of the macrocycle. The distortion of the pyrrole-modified porphyrins 11 and 14 was also 
assessed by measuring the Cβ-Cα-Cα-Cβ dihedral angle of the modified pyrrole, a metric well 
suited to predict the red-shifted optical spectra in morpholinobacteriochlorins; the larger this 
angle, the more red-shifted the corresponding spectrum.19 This dihedral angle for the thio-
derivative 14 is 40.9° compared to 90.4° for the urea-derived supersized pyrrole-modified 
porphyrin 11 (Figure 5-3A). This is also reflected in the much more red-shifted spectrum for 11 
(λmax = 741 nm) than for 14 (λmax = 668 nm) (Figure 5-3B). 
5.1.3 Modification of TPP-dione with semicarbazide and thiosemicarbazide 
The preparation of analogues with 6-membered rings annulated to the β,β’ bond of the 
porphyrin was also explored (Scheme 5-5). Unfortunately, reaction of dione 7 with an excess of 
oxamide yielded no product even after reflux for several days in pyridine. On the other hand, 
addition of an excess of semicarbazide·HCl yielded, within minutes at ambient temperature, a 
polar red and chemically unstable product with a UV-vis spectrum resembling that of a chlorin. 
Upon attempted isolation, this product 16 dehydrates to an isolable, stable and less polar green 
product 18. Its composition, as determined by HR-MS (ESI+, TOF), indicated successful 
addition of semicarbazide accompanied by a loss of a water molecule. The 1H NMR spectrum of 
the semicarbazide adduct 18 showed the presence of an asymmetric product with a sharp 
signal downfield at ~13 ppm that is exchangeable with D2O, as well as a pair of exchangeable 
protons at 4.5 and 5.3 ppm (Figure 5-4). 
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Scheme 5-5. Synthesis of 6-membered ring adducts. Reaction conditions: (i) oxamide, pyridine, Δ 
(ii) semicarbazide·HCl or thiosemicarbazide, pyridine, r.t. or Et3N/THF, r.t..  
An 1H-1H NOESY of the compound revealed that the two exchangeable protons at 4.5 and 
5.3 ppm are close to each other in space, but not neighboring the downfield-shifted 
exchangeable proton at 13 ppm, suggesting that they are on opposite sides of the annulated 
six-membered ring. A 15N-1H HSQC experiment revealed that the peak at 13 ppm corresponds 
to an N-H proton. An HMBC experiment showed that this proton is correlating with two carbons, 
further supporting the structure of semicarbazone 18 as the isolated product. 
The semicarbazide reaction can also be carried out using Et3N/THF instead of pyridine, 
successfully forming the putative chlorin species 16 in situ (by UV-vis). The attempted one-pot 
oxidative cleavage of this compound failed to produce the target supersized PMP, producing the 
ketone starting material 7 as well as semicarbazone 18 as a minor product. 
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Figure 5-4. 1H NMR spectra (CDCl3, 298 K) of the compounds indicated. * = residual solvent 
Similarly, the corresponding thiosemicarbazone 20 could be prepared by treatment of 7 with 
thiosemicarbazide, albeit in lower yields (~45%). The spectroscopic properties of thione 
derivative 20 were very similar to those of oxo-derivative 19, with three slightly shifted diagnostic 
exchangeable proton peaks in its 1H NMR spectrum (13.8 ppm, 6.4 and 6.1 ppm). Both the 
semicarbazone and thiosemicarbazone adducts possess relatively broadened featureless UV-
vis spectra, similar to the spectrum of dione 7 (Figure 5-5), likely an effect of the sp2-hybridized 
β-position of the adduct. Further exploration of the chemistry of the carbazone derivatives, 
particularly the semicarbazone 18, is currently underway. 
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Figure 5-5. UV-vis spectra (CH2Cl2) of dione 7 (blue trace) and semicarbazone 18 (orange trace). 
5.1.4 Formation of Adducts using Malonamide derivatives and their oxidative cleavage 
The addition of malonamide derivatives to diketones to form 7-membered rings has been 
reported.20 Thus, treatment of the diketone 7 with malonamide under the same reaction 
conditions afforded a very polar magenta product 20 (Rf = 0.38, 5% MeOH/CH2Cl2) in high 
yields (~96%), with a chlorin-like UV-vis spectrum (Scheme 5-6). HR-MS showed a mass 
corresponding to the addition of malonamide to the porphyrin, with no subsequent dehydration. 
However, the formation of the simple, symmetric and desired adduct can be excluded, as its 
1H NMR spectrum is complex, indicating an asymmetric addition of malonamide. A total of five 
exchangeable protons were observed, with one downfield-shifted at 9.0 ppm. The other four 
exchangeable protons were observed in the range of 5-7 ppm, the range expected for pyrroline 
O-H or N-H signals. The 13C NMR of the product revealed the expected signals for the 
annulated pyrrole moiety, as well as an upfield-shifted carbon at 55 ppm. 13C-1H HSQC analysis 
showed that this carbon correlates with a peak integrating to a single proton at 4.2 ppm. Taken 
together, the spectroscopic data suggest that the diol species is formed by asymmetric attack of 
malonamide, with one linkage formed, as desired, from the amide-NH2 end, but the other arising 
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from the malonyl position. An HMBC spectrum of this compound further strengthens this 
assignment, showing the expected multiple-bond correlations of the pyrroline carbons at 85 and 
94 ppm with the exchangeable protons (see experimental section). 
 
Scheme 5-6. Synthesis of malonamide adducts. Reaction conditions (i) malonamide, pyridine, Δ (ii) Pb(OAc)4, THF, 
r.t.(iii) N,N’-dimethylmalonamide, pyridine, Δ. 
Oxidative cleavage of the diol 20 with Pb(OAc)4 in dry THF afforded a nonpolar purple 
product with a porphyrin like UV-vis spectrum in moderate yields (~60%). A 1H NMR analysis of 
this compound revealed that it is a mixture of two compounds, with the second compound only a 
minor component. In our hands, these compounds proved inseparable. On the bright side, when 
we attempted to crystallize the mixture, crystals suitable for single crystal X-ray analysis of the 
minor component formed. This identified product 22 as an unprecedented spirobarbiturate. 
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Porphyrins with spiro-linked heterocycles at the β-positions prepared by modification of a 
porphyrin are generally rare.21 
 
Figure 5-6. X-ray crystal structure of spiro-barbiturate 22. Hydrogens removed for clarity. 
The formation of spirobarbiturate 22 can be rationalized via the putative ring-opened 
intermediate 27 (Scheme 5-7). After an oxidative rearrangement of 27 to 21, intramolecular 
cyclization by amide attack on the isocyanate provides spirobarbiturate 22. 
An examination of the spectroscopic data for 21 shows that its 1H NMR shows only two 
exchangeable protons at 5.4 and 6.9 ppm while no malonyl proton can be observed (as in 
chlorindiol 20). A 15N-1H HSQC spectrum revealed that these two exchangeable protons are 
attached to the same nitrogen atom, further strengthening the connectivity assignment of 
product 21. Attempts to grow crystals of the major component 21 suitable for a single crystal X-
ray structure analysis are ongoing. 
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Scheme 5-7. Proposed mechanism for the formation of oxidative cleavage products 21 and 22. 
N,N’-dimethylmalonamide also reacts with dione 7 to generate the corresponding 
N,N’-dimethyl-pyrrolidinone-annulated dihydroxychlorin 23, showing all expected analytical 
properties. A single crystal of this compound was grown, ultimately proving its connectivity (and, 
by extension, that of the diol 20 derived from malonamide). The chlorin chromophore in 23 
surprises by possessing an uncommonly saddled conformation (Figure 5-7). 
 
Figure 5-7. X-ray crystal structure of diol 23. Hydrogens removed for clarity. 
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Next to the major N,N’-dimethylmalonamide addition product 23 was isolated a polar red 
product that also had a chlorin-like UV-vis spectrum. Its composition, as determined by HR-MS 
(ESI+, TOF), indicated the loss of a CONHMe fragment from the major chlorin product. An 
inspection of the 1H NMR spectrum of this compound revealed that this could be supported: one 
methyl group as well as one N-H were missing, replaced by a pair of diastereotopic protons (2J 
= 17.5 Hz) at 3.2 and 2.8 ppm. A 13C-1H HSQC spectrum confirmed that the two peaks are 
connected to the same carbon.  
Unfortunately, both diols 23 and 24 derived from N,N’-dimethylmalonamide failed to produce 
ring-opened products by action of Pb(OAc)4; instead only the formation of complex reaction 
mixtures was observed. Treatment of diols 23 and 24 with NaIO4 heterogenized on silica gel in 
CH2Cl2 also failed to produce any products after several days. It is, however, likely that the 
target PMPs 25 and 26 formed by reaction of 23 and 24 with Pb(OAc)4, but that the constraints 
of the porphyrinic macrocycle led to rapid and non-specific degradation of the putative 10-
membered ring PMPs. The decomposition of diol 24 was slow enough that we could measure a 
UV-vis spectrum of the reaction mixture. The UV-vis spectrum of 24 treated with Pb(OAc)4  in 
dry THF after 7 minutes indicated the hallmarks of a ring-opened product (red-shifted λmax and 
broadened and red-shifted Soret band) (Figure 5-8), but the products 25 and 26 ultimately 
proved intractable.  
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Figure 5-8. UV-vis spectra of diol 24 (black trace, CH2Cl2) and reaction mixture 7 minutes after treatment with 
Pb(OAc)4 in dry THF at r.t. (red trace, THF). 
5.2 Conclusions 
In conclusion, a novel class of ring-expanded pyrrole-modified porphyrins incorporating an 
8-membered heterocycle could be accessed by using an annulation → oxidative cleavage 
strategy, i.e., using a reversal of our well-established ‘breaking and mending strategy’. The 
synthesis of the corresponding thiono-analogue provided further insight into the validity of a 
recent proposal that the optical properties of a porphyrinic macrocycle are to a large degree 
determined by the Cβ-Cα-Cα-Cβ dihedral angle of the modified pyrrole.19 The attempted 
preparation of analogues of greater ring-sizes proved unsuccessful, as all attempts were 
thwarted by various degradation pathways. Nevertheless, the exploration of the reactivity of 
dione 7 toward other bifunctional nucleophiles offered a glimpse into rich chemistry with the 
possibility of generating previously inaccessible pyrrole-modified porphyrins with medium ring 
sizes and other β-functionalized porphyrinic chromophores. 
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5.3 Experimental Section 
5.3.1 Materials and Instruments 
Urea, thiourea, N,N’-dimethylurea, N,N’-dimethyl thiourea, semicarbazide·HCl, thio-
semicarbazide, malonamide and Pb(OAc)4 were purchased from Sigma-Aldrich and were used 
without further purification. THF (dry) was distilled from sodium benzophenone ketyl prior to use. 
Oxoporphyrin 711a and N,N-dimethylmalonamide22 were prepared according to literature 
procedures. 
Aluminum-backed, silica gel 60, 250 µm thickness analytical plates were used for analytical 
TLC; 20 × 20 cm, glass-backed, silica gel 60, 500 µm thickness preparative TLC plates, and 
standard grade, 60 Å, 32−63 µm flash column silica gel were used for preparative 
chromatography. 
1H and 13C NMR spectra were recorded on a Bruker 400 MHz instrument in the solvents 
indicated, and were referenced to residual solvent peaks. High and low resolution mass spectra 
were provided by the Mass Spectrometry Facility, Department of Chemistry, University of 
Connecticut. The microwave synthesizer used was a discover microwave reactor. 
5.3.2 Synthesis and Characterization 
meso-Tetraphenyl imidazolidinone-annulated dihydroxychlorin 8. Porphyrin Dione 7 
(118.0 mg, 1.83 × 10-4 mol) was dissolved in pyridine (25.0 mL) in a RBF equipped with a 
magnetic stir bar. Urea (245 mg, 0.0041 mol, 22 equiv) was added and the mixture was heated 
to reflux for 30 min under a N2 atmosphere. The solvent was evaporated in vacuo. The 
remaining residue was taken up in CHCl3 and filtered through a glass frit. The filtrate was 
washed with 5 × 25 mL distilled water and dried over Na2SO4. The dried residue was separated 
by column chromatography (CH2Cl2-5% MeOH) recovering dione 7 in 8% yield (9 mg), followed 
by the magenta product 8 in 85% yield (111 mg): Rf (silica-CH2Cl2/5% MeOH) = 0.36; 1H NMR 
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(400 MHz, CDCl3): δ 8.64 (d, 3J = 4.7 Hz, H), 8.49 (s, 1H), 8.21 (s, 1H), 8.14 (d, 3J = 5.8 Hz, 
3H), 7.86 (d, 3J = 6.8 Hz, 1H), 7.72 (m, 6H), 5.34 (br s, 1H, exchangeable with D2O), 4.26 (br s, 
1H, exchangeable with D2O), -2.03 (br s, 1H, exchangeable with D2O) ppm; 13C NMR (100 MHz, 
DMSO-d6): δ 159.5, 158.5, 152.8, 141.4, 141.1, 140.0, 135.4, 135.2, 134.12, 134.10, 134.08, 
134.06, 133.18, 133.13, 128.55, 128.44, 127.50, 127.33, 127.26, 125.7, 123.1, 112.9, 93.5 ppm; 
UV-vis (CH2Cl2) λmax (log ε) 406 (5.29), 512 (4.12), 541 (4.22), 591 (4.00), 642 (4.44) nm; FT-IR 
(neat, diamond ATR): νC=O = 1715.7 cm-1; MS (ESI+, 100% CH3CN, TOF) m/z cald for 
C45H33N6O3 ([M·H]+) 705.2609, found 705.2605. 
 
Figure 5-9. UV-vis spectrum (CH2Cl2) of 8. 
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Figure 5-10. 1H NMR spectrum (400 MHz, CDCl3) of 8. 
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Figure 5-11. 13C NMR spectrum (100 MHz, CDCl3) of 8. 
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meso-Tetraphenyl-N,N’-dimethylimidazolidnone-annulated dihydroxychlorin 9. 
Prepared from 7 (30.0 mg, 4.65 × 10-5 mol) in pyridine (8.0 mL) as described for 8 using N,N’-
dimethylurea (82 mg, 9.31 × 10-4 mol, 20 equiv.) to afford the red dihydroxychlorin 9 in 54% 
yield (18.5 mg): Rf (silica-CH2Cl2/3% MeOH) = 0.56; 1H NMR (400 MHz, CDCl3): δ 8.57 (d, 3J = 
4.9 Hz, 1H), 8.45 (s, 1H), 8.16 (d, 3J = 6.7 Hz, 1H), 8.07 (d, 3J = 5.2 Hz, 4H), 7.78-7.67 (m, 6H), 
4.55 (s, 1H, exchangeable with D2O), 2.28 (s, 3H), -1.75 (s, 1H, exchangeable with D2O) ppm; 
13C NMR (100 MHz, CDCl3): δ 161.4, 154.2, 153.5, 141.4, 139.8, 136.0, 135.4, 134.1, 132.9, 
128.7, 127.97, 127.88, 127.6, 127.3, 126.81, 126.73, 125.3, 123.7, 112.8, 97.1, 26.4 ppm; UV-
vis (CH2Cl2) λmax (log ε) 410 (4.99), 520 (3.84), 549 (3.88), 596 (3.53), 649 (4.08) nm; FT-IR 
(neat, diamond ATR): νC=O = 1680.4 cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for 
C47H37N6O3 ([M·H]+) 733.2927, found 733.2941.  
 
Figure 5-12. UV-vis spectrum (CH2Cl2) of 9. 
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Figure 5-13. 1H NMR spectrum (400 MHz, CDCl3 of 9. 
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Figure 5-14. 13C NMR spectrum (100 MHz, CDCl3) of 9. 
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meso-Tetraphenyl-2-aza-3-oxoporphyrin xx. Dihydroxychlorin 8 (28.8 mg, 4.6 × 10-5 mol) 
was dissolved in dry THF (11.0 mL) and Et3N (5-6 drops) in a RBF equipped with a magnetic stir 
bar. Pb(OAc)4 (31.4 mg, 7.1 × 10-5 mol, 1.7 equiv.) was added in portions and the reaction 
mixture was stirred at ambient temperature. When the starting material was consumed (reaction 
control by UV-vis and TLC), the solvent was removed by rotary evaporation and the remaining 
residue was purified by preparative TLC (silica-CH2Cl2/1% MeOH) to afford well-known (J. 
Akhigbe, J. P. Haskoor, J. A. Krause, M. Zeller and C. Brückner, Org. Biomol. Chem., 2013, 11, 
3616–3628.) porpholactam 10 in 69% yield (17.8 mg): 1H NMR (400 MHz, CDCl3): δ  9.65 (s, 
1H, exchangeable with D2O), 8.79 (d, 3J = 5.0 Hz, 1H), 8.71 (d, 3J = 4.7 Hz, 1H), 8.64 (d, 3J = 
5.0 Hz, 1H), 8.61-8.54 (m, 3H), 8.16-8.12 (m, 4H), 8.10-8.07 (m, 2H), 7.99 (m, 2H), 7.81 (m, 
3H), 7.77-7.69 (m, 9H), -1.87 (s, 1H, exchangeable with D2O), -2.14 (s, 1H, exchangeable with 
D2O) ppm. 
 
Figure 5-15. UV-vis spectrum (CH2Cl2) of 10. 
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Figure 5-16.  1H NMR (400 MHz, CDCl3) of 10. 
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1,3,6-Triazocine-2,4-8-trione-based Pyrrole-modified Porphyrin 11. Dihydroxychlorin-
dimethylurea adduct 9 was dissolved in dry THF (5.0 mL) in a RBF equipped with a magnetic 
stir bar. Pb(OAc)4 (13.3 mg, 3.00 × 10-5 mol) was added and the reaction mixture was stirred at 
ambient temperature. When the starting material was consumed (reaction control by UV-vis and 
TLC), the solvent was evaporated and the residue separated by preparative TLC (silica-
CH2Cl2/3% MeOH) to afford 11 as a bright green solid in 71% yield (14.1 mg): Rf (silica-
CH2Cl2/2% MeOH) = 0.66; 1H NMR (400 MHz, CDCl3): δ 8.35 (d, 3J = 4.9 Hz, 1H), 8.28 (br s, 
1H), 8.16 (s, 1H), 8.04 (d, 3J = 4.9 Hz, 1H), 7.99 (br s, 2H), 7.70 (m, 4H), 7.56 (t, 3J = 7.5 Hz, 
1H), 7.43 (br s, 1H), 7.10 (br s, 1H), 3.28-3.15 (s, 3H), 1.88 (s, 1H, exchangeable with D2O) 
ppm; 13C NMR (100 MHz, CDCl3): δ 173.1, 155.5, 155.1, 147.3, 140.9, 140.21, 140.08, 136.5, 
135.5, 133.6, 131.9, 129.2, 128.41, 128.32, 128.13, 127.4, 126.3, 125.5, 119.5, 32.9 ppm; UV-
vis (CH2Cl2) λmax (log ε) 365 (3.98) 454 (4.76), 578 (3.54), 625 (3.55), 670 (3.40), 741 (3.59) nm; 
FT-IR (neat, diamond ATR): νC=O = 1709.6, 1614.8 cm-1; HR-MS (ESI+, 100% CH3CN, TOF) m/z 
cald for C47H34O6N3 ([M·H]+), 731.2771 found 731.2775. 
 
Figure 5-17. UV-vis spectrum (CH2Cl2) of 11. 
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Figure 5 18. 1H NMR (400 MHz, CDCl3) of 11. 
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Figure 5-19. 13C NMR (100 MHz, CDCl3) of 11. 
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(8Ni). Prepared from 7Ni (143 mg, 2.0 × 10-4 mol) as described for 8 using urea (234 mg, 
0.004 mol, 19 equiv) to afford recovered dione 7Ni (15 mg, 10%) and the blue dihydroxychlorin 
8Ni in 75% yield (116 mg): Rf (silica-CH2Cl2/5% MeOH) = 0.29; 1H NMR (400 MHz, DMSO-d6): δ 
8.29 (d, 3J = 3.9 Hz, 2H), 8.15 (s, 1H), 7.82 (two overlapping d, 3J = 3.7 Hz, 2H), 7.69-7.65 (m, 
5H), 7.59-7.54 (m, 3H), 6.74 (br s, 1H, exchangeable with D2O), 5.88 (br s, 1H, exchangeable 
with D2O) ppm; 13C NMR (100 MHz, DMSO-d6): δ 159.2, 146.4, 146.1, 140.9, 139.4, 137.99, 
137.88, 133.8, 133.03, 132.97, 129.6, 128.7, 128.04, 128.01, 127.97, 127.85, 123.8, 110.9, 94.2 
ppm; UV-vis (CH2Cl2) λmax (log ε) 415 (4.26), 575 (sh), 607 (3.49) nm; HR-MS (ESI+, 100% 
CH3CN, TOF) m/z cald for C45H29N6O3 ([M·H]-), 759.1655 found 759.1640. 
 
Figure 5-20. UV-vis spectrum (CH2Cl2) of 8Ni. 
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Figure 5-21. 1H NMR spectrum (400 MHz, CDCl3) of 8Ni. 
NN
N N
Ph
PhPh
N
N
OH
OHPh O
H
H
Ni
5. Supersizing Pyrrole-Modified Porphyrins 
 
210 
 
 
 
Figure 5-22. 13C NMR spectrum (400 MHz, CDCl3) of 8Ni. 
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(9Ni). Prepared from 7Ni (47.4 mg, 6.7 × 10-5 mol) in pyridine (20.0 mL) as described for 8 
using N,N’-dimethylurea (119 mg, 1.3 × 10-3 mol, 20 equiv.) and purified by preparative TLC 
(silica-CH2Cl2/5% MeOH) to afford the blue-green dihydroxymetallochlorin 9Ni in 68% yield 
(36.5 mg): Rf (silica-CH2Cl2/5% MeOH) = 0.28; 1H NMR (500 MHz, CDCl3): δ  8.29 (d, 3J = 4.9 
Hz, 1H), 8.16 (s, 1H), 8.02 (d, 3J = 4.9 Hz, 1H), 7.83 (dd, 3J = 7.7, 4J = 1.6 Hz, 2H), 7.74-7.72 
(m, 2H), 7.63-7.57 (m, 6H), 4.29 (s, 1H, exchangeable with D2O), 2.17 (s, 3H) ppm; 13C NMR 
(125 MHz, CDCl3): δ 161.4, 147.0, 142.3, 141.7, 139.5, 138.4, 137.5, 133.4, 132.79, 132.73, 
129.5, 128.5, 127.98, 127.94, 127.86, 127.80, 127.1, 125.0, 110.7, 97.2, 26.4 ppm; UV-vis 
(CH2Cl2) λmax (log ε) 409 (5.16), 562 (sh), 607 (4.38) nm; FT-IR (neat, diamond ATR): HR-MS 
(ESI+, 100 % CH3CN, TOF) m/z cald for C47H34N6NiO3+ ([M]+) 788.2045, found 788.2062. 
 
Figure 5-23. UV-vis spectrum (CH2Cl2) of 9Ni. 
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Figure 5-24. 1H NMR spectrum (400 MHz, CDCl3) of 9Ni. 
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Figure 5-25. 13C NMR spectrum (500 MHz, CDCl3) of 9Ni. 
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(10Ni.) Prepared as described for 10 on using 8Ni (19.5 mg, 2.6 × 10-5 mol), Pb(OAc)4 (12.6 
mg, 2.8 × 10-5 mol, 1.1 equiv.) and dry THF (6.5 mL) to afford the red 10Ni in 45% yield (9 mg); 
1H NMR (400 MHz, CDCl3): δ  9.68 (s, 1H, exchangeable with D2O), 8.60 (d, 3J = 5.0 Hz, 1H), 
8.55 (two overlapping doublets, 3J = 4.5 Hz, 2H), 8.49 (d, 3J = 4.6 Hz, 1H), 8.41 (dd, 3J = 11.7, 
4.8 Hz, 2H), 7.95 (d, 3J = 6.8 Hz, 3H), 7.92-7.88 (m, 2H), 7.80 (d, 3J = 4.1 Hz, 2H), 7.75-7.6 (m, 
12H) ppm; UV-vis (CH2Cl2) λmax (rel I.) 417 (1.0), 545 (sh), 589 (0.14) nm; νC=O = 1712.5; HR-MS 
(ESI+, 100% CH3CN, TOF) m/z cald for C43H28N5NiO ([M·H]+), 688.1642 found 688.1573. 
  
5. Supersizing Pyrrole-Modified Porphyrins 
 
215 
 
 
  
Figure 5-26. 1H NMR (400 MHz, CDCl3) of 10Ni. 
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(11Ni). Prepared according to the procedure for 11, starting from (9Ni) (36.5 mg, 4.6 × 10-5 
mol) in dry THF (12.0 mL) with Pb(OAc)4 (41 mg, 9.2 × 10-6 mol, 2 equiv.) and purified by 
column chromatography (silica-CH2Cl2) to afford the green 11Ni in 71% yield (26.0 mg): Rf 
(silica-CH2Cl2) = 0.52; 1H-NMR (400 MHz; CDCl3): δ  8.23 (d, 3J = 4.8 Hz, 1H), 8.06 (s, 1H), 7.88 
(d, 3J = 4.8 Hz, 1H), 7.84 (br s, 1H), 7.65-7.60 (br m, 3H), 7.48 (br s, 3H), 3.21 (s, 3H) ppm; 13C 
NMR (100 MHz; CDCl3): δ 171.7, 155.2, 148.3, 144.5, 140.6, 138.9, 137.8, 137.2, 134.4, 
132.96, 132.92, 131.0, 130.1, 128.4, 127.5, 118.4, 33.1; UV-vis (CH2Cl2) λmax (log ε) 441 (4.45), 
661 (3.72) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C47H33N6NiO3 ([M·H]+), 787.1968 
found 787.1979. 
 
Figure 5-27. UV-vis spectrum (CH2Cl2) of 11Ni. 
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Figure 5-28. 1H NMR (400 MHz, CDCl3) of 11Ni. 
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Figure 5-29. 13C NMR spectrum (100 MHz, CDCl3) of 11Ni. 
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meso-Tetraphenyl-2-thioxo-imidazole-annulated dihydroxychlorin 12. Prepared from 7 
(25.0 mg, 3.88 × 10-5 mol) in pyridine (10.0 mL) as described for 8 using thiourea (59 mg, 7.75 × 
10-4 mol, 20 equiv) and purified by column chromatography (silica-CH2Cl2/3% MeOH) to afford 
the dark red solid 12 in 92% yield (25.6 mg): Rf (silica-CH2Cl2/5% MeOH) = 0.25; δ 1H NMR (300 
MHz, CDCl3): δ 8.65 (d, 3J = 4.9 Hz, 1H), 8.50 (s, 1H), 8.39 (dd, 3J = 5.8 Hz, 4J = 1.6 Hz, 1H), 
8.20 (d, 3J = 5.0 Hz, 2H), 8.11 (dd, 3J = 7.6, 4J = 1.5 Hz, 2H), 7.77-7.70 (m, 6H), 6.67 (s, 1H, 
exchangeable with D2O), -2.04 (s, 1H, exchangeable with D2O) ppm; UV-vis (CH2Cl2) λmax (rel I.) 
405 (1.0), 515 (0.07), 545 (0.08), 590 (0.04), 645 (0.11) nm; FT-IR (neat, diamond ATR) νC=O = 
1680.4; This compound is unstable, reverting back to the diketone 7 when isolation is 
attempted. 
 
Figure 5-30. 1H NMR spectrum (400 MHz, CDCl3) of 12. 
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meso-Tetraphenyl-N,N’-dimethyl-2-thioxo-imidazole-annulated dihydroxychlorin 13. 
Prepared from 7 (92.0 mg, 1.42 × 10-4 mol) in pyridine (32.0 mL) as described for 8 using N,N’-
dimethylthiourea (297 mg, 2.9 × 10-3 mol) and purified by column chromatography (silica-
CH2Cl2/5% MeOH) to afford the dark red solid 13 in 89% yield (95.4 mg): Rf (silica-CH2Cl2/5% 
MeOH) = 0.65; 1H NMR (400 MHz, CDCl3): δ  8.59 (d, 3J = 5.0 Hz, 1H), 8.47 (s, 1H), 8.18 (d, 3J 
= 7.3 Hz, 1H), 8.08 (t, 3J = 7.6 Hz, 4H), 7.80-7.68 (m, 6H), 4.58 (s, 1H, exchangeable with D2O), 
2.58 (s, 3H), -1.75 (s, 1H, exchangeable with D2O) ppm; 13C NMR (125 MHz, CDCl3): δ 185.7, 
153.8, 152.6, 141.40, 141.35, 139.5, 136.1, 135.3, 134.4, 134.1, 133.1, 132.7, 129.0, 128.5, 
128.21, 128.15, 128.11, 127.97, 127.94, 127.5, 127.2, 126.98, 126.86, 125.4, 124.1, 112.8, 
100.3, 30.5 ppm; UV-vis (CH2Cl2) λmax (log ε) 400 (5.31), 510 (4.16), 539 (4.21), 585, (3.91), 638 
(4.38) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C47H37N6O2S ([M·H]+), 749.2699 
found 749.2684. 
 
Figure 5-31. UV-vis spectrum (CH2Cl2) of 13. 
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Figure 5-32. 1H NMR spectrum (400 MHz, CDCl3) of 13. 
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Figure 5-33. 13C NMR spectrum (125 MHz, CDCl3) of 13. 
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Oxidative cleavage of 13. Prepared according to the procedure for 10, starting from (13) 
(26.4 mg, 3.5 × 10-5 mol) in dry THF (10.0 mL) with Pb(OAc)4 (49.6 mg, 1.1 × 10-4 mol, 3.1 
equiv.) and purified by preparative TLC (silica-CH2Cl2)  to afford the known diketone 7 (2.0 mg, 
9% yield) and the green 14 in 67 % yield (17.6 mg): Rf (silica-CH2Cl2) = 0.59; 1H NMR (400 
MHz, CD2Cl2): δ  8.56 (s, 1H), 8.50 (d, 3J = 5.0 Hz, 1H), 8.34 (s, 1H), 8.18 (d, 3J = 5.0 Hz, 1H), 
8.03 (s, 1H), 7.75-7.68 (m, 4H), 7.59 (t, 3J = 7.5 Hz, 1H), 7.35 (s, 1H), 6.85 (s, 1H), 2.69 (s, 3H), 
-0.22 (s, 1H, exchangeable with D2O) ppm; 13C NMR (125 MHz, CD2Cl2): δ 186.9, 171.8, 155.4, 
148.3, 140.81, 140.78, 140.68, 140.03, 140.01, 137.4, 134.5, 134.20, 134.11, 134.06, 134.01, 
133.90, 133.86, 132.43, 132.39, 129.3, 128.61, 128.55, 128.51, 128.3, 127.8, 127.53, 127.41, 
127.37, 125.4, 115.2, 109.80, 109.69, 109.65, 109.56, 109.51, 109.48, 109.43, 109.37, 109.31, 
109.22, 109.16, 109.02, 108.96, 108.91, 108.88, 108.86, 35.6 ppm; UV-vis (CH2Cl2) λmax (log ε) 
360 (4.4), 432 (5.02), 536 (3.77), 572 (3.75), 607 (3.82), 668 (3.85) nm; HR-MS (ESI+, 100% 
CH3CN, TOF) m/z cald for C47H35N6O2S ([M·H]+), 747.2542 found 747.2558. 
 
Figure 5-34. UV-vis spectrum (CH2Cl2) of 14. 
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Figure 5-35. 1H NMR spectrum (400 MHz, CDCl3) of 14. 
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Figure 5-36. 13C NMR spectrum (125 MHz, CDCl3) of 14. 
N
N N
Ph
PhPh
Ph
N
N
NO
O
S
Me
Me
HH
5. Supersizing Pyrrole-Modified Porphyrins 
 
226 
 
Semicarbazide adduct (18). Prepared from 7 in 51% yield (16.5 mg) on a 4.65 × 10-5 mol 
(30.0 mg) scale using 103.8 mg (9.31 × 10-4 mol, 20 equiv.) of semicarbazide·HCl according to 
the general procedure except at r.t. and purified by column chromatography: Rf (silica-
CH2Cl2/3% MeOH) = 0.44; 1H NMR (400 MHz, CDCl3): δ 13.08 (s, 1H, exchangeable with D2O), 
8.78 (two overlapping doublets, 3J = 5.2 Hz, 2H), 8.62 (two overlapping doublets, 3J = 4.9 Hz, 
2H), 8.58 (d, 3J = 4.7 Hz, 1H), 8.54 (d, 3J = 5.7 Hz, 1H), 8.15 (dd, 3J = 5.9, 4J = 1.8 Hz, 4H), 
8.07-8.05 (m, 2H), 7.96-7.94 (m, 2H), 7.82-7.70 (m, 12H), 5.27 (s, exchangeable with D2O), 
4.50 (s, exchangeable with D2O), -2.24 (s, 1H exchangeable with D2O), -2.34 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): δ 187.7, 155.7, 155.4, 154.4, 146.5, 
142.4, 141.62, 141.48, 141.34, 140.4, 140.2, 138.9, 138.1, 137.6, 137.4, 134.4, 134.23, 134.18, 
133.8, 133.4, 132.4, 128.7, 128.07, 127.99, 127.92, 127.79, 127.55, 127.49, 127.29, 127.22, 
126.88, 126.84, 123.9, 122.0, 115.5, 112.2 ppm; UV-vis (CH2Cl2) λmax (log ε) 410 (5.17), 465 
(sh), 613 (sh), 666, (3.6) nm; FT-IR (neat, diamond ATR) νC=O = 1667.1; HR-MS (ESI+, 100% 
CH3CN, TOF) m/z cald for C45H32N7O2 ([M·H]+), 702.2617 found 702.2618. 
 
Figure 5-37. UV-vis spectrum (CH2Cl2) of 18. 
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Figure 5-38. 1H NMR spectrum (400 MHz, CDCl3) of 18. 
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Figure 5-39. 1H NMR spectrum (100 MHz, CDCl3) of 18. 
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Figure 5-40.  Partial 1H1H-NOESY spectrum (CDCl3) of 18. 
 
Figure 5-41. 15N-1H HSQC spectrum (CDCl3) of 18. 
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Figure 5-42. HMBC spectrum (CDCl3) of 18. 
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Thiosemicarbazide-fused adduct (19). Prepared from 7 in 45% (5.0 mg) yield on a 1.7 × 
10-5 mol (10.0 mg) scale using 28.0 mg (3.1 × 10-4 mol, 20 equiv.) of thiosemicarbazide 
according to the general procedure for 8 except at r.t. and purified by column chromatography: 
Rf (silica-CH2Cl2) = 0.31; 1H NMR (400 MHz, CDCl3): δ 13.75 (s, 1H, exchangeable with D2O), 
8.80 (t, 3J = 5.3 Hz, 2H), 8.62 (m, 3H), 8.55 (d, 3J = 4.9 Hz, 1H), 8.17 (dd, 3J = 6.2, 4J = 1.4 Hz, 
4H), 8.07 (dd, 3J = 7.4, 4J = 1.6 Hz, 2H), 7.97-7.95 (m, 2H), 7.84-7.72 (m, 12H), 6.39 (s, 1H, 
exchangeable with D2O), 6.09 (s, 1H, exchangeable with D2O), -2.22 (s, 1H, exchangeable with 
D2O), -2.30 (s, 1H, exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): δ 187.4, 180.9, 
155.8, 154.5, 145.9, 142.4, 141.54, 141.39, 141.27, 140.3, 140.0, 139.0, 138.2, 137.5, 137.1, 
134.5, 134.22, 134.18, 133.9, 133.3, 132.5, 128.7, 128.19, 128.10, 128.03, 128.00, 127.90, 
127.80, 127.70, 127.49, 127.39, 127.33, 126.89, 126.76, 124.0, 122.3, 115.5, 112.2, ppm; 
UV-vis (CH2Cl2) λmax (log ε) 414 (5.07), 480 (sh), 614 (3.59), 671 (3.59) nm. 
 
Figure 5-43. UV-vis spectrum (CH2Cl2) of 19. 
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Figure 5-44. 1H NMR spectrum (400 MHz, CDCl3) of 19. 
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Figure 5-45. 13C NMR spectrum (100 MHz, CDCl3) of 19. 
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Malonamide adduct 20. Prepared from 7 (71.0 mg, 1.1 × 10-4 mol) in pyridine (25 mL) as 
described for 8 using malonamide (225 mg, 2.2 × 10-3 mol) and purified by column 
chromatography (silica-CH2Cl2/5% MeOH) to afford the magenta solid 20 in 96.1% yield (79 
mg): Rf (silica-CH2Cl2/5% MeOH) = 0.38; 1H NMR (300 MHz, CDCl3): δ 8.97 (s, 1H, 
exchangeable with D2O), 8.65 (two overlapping doublets, 3J = 5.8 Hz, 2H), 8.50 (s, 2H), 8.32-
8.22 (m, 3H), 8.17 (d, 3J = 4.8 Hz, 1H), 8.11 (d, 3J = 5.8 Hz, 4H), 7.84-7.60 (m, 15H), 6.77 (s, 
1H, exchangeable with D2O), 6.36 (s, 1H, exchangeable with D2O), 5.75 (s, 1H, exchangeable 
with D2O), 5.40 (s, 1H, exchangeable with D2O), -2.15 (s, 2H, exchangeable with D2O) ppm; 13C 
NMR (100 MHz, DMSO-d6): δ 171.0, 170.3, 159.5, 157.7, 152.89, 152.81, 141.37, 141.25, 
141.0, 140.5, 139.8, 135.52, 135.43, 135.25, 134.6, 134.12, 134.04, 133.30, 133.24, 133.18, 
128.57, 128.48, 128.38, 128.24, 127.66, 127.52, 127.50, 127.3, 127.02, 126.97, 125.9, 123.1, 
114.6, 113.2, 95.5, 86.4, 55.4, 55.0 ppm; UV-vis (CH2Cl2) λmax (log ε) 408 (5.01), 516 (3.90), 542 
(3.90), 542 (3.90), 590 (3.56), 642 (4.13) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for 
C47H35N6O4 ([M·H]+), 747.2720 found 747.2706. 
 
Figure 5-46. UV-vis spectrum (CH2Cl2) of 20. 
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Figure 5-47. 1H NMR spectrum (500 MHz, CDCl3) of 20. 
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Figure 5-48. 13C NMR spectrum (125 MHz, CDCl3) of 20. 
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Figure 5-49. Partial 13C-1H HSQC spectrum (CDCl3) of 20. 
 
 
Figure 5-50. HMBC spectrum (CDCl3) of 20. 
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Dimethyl malonamide adducts 23 and 24. Prepared from 7 (50.0 mg, 7.8 × 10-5 mol) in 
pyridine (20 mL) as described for 8 using N,N’-dimethylmalonamide (105 mg, 8.0 × 10-4 mol, 10 
equiv.) and purified by column chromatography (silica-CH2Cl2/3% MeOH) to afford the purple 
diol-chlorin 23 in 38% yield (23 mg) and the red diol-chlorin 24 in 18% yield (10 mg). (23) Rf 
(silica-CH2Cl2/3% MeOH) = 0.32; 1H NMR (500 MHz, CDCl3): δ 8.65 (d, 3J = 5.0 Hz, 1H), 8.60 
(d, 3J = 4.9 Hz, 1H), 8.49 (s, 2H), 8.41 (d, 3J = 4.9 Hz, 1H), 8.35 (d, 3J = 7.4 Hz, 1H), 8.26 (s, 
1H), 8.22 (d, 3J = 7.4 Hz, 2H), 8.12 (d, 3J = 4.9 Hz, 1H), 8.08 (d, 3J = 7.4 Hz, 1H), 7.99 (s, 1H), 
7.92 (d, 3J = 7.4 Hz, 1H), 7.85 (t, 3J = 7.2 Hz, 1H), 7.75-7.60 (m, 12H), 6.14 (s, 1H, 
exchangeable with D2O), 5.62 (s, 1H, exchangeable with D2O), 5.57 (q, 3J = 4.7 Hz, 1H, 
exchangeable with D2O), 4.21 (s, 1H), 2.77 (d, 3J = 4.9 Hz, 3H), 2.41 (s, 3H), -1.91 (s, 1H, 
exchangeable with D2O), -1.95 (s, 1H, exchangeable with D2O) ppm; 13C NMR (125 MHz, 
CDCl3): δ 169.4, 169.1, 156.7, 154.0, 153.4, 151.3, 141.67, 141.64, 141.48, 140.7, 140.5, 
136.38, 136.29, 136.10, 135.4, 134.70, 134.56, 134.3, 133.3, 133.0, 128.6, 128.20, 128.05, 
127.90, 127.85, 127.74, 127.3, 127.0, 126.22, 126.05, 125.8, 125.5, 124.2, 123.3, 114.8, 113.8, 
100.6, 82.8, 77.2, 54.8, 26.60, 26.55 ppm; UV-vis (CH2Cl2) λmax (log ε) 400 (5.19), 413 (5.14), 
455 (sh), 511 (4.04), 538 (4.12), 582 (3.97), 634 (4.30) nm; HR-MS (ESI+, 100% CH3CN, TOF) 
m/z cald for C49H39N6O4 ([M·H]+), 775.3033 found 775.3041. (24): Rf (silica-CH2Cl2/3% MeOH) 
= 0.19; 1H NMR (500 MHz, CDCl3): δ  8.65 (d, 3J = 4.6 Hz, 1H), 8.60 (d, 3J = 4.7 Hz, 1H), 8.48 
(s, 2H), 8.29 (d, 3J = 4.6 Hz, 1H), 8.19-8.14 (m, 2H), 8.11 (d, 3J = 5.2 Hz, 4H), 8.07 (d, 3J = 4.7 
Hz, 1H), 8.04 (d, 3J = 7.3 Hz, 1H), 7.94 (d, 3J = 5.7 Hz, 1H), 7.74-7.66 (m, 12H), 4.59 (s, 1H, 
exchangeable with D2O), 3.60 (s, 1H, exchangeable with D2O), 3.19 (d, 2J = 17.5 Hz, 1H), 2.81 
(d, 2J = 17.5 Hz, 1H), 2.24 (s, 3H), -1.92 (s, 1H, exchangeable with D2O) ppm; 13C NMR (125 
MHz, CDCl3): δ 173.8, 157.0, 154.5, 153.9, 153.4, 141.72, 141.56, 141.50, 141.3, 140.22, 
140.06, 136.3, 136.0, 135.0, 134.5, 134.2, 133.8, 133.3, 133.0, 128.9, 128.5, 128.05, 127.92, 
127.69, 127.55, 126.98, 126.92, 125.40, 125.27, 124.3, 123.5, 113.4, 112.7, 100.3, 85.7, 44.9, 
5. Supersizing Pyrrole-Modified Porphyrins 
 
239 
 
26.0 ppm; UV-vis (CH2Cl2) λmax (log ε) 399 (5.17), 411 (sh), 437 (sh), 460 (sh), 508 (4.03), 535 
(4.06), 583 (3.90), 634 (4.31) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C47H36N5O3 
([M·H]+), 718.2813 found 718.2815. 
 
Figure 5-51. UV-vis spectrum (CH2Cl2) of 23.  
 
Figure 5-52. UV-vis spectrum (CH2Cl2) of 24. 
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Figure 5-53. 1H NMR spectrum (500 MHz, CDCl3) of 23. 
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Figure 5-54. 13C NMR spectrum (125 MHz, CDCl3) of 23. 
NN
N N
Ph
Ph
Ph
Ph HH
N O
Me
HO
OH
O
NHMe
5. Supersizing Pyrrole-Modified Porphyrins 
 
242 
 
 
Figure 5-55. 13C-1H HSQC spectrum (CDCl3) of 23. 
 
Figure 5-56. 1H-1H COSY spectrum (CDCl3) of 23. 
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Figure 5-57. 1H NMR spectrum (500 MHz, CDCl3) of 24. 
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Figure 5-58. 13C NMR spectrum (125 MHz, CDCl3) of 24. 
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Figure 5 59. Partial 13C-1H HSQC spectrum (CDCl3) of 24. 
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Oxidative Cleavage of Malonamide-adduct 20. Malonamide-diol 20 (42 mg, 5.6 × 10-5 
mol) was dissolved in dry THF (15.0 mL) in a round bottom flask equipped with a magnetic stir 
bar under N2 atmosphere. Pb(OAc)4 (total 56.7 mg, 1.28 × 10-4 mol, 2.3 equiv.) was added in 
portions and the reaction mixture was stirred at ambient temperature for 45 min-1h. When the 
starting material was consumed, (reaction control by TLC), the solvent was evaporated and the 
crude mixture was purified by preparative TLC (silica-CH2Cl2/2% MeOH) to afford the purple 21 
contaminated with a small amount of spiro-barbiturate 22 (24 mg, ~57% yield based on the 
mass of the main product): Rf (silica-CH2Cl2/2% MeOH) = 0.10; 1H NMR (400 MHz, CDCl3) δ 
8.71 (d, 3J = 4.9 Hz, 2H), 8.58-8.52 (m, 3H), 8.38 (d, 3J = 5.2 Hz, 1H), 8.14-8.10 (m, 4H), 7.96-
7.94 (m, 2H), 7.89-7.83 (m, 3H), 7.77-7.59 (m, 12H), 6.91 (s, 1H, exchangeable with D2O), 5.42 
(s, 1H, exchangeable with D2O), -2.02 (s, 1H, exchangeable with D2O), -2.08 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): δ 194.7, 166.9, 164.0, 155.98, 
155.90, 154.2, 141.45, 141.26, 141.15, 141.10, 139.71, 139.61, 139.49, 138.8, 138.2, 137.9, 
137.0, 134.7, 134.5, 134.32, 134.12, 134.07, 133.81, 133.64, 132.2, 129.01, 128.83, 128.6, 
128.11, 128.03, 127.99, 127.87, 127.80, 127.57, 127.42, 127.36, 127.30, 127.15, 127.07, 
126.91, 126.87, 124.8, 122.6, 116.6, 112.7 ppm; UV-vis (CH2Cl2) λmax (rel I.) 334 (0.16), 420 
(1.0), 522 (0.06), 562 (0.06), 590 (0.05), 642 (0.05) nm; HR-MS (ESI+, 100% CH3CN, TOF) m/z 
cald for C47H31N6O4([M·H]+), 743.2401 found 743.2437. 
 
Figure 5-60. UV-vis spectrum (CH2Cl2) of 21. 
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Figure 5-61. 1H NMR spectrum (400 MHz, CDCl3) of 21. 
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Figure 5-62. 13C NMR spectrum (100 MHz, CDCl3) of 21. 
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Figure 5-63. 15N-1H HSQC spectrum (CDCl3) of 21. 
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6 Substituted Imidazoloporphyrins 
Much of the contemporary work in the area of synthetic chemistry of porphyrins, 
hydroporphyrins,1 and their analogues aims at the optimization of their optical properties. 
Particularly prominent is the aim of generating porphyrinoids possessing NIR wavelengths of 
absorbance and emission because of their potential utility in medical applications;2 technical 
applications may also utilize their altered electronics.3 Less studied are derivatives with 
functionalized porphyrinic macrocycles that allow their utilization in ways unknown to regular, 
unmodified porphyrins. 
To illustrate this, while meso-tetraarylporphyrins such as 1 can coordinate a metal ion in 
their central cavity,4 and therefore have been used (as well as their analogues) as metal 
sensors (or non-reversible chemidosimeters),5 the binding (or release) of a metal ion is not very 
selective and kinetically challenging. Bearing otherwise only aromatic CH groups at their 
chromophore periphery, they do not interact with metals in any other way. On the other hand, 
the isomeric N-confused porphyrin 2 overcomes this limitation; it can readily coordinate a metal 
through the β-N atom on its periphery (in addition to coordination of metals to its center).5-6 
Since metal coordination involves the chromophore, any interaction with the metal is observed 
by diagnostic changes in its optical properties. However, the external monodentate coordination 
mode is necessarily weaker than any chelation mode (using comparable donor atoms). 
Ruppert, Callot, Jeandon, Richeter, and co-workers studied the construction of β-modified 
tetraarylporphyrin derivatives capable of forming conjugated chelates at their chromophore 
periphery, such as porphyrin 3,7 thereby increasing its affinity toward metals. We like to stress 
that the focus of this discussion is not on porphyrins that were appended to, e.g., a metal ion 
coordination motif that allows the binding of the ion without the direct involvement of atoms of 
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the macrocycle/chromophore, for which there are many examples.8 The optical response of the 
chromophore upon metal binding in these systems is often very weak. 
Imidazoloporphyrin 4 reported by our laboratory combines the N4-central cavity of a 
porphyrin with the peripheral β-N of N-confused porphyrins.9 The basicity of the peripheral 
nitrogen atom was demonstrated by the halochromic optical response upon protonation.9b Thus, 
we predicted imidazoloporphyrin 4 to be a competent ligand for transition metals, but even 
though it can be accessed along three independent pathways by modification of 1 (see also 
below), none were efficient enough to enable us to study the coordination chemistry in any 
depth, nor could we investigate the derivatization of its imidazole moiety.  
 
Porpholactones, such as the tetraphenyl derivative 6, possess a lactone functionality in 
place of a CH=CH double bond at their periphery (Scheme 6-1). The electrophilicity of this 
functionality, particularly in the meso-C6F5-substituted and metalated derivatives, could be 
utilized for high pH sensing in cementitious materials, aqueous solutions, and as cyanide 
sensors, among others.10 The lactone moiety also changes the optical, catalytic, and bio-
distribution properties of this chromophore in unexpected ways.11 Porpholactones are available 
along a number of alternative routes.12 The route of our choice is by step-wise oxidation of 
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porphyrin 1 (Scheme 6-1):12e Dihydroxylation to chlorin diol 5 and diol oxidation to lactone 6. 
This efficiently prepared lactone derivative served also as an intermediate toward the generation 
of imidazoloporphyrin 4: Lactone 6 was reacted with hydrazine and the resulting N-amino-
lactam intermediate reductively cleaved to porpholactam 9; this was dehydrated/chlorinated to 
form chloro-imidazole 10, that was finally hydrodehalogenated into imidazoloporphyrin 3. 
Importantly in the current context, the halogen atom on chloro-imidazole 10 could potentially be 
used as a synthetic handle toward further modifications of the imidazoloporphyrins, but when 
this work was reported in 2013,9b our access to porpholactam 9 via porpholactone 6 was limited 
enough to prohibit a full-fledged study. In 2016, we fortuitously discovered a short pathway 
toward porpholactam 9:13 meso-Tetraphenyl-2,3-dioxochlorin 7, readily available along a 
number of alternative pathways from porphyrin 1,12a,14 formed a novel chlorin diol 8 in high yields 
by reaction with urea. Upon oxidative diol cleavage, it fragmented and formed porpholactam 9. 
This much more economic and efficient pathway now allowed the study of its conversion to 
(functionalized) imidazoloporphyrin derivatives, to be presented here. 
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Scheme 6-1. Known synthesis of imidazoloporphyrin 3 and porpholactam 9. 
Thus, we report here the full details of the formation of the porpholactam 9 along the dione 7 
→ diol 8 → lactam 9 route mentioned as an incidental result in a preliminary report.13 We will 
then detail the conversion of porpholactam 9 to a number of imidazoloporphyrin derivatives 
designed to chelate transition metals at their periphery also involving the β-N atom of the 
imidazole moiety. In so doing, we are providing the synthetic methodology for the expansion of 
the utility of synthetic porphyrinoids. 
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6.1 Results and Discussion 
6.1.1 An Efficient Synthesis of Porpholactam 9 
The regular ketone reactivity of meso-tetraarylporphyrin diones, such as 7, was previously 
demonstrated,15 including its reaction with diamines to generate diimines.16 However, we found 
that the reaction of non-polar, yellow-brown 7 with urea did not generate a diimine but the non-
dehydrated precursor product, a polar, magenta-colored dihydroxychlorin 8 containing an 
imidazolidinone moiety annulated at the β,β’-position. Diagnostic for the formation of the 
dihydroxychlorin structure are the preservation of the two-fold symmetry of the dione in the 
product and the presence of OH and NH signals in its 1H NMR spectrum, the replacement of the 
pyrrolinone carbonyl signal in its 13C NMR spectrum (at 188 ppm) by a signal at δ = 159.5 ppm 
assigned to the imidazolidinone moiety, and its regular chlorin-like spectrum compared to the 
much broadened spectra for dione 7 (Figure 6-1),17 and a composition (C45H33N6O3 for MH+, as 
per HR-MS) consistent with the structural assignment. For a reproduction of the spectra of all 
new products, see experimental section. Chlorin 8 is available in multi-100 mg batches. 
 
Figure 6-1. UV-vis spectra (CH2Cl2) of dione 7 (blue trace) and dihydroxychlorin 8 (red trace). 
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We previously reported multiple methods for the oxidative cleavage of the pyrroline β,β’-
bond of dihydroxychlorins.18 Thus, treatment of diol 8 under classic diol cleavage reaction 
conditions using Pb(OAc)419 resulted in the formation of a red, non-polar compound 9 in good 
yields (69%). Its porphyrin-like UV-vis spectrum (Figure 6-2), NMR spectra, and its composition 
as determined by HR-MS identified it to be the known porpholactam.9b Evidently, the expulsion 
of smaller fragments CO2 + HCN from the putative pyrrole-modified derivative containing an 8-
membered heterocycle, thereby establishing a stable ‘tetrapyrrolic’ architecture, drove the 
reaction. We have previously seen these types of ring-contraction reactions.9a,20 The 
mechanism of this reaction was not studied and is undoubtedly complex, but the fragmentation 
can be halted by formal N-methylation of the urea adduct (formation of the chlorin diol adduct 
from N,N’-dimethylurea) and the unusual 1,3,6-triazocine-2,4,8-trione-derived porphyrinoid 
could be isolated.13 This 3-step pathway toward porpholactam 9 from meso-tetraphenylchlorin 
diol 6 involving high-yielding steps (6 → 7 → 8 → 9) is much more convenient, economic, and 
significantly higher yielding (overall 29% at a 50 mg scale) than the previously described 4-step 
synthesis from 1 (~13% along 6 → 5 (two steps) → 9). 
 
Figure 6-2. UV-vis spectrum (CH2Cl2) of the compound indicated. 
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6.1.2 Conversion of Porpholactam 8 to Reactive Imidazoloporphyrin Triflate 12 
Initial experiments on the substitution of the Cl-atom in chloro-imidazoloporphyrin 10 were 
disappointing. Thus, we set out to prepare the analogous triflate compound (Scheme 6-2). 
Parallel to the iminolization with concomitant OH-to-Cl substitution of porpholactam 8 using 
POCl3 to prepare 10, we reacted purple porpholactam 9 with trifluoromethanesulfonic anhydride 
(Tf2O) in CH2Cl2 under an inert atmosphere at –78 °C for an iminolization with concomitant OH-
to-OTf exchange. Upon warming to ambient temperature, one major nonpolar (Rf  = 0.88, silica-
CH2Cl2) purple compound was obtained in good yields (76%). Its composition (C44H29F3N5SO3 
for MH+, as determined by ESI+ HR-MS), corresponded to the composition of the target 
imidazoloporphyrin triflate 12. Notably absent from its 1H NMR spectrum was the diagnostic N-H 
peak of the porpholactam (at 9.7 ppm), any sign for a lactam carbonyl oxygen in its 13C NMR, 
and the presence of a single diagnostic peak (s at -71.1 ppm) in its 19F NMR indicating the 
presence of the triflate group. Once crystallized, the compound is stable and can be stored for 
months in the freezer. 
Owing to the ready substitution of the triflate group in triflate imines,21 imine 12 was 
expected to react with a range of nucleophiles. Indeed, in situ substitution of the triflate group 
when the reaction of lactam 8 with Tf2O was performed in the presence of pyridine generated 
the pyridinium-substituted imidazoloporphyrin 13 in excellent yields. Its spectroscopic and 
analytical data (e.g., composition of C48H33N6 for MH+, as per ESI+ HR-MS) confirm its assigned 
structure. Significantly, its UV-vis spectral properties (λmax = 683 nm) are, owing to the presence 
of the positive charge of the pyridinium substituent located on a β-position of the chromophore, 
significantly altered compared to the porphyrin-like spectra observed for 10 (λmax = 655 nm) or 
12 (λmax = 654 nm) that are similar to each other (Figure 6-3). The influence of a cationic charge 
on the optical properties of the chromophore were previously also shown in β,β’-annulated 
imidazolium porphyrins. 22 
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The pyridinium-substituted imidazoloporphyrin 13 exhibit a red-shifted and hyperchromic 
UV-vis spectrum with much broadened Q-band region under acidic conditions (10% TFA in 
CH2Cl2) (Figure 6-3). While some features of this spectrum are similar to that of the spectra of 
porphyrins protonated at the central nitrogens (bathochromically shifted Soret band, reduction of 
the number of side bands), particularly the red-shifted Q-bands are untypical and suggestive of 
a protonation of the peripheral imidazole nitrogen (that may or may not be accompanied by 
central nitrogen protonation).9a,23 
 
Figure 6-3. UV-vis spectra (CH2Cl2) of the compounds indicated.   
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Scheme 6-2. Conversion of porpholactam 9 to imidazoloporphyrin β-substituted derivatives. Reaction conditions: (i) 
Tf2O, CH2Cl2, N2, -78 °C to 25 °C (ii) Tf2O, CH2Cl2/py, N2, -78 °C to 25 °C (iii) N,N-diethylamine, Na2CO3, CH2Cl2, r.t. 
(iv) diethyliminodiacetate, Na2CO3, acetone, Δ (v) 1M KOH: THF (1:1 v/v), Δ (vi) DPA, Na2CO3, CH2Cl2, r.t. (vi) 
cyclen, Na2CO3, CH2Cl2, r.t. 
Reaction of triflate 12 with Et2NH (in the presence of Na2CO3 in CH2Cl2) at ambient 
temperature smoothly afforded the diethylamine-substituted imidazoloporphyrin 14 (Scheme 
6-2). Diagnostic for the connectivity of this compound was the appearance of the signals for the 
two ethyl groups in its 1H NMR spectrum; all other spectroscopic and analytical data (e.g., 
composition of C47H39N6 for MH+, as per ESI+ HR-MS). Interestingly, the UV-vis spectrum of this 
compound is significantly broadened and features a split Soret band (Figure 6-4). No change in 
this UV-vis spectrum was observed upon addition of an excess of Et3N, but the addition of acid 
leads to protonation-related changes in the spectrum that suggest that protonation had also 
taken place at the outside and/or the inside nitrogens of the molecule (Figure 6-4). 
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Figure 6-4. UV-vis spectra (CH2Cl2) of the compounds indicated. 
6.1.3 Modification of Imidazoloporphyrin with Potential Chelating Motifs 
With the proof of concept in hand that triflate 12 can be efficiently derivatized with amines, 
we investigated whether amine-based metal chelates could be introduced that would chelate a 
metal ion in a way that would also involve the external nitrogen donor atoms of the 
imidazoloporphyrin cooperatively. We thus hoped to be able to sense the presence of a specific 
metal ion though the changes in the optical properties of the chromophore, while the chelating 
interaction was designed to increase the binding affinity and selectivity of the sensor.  However, 
we also realized that the Nimidazole,Namine-bite angle of this sensing platform might be a bit smaller 
than ideal. 
 
Iminodiacetate moieties are excellent and versatile chelates. Thus, reaction of triflate 
imidazole 12 with diethyliminodiacetic acetate in the presence of Na2CO3 in hot acetone 
N N
N
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afforded a polar brown compound after ~24 h (the reaction with the corresponding free acid was 
unsuccessful). The composition of the product (C51H43N6O4 for MH+, as per ESI+ HR-MS) 
matched that of the target chelate 15. Also observed in its 1H NMR were the peaks 
corresponding to the ethyl ester groups, as well a peak at 4.4 ppm corresponding to the 
methylene group of the iminodiacetic acid moiety. A single crystal of 15 could be grown to 
ultimately confirm the connectivity of the chromophore, revealing also its slight ruffling (Figure 
6-5). The Nimidazole,Namine-bite angle was measured to be 119.36. 
  
Figure 6-5. X-ray structure of substituted imidazoloporphyrin 15, hydrogens removed for clarity. 
Reaction of the diester 15 under classic saponification conditions (KOH, wet THF) afforded 
a very polar, streaking brown product after 2 h of reflux. After neutralization of the reaction 
mixture and extraction into CH2Cl2, the product was purified by column chromatography 
(CH2Cl2/10% MeOH) to afford a brown residue that displayed a loss of two ethanol molecules by 
HR-MS. The resulting free acid was only slightly soluble in CHCl3 and CH2Cl2, but soluble in 
CH2Cl2/MeOH mixtures as well as pure MeOH. The 1H NMR of the free acid indicated a slight 
upfield shift but retention of the methylene peaks (~4 ppm) of the iminodiacetic acid moiety. Due 
to solubility issues of the free acid 16, the NMR spectra were recorded in CD2Cl2/MeOD 
mixtures and thus, the carboxylic acid and inner N-H protons were not observed.  
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Likewise, the DPA-substituted imidazoloporphyrin 17 could be prepared by treatment of 12 
with a 50-fold molar excess of di-(2-picolyl)amine (DPA) in the presence of sodium carbonate in 
CH2Cl2 at ambient temperature. The presence of eight additional peaks in the aromatic region in 
the 1H NMR spectrum, along with a peak corresponding to the methylene unit of the DPA moiety 
indicated successful substitution. The peaks corresponding to the DPA moiety were identified by 
the observation of a pair of doublets and a pair of triplets in the aromatic region exhibiting 
diagnostic 1H-1H COSY correlations of the 2-substituted pyridine moiety (see ESI). 
The triflate imidazole 12 could also be converted to the corresponding cyclen-substituted 
imidazoloporphyrin 18 in 62% yield, by treatment with cyclen in the presence of sodium 
carbonate in CH2Cl2 at ambient temperature. A series of four peaks in the aliphatic region of the 
1H NMR, each integrating to four protons, indicated the presence of the cyclen unit. The correct 
mass was confirmed by HR-MS (ESI+, 100% CH3CN). Next to the main cyclen-substituted 
product 18, another less polar, brown product was isolated in 16% yield with a similar but 
slightly broadened UV-vis spectrum than that of 18. The HR-MS (ESI+, 100% CH3CN) of the 
nonpolar brown compound indicated the presence of a dimeric species arising from the 
conjugation of two porphyrins to one cyclen unit. 
6.1.4 Interaction of iminodiacetic acid-substituted imidazoloporphyrin 16 with Zn2+  
We hypothesized that external coordination of the iminodiacetic acid-substituted 
imidazoloporphyrin 16 with M2+ cations would lead to a spectrophotometric response associated 
with donation of the imidazole lone-pair to the metal cation (Scheme 6-3). 
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Scheme 6-3. Proposed mode of binding of substituted-imidazoloporphyrin 16 with  M2+  cations in MeOH solution.   
Indeed, titration of 16 with Zn2+ shows marked effects on the native UV-Vis spectrum, 
causing a gradual increase and sharpening of the Soret band, along with a small 
hyposochromic shift (Figure 6-6). The titration resulted in the gradual decrease of the first Q 
band and enhancement of all subsequent Q bands. All of these aspects are consistent with 
porphyrin metallation; however, the conditions in which these titrations were performed are not 
suitable for internal complexation of most metals. As such, this spectrum is indicative of 
peripheral metalation of 16. 
 
Figure 6-6. Absorbance titration of 16 with Zn2+. Conditions: [16] 6.4 × 10-6 M, MeOH, 25 °C, aerated solution, 
addition of Zn2+ as a 1.00 mM methanolic solution. 
N N
N
NN
Ph
Ph
Ph
Ph N
O
O
O
O
M2+·(MeOH)n
N N
N
NN
Ph
Ph
Ph
Ph N
CO2H
CO2H
M2+L+M M
+ MeOH
6. Substituted Imidazoloporphyrins  
 
265 
 
6.2 Conclusions 
In conclusion, we introduced a new and significantly more efficient (and non-obvious) 
synthetic pathway toward known meso-tetraphenylporpholactams. We demonstrated the 
conversion of meso-tetraphenylporpholactams to an imidazoloporphyrin triflate derivative that 
proved most useful in the preparation of imidazoloporphyrins carrying a substituted amine 
adjacent to the outside N atoms of the imidazole moiety. This provides a platform for the 
synthesis of chromophore periphery-functionalized porphyrinoids and invites the continued 
exploration of the reactivity of the imidazole triflate. 
When choosing amines substituted with chelating units, a number of derivatives could be 
prepared that were designed to chelate a metal ion while also involving the outside imidazole 
nitrogen atom in their coordination sphere, thus setting the stage for the generation of high-
affinity and selective optical metal ion chemosensors. Preliminary reports on the metal ion 
response of one of such system lends credence to this hypothesis, but the detailed acid/base 
and metal-induced optical response profiles of all the potential sensors will be reported in due 
course. 
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6.3 Experimental Section 
6.3.1 Materials and Instruments 
All solvents and reagents were used as received. Lactam 9 was prepared as described in 
the literature.13-14  
6.3.2 Synthesis and Characterization 
meso-Tetraphenyl-2-aza-3-trifluoromethylsulfonylporphyrin (12). To a flame-dried 
25 mL round-bottom flask equipped with a septum was added 10 mL of dry CH2Cl2 and meso-
tetraphenyl-2-aza-3-oxo-porphyrin 9 (21 mg, 3.35 × 10-5 mol) was dissolved under an 
atmosphere of dry N2. The mixture was cooled to –78 ˚C and stirred for 20 min. 
Trifluoromethanesulfonic anhydride (300 µL) was added drop-wise via syringe to the reaction 
flask. The mixture was stirred for 20 min at –78 ˚C (acetone/dry ice bath), then warmed to 0 ˚C 
(ice/water bath) and stirred for an additional 20 min. The reaction mixture was allowed to warm 
to ambient temperature and stirred for 15 h until the starting material was consumed (reaction 
control by UV-vis and TLC). The reaction was quenched by addition of a saturated aq solution 
of sodium bicarbonate (NaHCO3, 5 mL) and CH2Cl2 (5 mL). The biphasic mixture was poured 
rapidly in a separation funnel and the organic layer was separated from the aqueous layer. The 
aqueous layer was extracted with CH2Cl2 (2 × 5 mL), and the combined organic layers were 
dried over anhyd Na2SO4. The crude material was purified by preparative TLC (CH2Cl2/20% 
petroleum ether 30–60) to furnish 12 as a purple solid in 76% (20 mg) yield. Rf (silica-CH2Cl2) = 
0.88; 1H NMR (400 MHz, CDCl3): δ 9.17 (d, 3J = 5.2 Hz, 1H), 8.96 (d, 3J = 5.0 Hz, 1H), 8.90 and 
8.88 (two overlapping d, 3J = 5.0 Hz, 2H) 8.74 (s, 2H), 8.27 (d, 3J = 7.7 Hz, 2H), 8.20 (t, 3J = 7.7 
Hz, 4H), 8.11 (d, 3J = 7.0 Hz, 2H) 7.85–7.77 (m, 12H) –2.46 (s, 1H, exchangeable with D2O); 19F 
NMR (376 MHz, CDCl3, external reference CFCl3): δ -71.1 (s) ppm; 13C NMR (100 MHz, CDCl3): 
δ 163.6, 157.5, 157.2, 153.0, 141.6, 140.6, 140.3, 140.1, 139.3, 139.0, 138.8, 136.2, 135.7, 
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135.6, 134.8, 134.7, 134.5, 133.6, 130.2, 129.6, 129.0, 128.8, 128.3, 127.9, 127.8, 127.2, 127.1, 
126.9, 121.6, 121.4, 121.1, 120.6, 119.2, 117.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 422 (5.80), 
524 (4.40), 562 (3.94), 598 (3.90), 654 (4.42) nm, UV-vis (CH2Cl2 + 10% TFA) λmax (log ε) 447 
(5.62), 680 (4.76) nm; HR-MS (ESI+, cone voltage = 30 V, 100% CH3CN, TOF) m/z calcd for 
C44H29F3N5SO3 764.1943 ([M·H]+), found 764.1983. 
meso-Tetraphenyl-2-aza-3-(N-pyridinium)-porphyrin triflate (13). Compound 13 was 
prepared similarly to 12, except that pyridine (1 mL) was also present in the reaction flask. The 
crude material was purified by preparative TLC (CH2Cl2/5% MeOH) to furnish 13 as a purple 
solid in 86% yield (15.0 mg): Rf (silica-CH2Cl2/10% MeOH) = 0.38; 1H NMR (400 MHz, CDCl3): δ 
9.12 (d, 3J = 5.4 Hz, 2H), 9.05 (d, 3J = 4.9 Hz, 1H), 8.90 (d, 3J = 4.9 Hz, 1H), 8.85 (s, 2H), 8.68 
(s, 2H), 8.38 (t, 3J = 7.5 Hz, 1H) 8.25 (dd, 3J = 5.8, 1.6 Hz, 2H), 8.19–8.17 (m, 4H), 7.99 (br d, 3J 
= 4.8 Hz, 4H), 7.83–7.76 (m, 6H) 7.61 (br d, 3J = 5.1 Hz, 3H), 7.46–7.43 (m, 3H), –1.99 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (100 MHz, CDCl3): δ 159.3, 158.9, 152.8, 147.5, 145.9, 
142.7, 142.2, 141.0, 140.9, 140.4, 139.5, 139.3, 137.8, 136.5, 136.4, 135.8, 135.1, 134.9, 134.8, 
131.5, 130.9, 129.8, 129.5, 128.6, 128.5, 128.4, 128.3, 127.4, 127.3, 127.2, 123.5, 121.7, 121.6, 
119.4 ppm; UV-vis (CH2Cl2) λmax (log ε) 431 (5.07), 538 (3.93), 528 (3.45), 630 (3.51), 683 
(4.07) nm, UV-vis (CH2Cl2 + 10 % TFA) λmax (log ε) 463 (5.14), 728 (4.37) nm; HR-MS (ESI+, 
cone voltage = 30 V, 100% CH3CN, TOF) m/z calcd for C48H33N6 693.2767 ([M]+), found 
693.2816. 
meso-Tetraphenyl-2-aza-3-diethylamino)-porphyrin (14). To a 25 ml round bottom flask 
equipped with magnetic stir bar was added triflate 12 (40.1 mg, 0.0525 mmol), sodium 
carbonate (13.8 mg, 0.1302 mmol), diethylamine (0.10 mL) and CH2Cl2 (5 mL). The mixture was 
stirred at room temperature for 20 h. After the starting material was consumed, the solvent and 
excess diethylamine were evaporated and the product was purified by column chromatography 
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(silica-CH2Cl2/1% MeOH) to obtain 14 as a yellow/brown solid in 87% yield (31.5 mg): Rf (silica-
CH2Cl2/5% MeOH) = 0.75; 1H NMR (500 MHz, CDCl3): δ 8.91 (d, 3J = 4.9 Hz, 1H), 8.78 (d, 3J = 
4.9 Hz, 1H), 8.75 (d, 3J = 4.9 Hz, 1H), 8.70 (d, 3J = 4.9 Hz, 1H), 8.62 (d, 3J = 4.56 Hz, 1H), 8.61 
(d, 3J = 4.56 Hz, 1H), 8.34-8.31 (m, 4H), 8.23-8.20 (m, 4H), 7.79-7.73 (m, 10H), 7.71-7.68 (m, 
2H), 3.48 (q, 3J = 7.1 Hz, 4H), 1.01 (t, 3J = 7.1 Hz, 6H), -1.90 (broad s, 2H, exchangeable with 
D2O) ppm; 13C NMR (125 MHz, CDCl3): δ 171.6, 160.8, 155.8, 154.1, 142.38, 142.25, 142.0, 
140.6, 140.2, 139.6, 138.6, 137.6, 136.1, 135.7, 134.85, 134.81, 134.73, 134.1, 133.4, 128.29, 
128.25, 128.20, 127.89, 127.79, 127.66, 127.04, 126.97, 126.90, 126.86, 126.81, 126.73, 121.7, 
119.6, 117.9, 116.3, 77.2, 46.2, 12.5 ppm; UV-vis (CH2Cl2) λmax (log ε) 406 (4.89), 449 (4.95, 
538 (4.19), 615 (3.64) 673 (3.16) nm; FT-IR (neat, diamond ATR): νC=O = 1522.4 cm-1; HR-MS 
(ESI+, 100% CH3CN, TOF) m/z cald for C47H39N6 ([M·H]+) 687.3236, found 687.3242.  
 
Figure 6-7. UV-vis spectrum (CH2Cl2) of 14. 
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Figure 6-8. 1H NMR spectrum (125 MHz, CDCl3) of 14. 
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Figure 6-9. 13C NMR spectrum (125 MHz, CDCl3) of 14. 
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meso-Tetraphenyl-2-aza-3-diethyliminodiacetate)-porphyrin (15). To a 25 ml round 
bottom flask equipped with magnetic stir bar was added triflate 12 (49.0 mg, 6.4 × 10-5 mol), 
sodium carbonate (15 mg, 1.4 × 10-4 mol, 2.2 equiv), diethyl iminodiacetate (250 µl, 1.4 mmol, 
21 equiv.) and acetone (8 mL). The mixture was heated to reflux overnight. After 23-27 h, the 
reaction mixture was evaporated to dryness. Flash column chromatograpy (silica-CH2Cl2/5% 
MeOH) afforded recovered 12 (10-13 mg, 20-27%) and 15 as a yellow/brown solid (36-39 mg, 
70-76%): Rf (silica-CH2Cl2/2% MeOH) = 0.63; 1H NMR (500 MHz, CDCl3): δ 8.93 (d, 3J = 5.0 Hz, 
1H), 8.83 (d, 3J = 4.9 Hz, 1H), 8.75 (two overlapping doublets, 3J = 4.5 Hz, 2H), 8.65 (s, 2H), 
8.43 (d, 3J = 7.1 Hz, 2H), 8.24-8.20 (m, 6H), 7.82-7.70 (m, 13H), 4.39 (s, 4H), 4.03 (q, 3J = 7.1 
Hz, 4H), 1.16 (t, 3J = 7.1 Hz, 6H), -2.11 (br s, 2H, exchangeable with D2O) ppm; 13C NMR (100 
MHz, CDCl3): δ (ppm) 170.0, 158.6, 156.1, 154.6, 142.2, 141.8, 140.1, 139.9, 139.9, 139.6, 
138.9, 138.0, 136.2, 134.9, 134.5, 134.4, 133.8, 133.6, 128.6, 128.5, 128.3, 128.3, 128.0, 127.9, 
127.9, 127.7, 127.0, 126.97, 126.9, 126.6, 121.7, 119.9, 118.2, 117.2, 77.4, 77.2, 76.9, 60.7, 
54.4, 30.0, 14.2 ppm;  UV-vis (CH2Cl2) λmax (log ε) 439 (5.07), 532 (4.06), 568 (sh), 610 (3.5), 
664 (3.1) nm; FT-IR (neat, diamond ATR); HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for 
C51H43N6O4 ([M·H] +) 803.3346, found 803.3368.  
 
Figure 6-10. UV-vis spectrum (CH2Cl2) of 15. 
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Figure 6-11. 1H NMR spectrum (500 MHz, CDCl3) of 15. 
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Figure 6-12. 13C NMR spectrum (125 MHz, CDCl3) of 15. 
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meso-Tetraphenyl-2-aza-3-dicarboxylamino-porphyrin (16). Diester 15 (35.0 mg, 
4.3 × 10-5 mol) was dissolved in THF (10.0 mL) in a round bottom flask equipped with a 
magnetic stir bar and stirred for 5 minutes. 1M aqueous KOH (10.0 mL) was added and the 
reaction mixture was heated to reflux for 2 h. After the starting material was consumed (reaction 
control by TLC), the reaction mixture was allowed to cool and as much THF as possible was 
removed by rotary evaporation. 1M aqueous HCl was added to neutralize the aqueous phase, 
and the aqueous phase was extracted with CH2Cl2 (4 × 20.0 mL). The organic extracts were 
combined and evaporated to dryness. The remaining residue was purified by column 
chromatography (silicia-CH2Cl2/10% MeOH) to afford 16 as a yellow/brown solid in 80 % yield 
(26 mg): 1H NMR (400 MHz, CD2Cl2/10% MeOD): δ 8.92 (d, 3J = 5.0 Hz, 1H), 8.90 (d, 3J = 5.0 
Hz, 1H), 8.87 (d, 3J = 5.0 Hz, 1H), 8.80 (d, 3J = 5.0 Hz, 1H), 8.65 (s, 2H), 8.32 (d, 3J = 7.1 Hz, 
2H), 8.21-8.17 (m, 6H), 7.88 (t, 3J = 7.4 Hz, 2H), 7.83-7.77 (m, 10H), 3.97 (s, 4H) ppm; 13C NMR 
(125 MHz, CD2Cl2/10% MeOD): δ 171.9, 169.2, 157.0, 155.4, 153.8, 141.5, 141.0, 140.2, 
139.41, 139.32, 138.8, 137.6, 135.5, 134.9, 134.67, 134.57, 134.2, 128.97, 128.79, 128.3, 
128.02, 127.92, 127.3, 126.96, 126.86, 122.2, 120.4, 119.5, 115.7, 56.7 ppm; UV-vis (MeOH) 
λmax (log ε) 442 (4.86), 534 (3.92), 571 (sh), 612 (3.51), 676 (3.0) nm; FT-IR (neat, diamond 
ATR): ν= 1603.5 cm-1, 1216.0 cm-1, 1151.7cm-1, 796.0 cm-1, 752.3 cm-1, 698.5 cm-1; MS (ESI+, 
100% CH3CN, TOF) m/z cald for C47H35N6O4 ([MH] +) 747.268, found 747.439.  
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Figure 6-13. UV-vis spectrum (MeOH) of 16. 
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Figure 6-14. 1H NMR spectrum (400 MHz, CD2Cl2/10% MeOD) of 16. 
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Figure 6-15. 13C NMR spectrum (125 MHz, CD2Cl2/10% MeOH) of 16. 
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DPA-substituted Imidazoloporphyrin (17). To a round-bottom flask equipped with a 
magnetic stir bar under N2 was added triflate-imidazole 12 (31 mg, 4.1 × 10-5 mol), Di-(2-
picolyl)amine (365 µl, 2 × 10-3 mol, 50 equiv), Na2CO3 (17.0 mg, 1.6 × 10-4, 4 equiv) and CH2Cl2 
(10 mL). The reaction mixture was stirred for 24 h. When the starting material was consumed 
(reaction control by TLC), the reaction mixture was filtered through a glass frit and the filtrate 
washed with water (3 × 20.0 mL). The organic layer was dried over Na2SO4 and the residue was 
purified by preparative TLC (silica-CH2Cl2/10% MeOH) to afford DPA-substituted 
imidazoloporphyrin 17 as a yellow/brown solid in 76 % yield (25 mg): Rf (silica-CH2Cl2/10% 
MeOH) = 0.41; 1H NMR (400 MHz, CDCl3): δ 8.91 (d, 3J = 5.0 Hz, 1H), 8.80 (d, 3J = 5.0 Hz, 1H), 
8.72 (d, 3J = 4.7 Hz, 1H), 8.69 (d, 3J = 4.9 Hz, 1H), 8.62-8.60 (m, 2H), 8.43 (s, 2H), 8.26 (d, 3J = 
6.7 Hz, 2H), 8.19 (dd, 3J = 7.2, 4J = 2.0 Hz, 6H), 7.76-7.67 (m, 12H), 7.38 (td, 3J = 7.7, 4J = 1.6 
Hz, 2H), 7.12 (d, 3J = 7.8 Hz, 2H), 7.03 (dd, 3J = 7.0, 4J  = 5.3 Hz, 2H), 4.77 (s, 4H), -2.03 (s, 
2H) ppm; 13C NMR (125 MHz, CDCl3): δ 171.3, 158.1, 156.1, 154.5, 149.0, 142.1, 141.84, 
141.78, 140.3, 139.9, 139.7, 138.8, 137.9, 136.19, 136.03, 135.3, 134.87, 134.71, 134.4, 133.7, 
128.51, 128.42, 128.31, 128.26, 127.95, 127.88, 127.5, 127.10, 127.02, 126.97, 126.91, 126.76, 
123.6, 122.0, 121.8, 119.8, 118.2, 116.7, 77.4, 77.2, 76.9, 58.8 ppm; UV-vis (CH2Cl2) λmax (log ε) 
403 (sh), 449 (5.17), 542 (4.07), 588 (3.77), 618 (3.71), 681 (3.66) nm, UV-vis (CH2Cl2 + 10% 
TFA) λmax (log ε) 473 (5.15), 629 (sh), 680 (4.40) nm; Fl (DMF, λexcitation = Soret) λmax 693, 750 
nm, φ F (DMF) = 0.01; FT-IR (neat, diamond ATR); HR-MS (ESI+, 100% CH3CN, TOF) m/z cald 
for C55H41N8 ([M·H]+) 813.3454, found 813.3485.  
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Figure 6-16. UV-vis spectrum of 17 in CH2Cl2 (solid trace) and CH2Cl2 + 10% TFA (broken trace). 
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Figure 6-17. 1H NMR (125 MHz, CDCl3) of 17. 
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Figure 6-18. Partial H-H COSY spectrum (CDCl3) of 17. 
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Figure 6-19. 13C NMR (125 MHz, CDCl3) of 17. 
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Cyclen-substituted Imidazoloporphyrin (18). To a round-bottom flask equipped with a 
magnetic stir bar was added cyclen (7.0 mg, 4.1 × 10-5 mol, 1.6 equiv), Na2CO3 (11.0 mg, 1.0 × 
10-4 mol, 4 equiv) and CH2Cl2 (3.0 mL). A solution of triflate-imidazole 12 (20.0 mg, 2.6 × 10-5 
mol) in CH2Cl2 was added to the stirred solution under N2. The reaction mixture was stirred at 
r.t. for 2h. The reaction mixture was filtered through a glass frit and the filtrated was washed with 
H2O (2 × 10.0 mL), brine, and dried over Na2SO4. The remaining residue was purified by 
preparative TLC (silica-CH2Cl2/10% MeOH) to afford recovered 12 (2.0 mg, 10 %), 18 (13.0 mg, 
62 %), and 19 (6 mg, 16 %): (18) Rf (silica-CH2Cl2/10% MeOH) = 0.09; 1H NMR (500 MHz, 
CDCl3): δ 8.91 (d, 3J = 5.0 Hz, 1H), 8.86 (two overlapping d, 3J = 4.1 Hz, 2H), 8.78 (d, 3J = 4.9 
Hz, 1H), 8.65(d, 3J = 4.6 Hz, 1H), 8.63 (d, 3J = 4.6 Hz, 1H), 8.27 (two overlapping d, 3J = 7.5, 7.0 
Hz, 4H), 8.21-8.17 (m, 4H), 7.84 (td, 3J = 7.4, 4J = 3.4 Hz, 4H), 7.80-7.75 (m, 8H), 3.47 (s, 4H), 
2.80 (s, 4H), 2.46 (s, 4H), 2.22 (s, 4H), -2.14 (s, 1H, exchangeable with D2O), -2.24 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (125 MHz, CDCl3): δ 170.5, 156.9, 155.4, 142.3, 141.8, 
141.4, 140.24, 140.16, 139.49, 139.43, 139.31, 138.7, 135.4, 135.14, 135.07, 134.86, 134.79, 
134.72, 134.68, 134.63, 134.3, 129.0, 128.78, 128.73, 128.66, 128.57, 128.42, 128.35, 128.28, 
128.20, 128.11, 127.9, 127.5, 127.13, 127.03, 126.94, 122.4, 121.9, 120.3, 119.36, 119.29, 
116.0, 51.0, 47.3, 44.0 ppm; UV-vis (CH2Cl2) λmax (log ε) 438 (5.0), 533 (4.0), 570 (sh), 610 
(3.54), 670 (3.58) nm, UV-vis (CH2Cl2 + 10% TFA) λmax (log ε) 470 (4.9), 624 (sh), 682 (4.27) 
nm; Fl (DMF, λexcitation = Soret) λmax 678, 739 nm, φF (DMF) = 0.02; FT-IR (neat, diamond ATR); 
HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C51H48N9 ([M·H]+) 786.4033, found 786.4061. 
(19) Rf (silica-CH2Cl2) = 0.45; 1H NMR (400 MHz, CDCl3): δ 8.82 (d, 3J = 4.9 Hz, 1H), 8.79 (d, 3J 
= 4.9 Hz, 1H), 8.70 (d, 3J = 4.6 Hz, 1H), 8.67 (d, 3J = 4.6 Hz, 1H), 8.42 (d, 3J = 5.0 Hz, 1H), 8.24 
(d, 3J = 6.4 Hz, 2H), 8.15 (t, 3J = 8.6 Hz, 5H), 7.85-7.74 (m, 8H), 7.59-7.54 (m, 3H), 6.40 (s, 1H), 
5.88 (s, 1H), 3.36 (s, 4H), 2.61 (s, 4H), -1.92 (s, 1H, exchangeable with D2O), -2.36 (s, 1H, 
exchangeable with D2O) ppm; 13C NMR (125 MHz, CDCl3): δ 170.2, 157.6, 156.8, 155.0, 142.0, 
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141.5, 140.7, 140.4, 139.4, 139.0, 138.7, 138.4, 135.04, 134.98, 134.7, 134.38, 134.23, 132.9, 
129.0, 128.66, 128.47, 128.36, 128.22, 128.13, 128.03, 127.94, 127.35, 127.31, 127.21, 127.13, 
127.08, 126.99, 126.92, 125.9, 125.13, 125.05, 122.3, 119.8, 118.6, 115.6, 77.2, 50.4, 48.3 
ppm; UV-vis (CH2Cl2) λmax (log ε) 404 (sh), 438 (5.14), 570 (sh), 534 (4.29), 608 (3.86), 665 
(3.58) nm, UV-vis (CH2Cl2 + 10% TFA) λmax (log ε) 470 (5.18), 495 (sh), 570 (sh), 622 (sh), 679 
(4.59) nm; Fl (DMF, λexcitation = Soret) λmax 684, 743 nm, φF (DMF) = 0.01; FT-IR (neat, diamond 
ATR); HR-MS (ESI+, 100% CH3CN, TOF) m/z cald for C94H75N14 ([M·H]+) 1400.6330, found 
1400.6337. 
 
Figure 6-20. UV-vis spectrum of 18 in CH2Cl2 (solid trace) and CH2Cl2 + 10% TFA (broken trace). 
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Figure 6-21. 1H NMR spectrum (500 MHz, CDCl3) of 18. 
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Figure 6-22. 13C NMR spectrum (125 MHz, CDCl3) of 18. 
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Figure 6-23. UV-vis spectrum of 19 in CH2Cl2 (solid trace) and CH2Cl2 + 10% TFA (broken trace). 
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Figure 6-24. 1H NMR spectrum (125 MHz, CDCl3) of 19. 
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Figure 6-25. Partial 1H-1H COSY spectrum (CDCl3) of 19. 
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Figure 6-26. 13C NMR (125 MHz, CDCl3) of 19. 
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